Probing human cytochromes P450: mutational and spectroscopic analysis of CYP2D6 by Keizers, P.H.J.
VU Research Portal




Publisher's PDF, also known as Version of record
Link to publication in VU Research Portal
citation for published version (APA)
Keizers, P. H. J. (2006). Probing human cytochromes P450: mutational and spectroscopic analysis of CYP2D6.
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            • Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            • You may not further distribute the material or use it for any profit-making activity or commercial gain
            • You may freely distribute the URL identifying the publication in the public portal ?
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
E-mail address:
vuresearchportal.ub@vu.nl
Download date: 27. May. 2021
Probing human cytochromes P450: 
mutational and spectroscopic analysis of CYP2D6 
Probing human cytochromes P450: mutational and spectroscopic analysis of CYP2D6 
Peter H.J. Keizers 
For the printing of this thesis the Jurriaanse Stichting and the Nederlandse Vereniging voor 
Toxicologie (NVT) are acknowledged for their grant and presentation award respectively. 
Printed by Printpartners Ipskamp 
Cover: steel covered with ironoxide 
© Peter H.J. Keizers, Utrecht 2006. All rights reserved. No part of this thesis may be 
reproduced in any form or by any means without permission from the author. 
VRIJE UNIVERSITEIT 
Probing human cytochromes P450: 
mutational and spectroscopic analysis of CYP2D6 
ACADEMISCH PROEFSCHRIFT 
ter verkrijging van de graad Doctor aan 
de Vrije Universiteit Amsterdam, 
op gezag van de rector magnificus 
prof.dr. T. Sminia, 
in het openbaar te verdedigen 
ten overstaan van de promotiecommissie 
van de faculteit der Exacte Wetenschappen 
op maandag 26 juni 2006 om 13.45 uur 
in de aula van de universiteit, 
De Boelelaan 1105 
door
Peter Henricus Jozef Keizers 
geboren te Stad Delden 
promotoren:  prof.dr. N.P.E. Vermeulen  
  prof.dr. S.M. van der Vies 
copromotor:  dr. J.N.M. Commandeur 
hic igitur, penitus qui in ferrost abditus aeër, 
sollicito motu semper iactatur eoque 
thus then, this air in iron so deeply stored,
is tossed evermore in vexed motion 
Titus Lucretius 50 BC
Leescommissie: prof.dr. M. Ingelman-Sundberg 
prof.dr. C. Gooijer 
  prof.dr. K. Lammertsma 
  prof.dr. S. de Vries 
  prof.dr.ir. I.M.C.M. Rietjens 
The investigations described in this thesis were carried out in the Leiden Amsterdam Center 
for Drug Research (LACDR), Division of Molecular Toxicology, Department of Chemistry and 
Pharmaceutical Sciences, Faculty of Sciences, Vrije Universiteit, De Boelelaan 1083, 1081 HV 
Amsterdam, the Netherlands. 
Contents
Introduction
Chapter 1: General introduction
Part I: Key determinants of CYP2D6 activity
Chapter 2: Influence of phenylalanine 120 on cytochrome P450 2D6
catalytic selectivity and regiospecificity: crucial role in 7-
methoxy-4-(aminomethyl)-coumarin metabolism 
Chapter 3: The role of phenylalanine 483 in cytochrome P450 2D6 is
strongly substrate dependent
Chapter 4: Metabolism of N-substituted 7-methoxy-4-(aminomethyl)-
coumarins by cytochrome P450 2D6 mutants indicates 
additional substrate interaction points
Chapter 5: Role of the conserved threonine 309 in mechanism of oxidation 
by cytochrome P450 2D6 
Part II: Spectroscopy and modeling of CYP2D6
Chapter 6: Metabolic regio- and stereoselectivity of cytochrome P450 2D6 
towards  3,4-methylenedioxy-N-alkyl-amphetamines: in silico 
predictions and experimental validation 
Chapter 7: The conserved threonine 309 influences spin state equilibrium
in cytochrome P450 2D6: a resonance Raman scattering study 
Chapter 8: Binding of 7-methoxy-4-(aminomethyl)-coumarin to wild-type 
and W128F mutant cytochrome P450 2D6 studied by time
resolved fluorescence spectroscopy
Summary, conclusions and perspectives 













Appendices: List o  publications 172
Curriculum vitae 173
  Nawoord 174








All organisms express enzymes that can convert both endogenous and exogenous 
compounds into more water-soluble compounds. This process, known as biotransformation,
holds a central position in the detoxification processes in the organisms, but as a paradigm
it can also lead to increased toxicity of the parent compound by bioactivation [1, 2]. In man,
these enzymes are predominantly expressed in the liver and they determine the fate of 
compounds like drugs, industrial chemicals, pyrolysis products in cooked food and also plant
and animal toxins [3]. Biotransformation, or drug metabolism, is usually divided in to three 
phases. Phase I reactions involve the introduction of functional groups by hydrolysis,
reduction and oxidation. In phase II reactions, cofactors react with the functional groups 
that were already present on the molecule or that are introduced by phase I reactions. The 
phase II reactions involved are glucuronidation, sulphonation, acetylation, methylation and 
conjugation with amino acids or glutathione. As an example, the metabolism of 3,4-
methylenedioxymethylamphetamine (MDMA) is shown in Figure 1, showing that in both
phase I and phase II reactions several enzymes can be involved in the metabolism of the 
same substrate. Phase III metabolism involves further modifications of the phase II 
products in order to facilitate urinary excretion even more. In phase I the most important
enzymes are cytochromes P450 (CYPs). These enzymes have been subject of elaborate
research over the last thirty years, mainly because of their important role in
biotransformation of carcinogens, steroids and drugs. Because of their involvement in drug 
metabolism, a good understanding of these enzymes at the molecular level would be 
advantageous in the process of drug discovery and development, to prevent drug-drug 
interactions and decrease the risks of side effects. 
Cytochromes P450 
It was in the Netherlands in 1932 that Verkade et al. isolated urinary dicarboxylic acids from 
dogs and human volunteers after feeding fatty acids [4]. This was the first observation of 
fatty acid -oxidation, where the insertion of the oxygen is at the least reactive position. 
Whenever biological oxidations occur through unpredictable chemical principles, usually
cofactors such as metals or coenzymes or specific amino acid residues are required in the 
reaction [5]. Later it was found that the oxidation of 2,2-dimethyloctanoic acid occurred in
liver tissue, by an unstable membrane bound enzyme system [6]. Using ion exchange 
column chromatography the components of this enzyme system that was also responsible
for -hydroxylation of lauric acid, could be purified from rabbit liver and activity could be 
reconstituted after mixing of the components [7].
The hemeprotein nature of these hepatic enzymes became known by the experiments of
Omura and Sato [8]. It was already shown before that mammalian liver pigments could bind
CO when reduced, thus giving a typical absorbance maximum at 450 nm [9]. Omura and 
Sato showed that an unusual cysteine ligated hemeprotein was responsible for this 
absorption and that this protein was reducible by both NADPH and NADH. The hemeprotein 
was named cytochrome because it was a pigment (in Greek: chromos) within the cells (in
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Greek: cyto), and P450 because the pigment gave a typical absorbance band at 450 nm.
Later, it was again Omura who showed that these cytochromes P450 (CYPs) were involved 
in the hydroxylation of steroids and drugs [10].
The expression of CYPs is not restricted to mammals but can be found in virtually all
organisms, in all kinds of tissues. They are involved in synthesis and breakdown of a large 
variety of different compounds, dependent on the isoenzyme. So far there are about 4500
unique named sequences of CYPs known (drnelson.utmem.edu). They are named according
to sequence homology [11-15]. In general, when their amino acid sequences are less then 
40% identical, CYPs are assigned to different gene families, indicated by a number. When 
sequences are between 40 and 55% identical, they are assigned to different subfamilies, 
indicated by a capital letter. When the sequences are more then 55% identical, they are 
classified as members of the same subfamily and if the sequences and the function are 
similar, then they get the same gene number. For instance, a CYP from the family 2,




















































Figure 1: Metabolic fate of 3 4-methylenedioxymethylamphetamine (MDMA or XTC) in man, showing
phase I O-demethylenation and N-dealkylation catalyzed by CYPs, and phase II methylation, sulfonation 
and glucuronidation catalyzed by ca echol O-methyl transferase (COMT , sulfotransferase (SULT  and
UDP-glucuronyl transferase (UGT), respectively (adapted from de la Torre [16]). The thickness of the





Drug metabolism by CYPs 
There are currently about 60 different human CYPs known (drnelson.utmem.edu).
Approximately a dozen of these are involved in drug metabolism; the CYP isoforms, 1A2, 
2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, 3A4, 3A5 and 3A7 [17]. All together these CYPs 
account for the phase I metabolism of about 90% of the currently marketed drugs [18]. In
Figure 3 the relative amounts of the major human liver CYP isoenzymes involved in drug 
metabolism in a group of 30 Caucasian patients is shown. CYP3A4 is the most abundant 
isoenzyme, followed by the CYP2C family members, and than CYP1A [19]. When it comes to
the number of metabolized drugs in which a CYP isoenzyme is involved again CYP3A4 takes
the largest share, followed by the CYP2C family members and CYP2D6. So although the 
hepatic concentration of CYP2D6 is relatively low, i.e. an average of 3% of the total amount 




























Figure 3 Relative amounts of the drug metabolizing CYPs in human liver (A), and the contribution of 
these CYPs in the metabolism of the currently prescribed drugs (B) [19, 22]. 
:
Polymorphisms of CYPs 
The efficacy and pharmacokinetics of a drug can be determined genetically. Genes encoding 
proteins involved in the functioning, transport, or metabolism of the drug for instance, can
be present in the population in two or more allelic forms and can therefore affect the 
activity of the drug. When at least two alleles have frequencies larger than 1% this is called 
a genetic polymorphism. In some occasions these polymorphisms are caused by a mutation, 
13
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deletion or insertion of just a single nucleotide, thus called single nucleotide polymorphisms
(SNPs). Many drug-metabolizing enzymes are known to be polymorphic. Aldehyde 
dehydrogenase (ALDH) activity for instance, is severely lowered in half of the populations in 
Japan, China, Korea, Taiwan and Vietnam, due to an ALDH3 deficiency. Other known 
polymorphic enzymes involved in drug metabolism are: UDP-glucuronyltransferases 2 family
members, sulfotransferase SULT1A3, catechol O-methyl transferase, N-acetyl transferases 1 
and 2, glutathion S-transferase M1, and many CYPs [3, 23]. There are as much as 22 
human CYPs expressed from different alleles (www.imm.ki.se/CYPalleles). Nevertheless, of 
these 22 enzymes, only few were found with significant clinical effects caused by the
polymorphisms. Minor clinical effects were reported for CYPs 1A2, 2A6, 2B6 and 2C8 
polymorphisms, and major effects of polymorphism for CYPs of the 2 family, namely
CYP2C9, CYP2C19 and CYP2D6 [24]. 
Figure 2  The catalytic cycle of CYPs, adapted from [25-27]. The cycle is subdivided in seven stages (1
7), artificial oxidants short-circuits (a), and uncoupling pathways are indicated (b), the horizontal bars
represent the porphyrin ring. 
: -
CYP catalytic activity 
Although CYPs are involved in what appears to be a multitude of different reactions, the
activity of all CYPs can be summarized in a general catalytic cycle [25, 27-29], as shown in 
14
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Figure 2. The cycle starts (Stage 1) in the resting state, in which the ferric iron is often
bound to a water molecule in the axial position. In most CYPs, the heme iron atom in Stage
1 is predominantly in the low spin state. Then (Stage 2), a substrate enters the active site, 
displaces the 6th ligand, which often causes the iron spin state to change from low to high.
Whether the spin change triggers the next step, followed by the rest of the cycle is still 
under debate [30, 31]. At Stage 3, the five-coordinated iron accepts the first electron, 
delivered by the cytochrome P450 NADPH-reductase (CPR), so that to the ferrous iron atom 
formed can bind molecular oxygen (Stage 4). Subsequently, a second electron is delivered,
yielding a negatively charged iron peroxo intermediate (Stage 5). This species is protonated 
to the hydroperoxo-iron (Stage 6), which after the loss of water yields the oxenoid-iron, also 
known as compound I, the originally presumed active oxidant species (Stage 7). The 
oxenoid-iron oxygenates the substrate, the product is released and a water molecule binds 
again to the ferric iron (Stage 1).
The general catalytic cycle can be short-circuited when artificial oxygen delivering agents 
are used, such as hydrogen peroxide or organic peroxides. In these cases, the cycle is
shortened, and turns immediately from Stage 2 to Stage 6 or 7, depending on the nature of 
the oxidant, indicated by dashed arrows (a) [29, 32, 33]. On the other hand, uncoupling or
autoxidation may occur [34], in which the cycle is started and molecular oxygen is reduced 
without leading to product formation. These processes are also known as the oxygen 
reductase activity of a CYP [35], and are indicated by arrows (b). Then superoxide anion 
can be formed from Stage 4, hydrogen peroxide can be formed from Stage 5, or water can
be formed from Stage 6 [26].
Currently it is under debate whether just one oxidant (the oxenoid-iron, Stage 7) can create 
all the experimentally detected reactivity patterns. The proton needed to form the oxenoid-
iron (from Stage 6 to 7) is thought to be delivered by a conserved I-helix threonine residue 
in the CYP [36]. Mutation of this residue to an alanine in CYPs 2B4 and 2E1 led to a 
drastically changed regioselectivity in catalysis [37, 38]. While some model activities of the 
mutated CYPs were decreased, others were increased. This could be explained by
hypothesizing the threonine to be responsible for the ultimate proton donation to form 
Stage 7, and by introducing the iron-oxo species preceding the oxenoid-iron, i.e. the iron-
peroxo and the iron hydroperoxo (Stages 5, and 6 respectively) to be reactive oxygenating 
species as well. Together these multiple oxygenating species were thought to be responsible
for the different reactions CYPs can catalyze, each with their own preferences for certain
types of reactions, ranging from nucleophilic to electrophilic [39]. The use of alternative 
oxidants and kinetic isotope studies experimentally strengthened this hypothesis [40].
Furthermore, in recent studies the hydroperoxo-iron was experimentally detected using 
electron magnetic resonance (EMR) techniques, and shown to be stabilized by the presence 
of substrates (vide infra) [41]. However, the identity of a second (or more) electrophilic 
oxidant remains speculative. The hydroperoxo-iron is experimentally not yet distinguishable 
from iron-complexed hydrogen peroxide [42]. Furthermore, it has been suggested from 
theoretical computational studies that the hydroperoxo-iron is a poor oxidant, not capable to 
compete with the reactivity of the oxenoid iron [43]. As an alternative, using density 
functional theoretical studies it has been suggested that the oxenoid-iron exists in 
degenerate spin states and can therefore act (chameleon wise) like two different oxidants
[43, 44].
Reactions catalyzed by CYPs
Although the catalytic activity may be represented in one schematic cycle, it can lead to
many reactions: i.e. aromatic and aliphatic hydroxylation, epoxidation, heteroatom
15
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oxygenation, heteroatom dealkylation, dehalogenation, dehydrogenation, cleavage of esters,
oxidative group transfer, substrate reduction and oxygen reduction [26]. Examples of these 
reactions are listed in Table 1. The multitude of reactions CYPs can catalyze makes the
enzymes highly versatile.
Table 1: Types o  reactions catalyzed by CYPs with examples of each reac ion [3, 26, 35].f t
Reaction Example
Aliphatic hydroxylation Lauric acid -hydroxylation by CYP4A
Aromatic hydroxylation Coumarin 7-hydroxylation by CYP2A6 
Epoxidation Verlukast epoxidation by CYP1A1
Heteroatom oxygenation Omeprazole sulfoxidation by CYP3A4
Heteroatom dealkylation Dextromethorphan O-dealkylation by CYP2D6
Dehalogenation Halothane to trifluoroacetylchloride by CYP2E1 
Dehydrogenation Acetaminophen to N-acetylbenzoquinoneimine by CYP2E1 
Cleavage of esters Loratadine to desloratadine by CYP3A4
Oxidative group transfer Amphetamine to phenylacetone by CYP2C
Reduction Dimethylaminoazobenzene reduction by CYP2B
Oxygen reduction 2,3,5,6-tetramethylbenzoquinone by CYP1A 
Dynamics of CYPs 
It is thought that CYPs need to undergo conformational changes upon substrate binding, 
substrate conversion and product release for several reasons. At first, substrates can be 
relatively large and bulky but need to enter the inside of the CYP to reach the active site. So 
it is thought that substrate entrance channels [45], need to open to accommodate a 
substrate [46]. Secondly, single CYPs usually have a wide range of compounds that are 
substrates, so their active site and substrate entrance channels need to be able to adapt 
their sizes to the substrate. Thirdly, after the oxidative metabolism the physico-chemical
character of the substrates has changed from hydrophobic to more hydrophilic. To enable
the product to leave the buried active site, a product egress channel needs to be present to 
accommodate the product on the way out [47]. At fourth, CYPs interact with reducing 
partner proteins, like the CPR, cytochrome b5 and maybe even other CYPs by forming 
dimers [48]. Because of the relatively low concentration of CPR in mammalian hepatic 
membranes, a conformation driven regulation of interaction between CYPs and CPR is likely 
[49]. Therefore, conformational changes of CPR and/or CYP are thought to take place [50].
For all the reasons listed above, CYPs are thought to be highly dynamic proteins [51]. To 
measure the dynamics of proteins fast spectroscopic techniques are needed in combination 
with fast triggers, stop flow or freeze quenching techniques (vide infra).
The isoform CYP2D6 
The relatively large share CYP2D6 takes in drug oxidation while being a low abundant 
hepatic CYP, in combination with its polymorphic nature make CYP2D6 one of the most
relevant CYPs in human drug metabolism. The history of the enzyme starts in the late 
seventies. In 1975 it was shown that debrisoquine, an antihypertensive drug, was 
predominantly 4-hydroxylated in man after oral administration [52]. A few years later, a 
typical bimorphically distribution was found of this metabolite in the urine of 94 volunteers 
after a 10 mg oral dose [53, 54]. The 4-hydroxylation of debrisoquine was subsequently 
shown to be metabolized by a specific CYP, relating polymorphisms with this large family of 
drug metabolizing enzymes [55]. The rat debrisoquine 4-hydroxylase was purified in 1984
16
Chapter 1 
by Larrey et al. [56], which was followed by the purification of the responsible human
enzyme [57]. It was later found that the gene for this human enzyme was located on
chromosome 22 [58]. Two debrisoquine hydroxylase genes were found in the rat and
classified in a new family; P450II [59]. In humans the cDNA and amino acid sequences
were found of a single gene encoding the debrisoquine hydroxylase and originally named 
P450IID1 [60].
Soon afterwards, mutant alleles and gene deletions of cytochrome P450IID1 were observed 
explaining for the deficient metabolism of debrisoquine and other drugs [61]. After 
establishment of the official cytochrome P450 nomenclature in 1993, the unique name 
CYP2D6 was given to the human debrisoquine hydroxylase [12]. The high frequency of
mutations in the gene was hypothesized to be caused by the presence of a downstream 
CYP2D7 with a disrupted reading frame and CYP2D8, a pseudogene, likely to transfer
mutations easily via gene conversions into CYP2D6 [62]. Currently, the polymorphism of 
CYP2D6 is characterized by multiple alleles, in total numbering up to more than 80 
sequences (www.imm.ki.se/CYPalleles/cyp2d6.htm). The consequence of these different 
alleles is an interindividually varying activity of the enzyme. Thus 10% of the Caucasians 
and 1% of the Asians have two null alleles. The resulting poor metabolizer (PM) phenotype 
is characterized by the inability to use CYP2D6 dependent metabolic pathways. On the other
end of the spectrum, 2% of the Caucasians and up to 29% of the Ethiopians display the
ultrarapid metabolizer (UM) phenotype, caused by alleles carrying multiple gene copies, or 
by promotor mutations [63]. Individuals having the UM phenotype are typical in having a 
high metabolic ratio for CYP2D6 substrates. In between PM and UM are the normal
extensive metabolizer (EM) phenotype, with one or two functional genes and the
intermediate metabolizer (IM) phenotype, characterized by at least one partially deficient 
allele.
CYP2D6 is known for its role in drug metabolism. It is involved in the metabolism of about 
20-30% of all currently prescribed drugs [19]. These include often prescribed drugs like -
blockers, neuroleptics, antidepressants and antiarythmics [21, 64]. A selection of the drugs 
that are (partly) metabolized by CYP2D6 dependent pathways is shown in Table 2.
Table 2:  Examples o  drugs of di erent therapeutic classes known to be metabolized by CYP2D6
adapted from [3, 64]. A more extended table including the relevant other human drug metabolizing 
CYPs was made by Rendic [65].
f ff ,









Anti-ADHD drugs Atomoxetine Aromatic hydroxylation
Antiarrhythmics Aprindine Aromatic hydroxylation
Encainide O-demethylation








Antidementia drugs Galanthamine O-demethylation
Nicergoline N-demethylation















Antidiabetics Phenformine Aromatic hydroxylation
Antiestrogens Tamoxifen Aromatic hydroxylation
Antihypertensives Debrisoquine Benzylic hydroxylation
Guanoxan Aromatic hydroxylation
Indoramin Aromatic hydroxylation
Antiemetics Dolasetron Aromatic hydroxylation
Ondansetron Aromatic hydroxylation
Tropisetron Aromatic hydroxylation










Appetite suppressants Dexfenfluramine N-dealkylation














Recreational drugs Methoxyamphetamine O-demethylation
MDMA1, MDEA2 O-demethylenation
Methoxyphenamine O-dealkylation
Vasodilatators Cinnarizine Aromatic hydroxylation
Flunarizine Aromatic hydroxylation
1 3,4-methylenedioxymethylamphetamine, 2 3,4-methylenedioxyethylamphetamine
18
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Sometimes the use of drugs can result in serious side effects that could not be predicted 
from the prior clinical studies. These so-called adverse drug reactions (ADR’s) are a
significant cause of morbidity and mortality. Although many ADR’s are considered not
preventable, it has been suggested that these reactions may be avoided through 
individualization of drug therapies based on genetic information [66]. Based upon a search 
on adverse drug reaction studies published between January 1995 and June 2000, it was
found that drug therapy based on individual genetic makeup could result in a clinically 
important reduction in adverse outcomes. In relation to this, it was shown that the 
polymorphic CYP2D6 is involved in 38% of all ADR’s [67]. 
The highest expression levels of CYP2D6 are found in the human liver, but also in the skin 
[68], and in the brain significant levels of CYP2D6 mRNA and protein can be found [69]. A 
frameshift mutation in the pseudogene CYP2D7 leads to a brain specific expression of a 
splice variant of this enzyme in Indian people [70]. This splice variant was shown to be even 
more active than CYP2D6 in morphine formation from codeine. Besides roles in drug 
metabolism, there seem to be endogenous functions for the enzyme as well. It was shown 
that CYP2D6 selectively metabolizes 5-methoxytryptamine, 5-methoxy-N,N-
dimethyltryptamine and pinoline, with high turnovers while other structurally similar
endogenous compounds were not significantly metabolized [71-73]. The association with 
serotonin metabolism suggests that the enzyme may influence mood and mental health.
This hypothesis was strengthened by clinical studies revealing a high amount of patients
with persistent mood disorders having the UM phenotype [74]. 
Computer modeling of CYP2D6 
As outlined above, CYPs play a major role in the disposition of drugs and their
pharmacological and toxicological effects. The absorption, distribution, metabolism and 
excretion (ADME) properties of new drug-like compounds in relation to CYPs can be 
screened in vitro. However, to reduce screening efforts and also to predict the ADME 
properties of theoretical compounds, in silico predictions approaches to study CYP-
compound interactions are a necessity [75]. Computational studies on ligand-to-CYP
interactions can be divided into two different approaches, one starting from a model based 
on the known ligands (pharmacophore modeling) and the other starting from a model of the
protein. Both approaches were used to examine oxidative metabolism of compounds by
CYP2D6 and will shortly be discussed.
Pharmacophore modeling
CYP2D6 is one of the CYP isoforms most extensively studied computationally [75, 76],
because of its important role in drug metabolism and being a polymorphic enzyme. As yet, 
the X-ray structure of CYP2D6 is unknown. Furthermore, the apparent narrow substrate 
selectivity of this enzyme compared to other CYPs, makes this enzyme suitable for a 
pharmacophore modeling approach. Practically all compounds that are metabolized by
CYP2D6 contain a basic nitrogen atom and at least one aromatic moiety (Table 2). The 
initial substrate models of CYP2D6 were not in agreement with the distance between the 
substrate basic nitrogen and the predicted site of oxidation distance being 5 Å [77], or 7 Å 
[78]. A new substrate model was developed, hypothesizing the presence of a carboxylate 
group in the protein to interact with the substrate basic nitrogen (Figure 4). The substrate 
nitrogen atoms were proposed to interact with either one of the two carboxylate oxygen
atoms, thus explaining the two different distances between the nitrogen atom and the site
19
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of oxidation [79]. This model had a higher predictive value compared to the previous 
models. This was further confirmed by experimental validation of the two predicted
metabolites of the new compound GBR12909 [80]. Later, the model was extended with a 
large set of substrates [81]. In this model also the heme moiety and the I-helix containing
D301 were incorporated leading to a refined and more restrictive substrate model. 
Figure 4: Confo mations of the templa e subs rates debrisoquine and dextromethorphan used to
cons uct the pharmacopho e model of CYP2D6 [79]. The sites of oxidation are fixed and the dotted
surface represents a part in the molecule where all substrates exhibit a negative electrostatic potential.




The availability of crystallographic data of bacterial CYPs made it possible to build protein
models of CYP2D6 based upon homology. At first, in the late eighties the crystal structure of 
bacterial CYP101 was resolved [82-84], and this was used as a template to construct a 
homology model of CYP2D6 [85]. This protein model was able to accommodate 
debrisoquine and dextromethorphan, and aspartic acids 100 or 301 were proposed as the 
carboxylate interacting with the substrate basic nitrogen atoms. However, due to relatively 
low homology (15%), not all regions of the enzyme could be modeled well. Better templates 
were the crystal structures of the slightly higher homologous (20%) CYP102 [86, 87], for 
developing CYP2D6 protein models [88, 89]. Including experimental spectroscopic data 
strengthened the CYP102 based homology model. The active site orientation of the 
substrate codeine was determined using the spin lattice relaxation NMR technique (vide
infra). This codeine active site orientation was then used in the homology model to fixate
D301 in the active site in a way that it would interact with the codeine nitrogen atom [88]. 
It was concluded that CYP2D6 resembled CYP102 more than CYP101 or CYP108 and thus 
relative positions of active site residues could be better predicted with this model. More
modeling studies were performed to compare the different available crystal structures as 
templates for a CYP2D6 protein model and also parts of structures were combined in order
to use the best resolved parts of the crystal structures in order to get better 
accommodations of the substrates in the enzyme active site [90-92].
20
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To utilize the strengths of the two modeling approaches, pharmacophore modeling and 
protein modeling, these were also combined. This way, the metabolism of a wide variety of 
compounds could be correctly predicted, even the relatively often by CYP2D6 catalyzed N-
dealkylation reactions (Table 2), which were not included before [91, 93, 94]. 
Figure 5: Protein model of CYP2D6 using the crystal-structure of CYP2C5 as a template [95 . The
porphyrin ring is depicted (in dark), with the centering iron atom as a sphere.
]
Further improvement of the protein models of CYP2D6 was possible after the first crystal
structure of a mammalian CYP, rabbit CYP2C5, was solved [96]. Because of the higher 
homology of CYP2C5 with CYP2D6 (40%), compared to CYPs 101 and 102 (15-20%), the 
predictive quality of the new model could be significantly increased [95, 97]. Rigid docking 
of substrates in the protein model resulted in orientations with predicted sites of oxidation
corresponding to experimental product formation. From the rigid docking of 12 ligands into
the protein model, the interacting active site residues were determined. In a comparative 
study of CYP2 family member sequences, 6 substrate recognition sites (SRS) were 
appointed [98]. In analogy, these 6 SRS were identified in CYP2D6, containing in total 22 
residues in the B/C interhelical loop (SRS 1), helices F G and I (SRS 2, 3 and 4 respectively), 
the strands 1-4 and 2-1 of betasheets 1 and 2 (SRS 5) and a part of betasheet 4 (SRS 6). 
This model (shown in Figure 5), was capable of accommodating codeine in the 
experimentally determined orientation [88], and did place the experimentally validated D301 
[99, 100] in the active site, but not as the residue interacting with the basic nitrogen atom. 
So although the protein model predicted D301 to be located in the active site, in many cases 
it was not involved in fixation of the substrate basic nitrogen atom, as it was suggested in
the previous CYP2D6 models. The residue E216 was subsequently proposed to fulfill this 
role [95], and later mutagenesis studies confirmed this prediction [101, 102]. It appeared 
that using the mammalian CYP2C5 crystal structure as a template was indeed a big
improvement for the CYP2D6 homology model. The carboxylate of D301 now appeared to 
21
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form hydrogen bonds with the backbone nitrogen atoms of V119 and F120. This 
phenylalanine, F120 and also F483, were thought to be responsible for -stacking and van 
der Waals interactions with substrates like codeine, and eventually the experimental 
evidence for this was delivered (this thesis and [103, 104]). 
Table 3: Site-directed mutation studies of CYP2D6.
Residue Mutated to Substrates used Possible roles 
P34 S Debrisoquine, bunitrolol Known SNP, small effect on metabolism
[105].
G42 R K V F S E Debrisoquine, bunitrolol Residue appears to be involved with
enzyme stability and membrane anchoring
[105].
F120 A L T S H W M Dextromethorphan, bufuralol,
MAMC, MDMA
Residue involved in binding and
orientation of substrates, although 
mutation and substrate dependent [103,
104], (this thesis).
W128 F MAMC May be involved in porphyrin anchoring
(this thesis). 




Role in fixation of basic nitrogen atom 
present in typical substrates [101, 102]. 
E222 A Bufuralol Residue just out of active site, might have 
a role like E216 [104]. 
R296 C Debrisoquine, bunitrolol Known SNP, no effect on metabolism
[105].
D301 E N G Q A Dextromethorphan, bufuralol,
diclofenac, testosterone, 
tolbutamide, nifedepine 
Residue involved in fixation of substrate
basic nitrogen atom, and/or involved in 
positioning of F120, and contributing to a 
net negative charge of part of the active
site [99-101, 106, 107], (this thesis).
S304 A Metoprolol, propranolol,
debrisoquine
Residue not involved in substrate binding,
mutation does not lead to large changes
in enzyme activity [108]. 
T309 V Dextromethorphan, bufuralol,
MAMC, MDMA
Residue involved in activation of iron 
bound oxygen (this thesis). 
T312 V Dextromethorphan, bufuralol,
MAMC, MDMA
Residue not involved in activation of iron 
bound oxygen, mutation has no effect on
activity (this thesis). 
M374 V Metoprolol Residue seems to be mutated in initial
cloning experiments. Mutation does to
small extent influence regio- and
enantioselective metabolism of metoprolol
[109].
F481 Y N G Metoprolol, debrisoquine,
dextromethorphan
Residue seems to be outside active site.
However mutation leads to lower affinity
to some substrates [110]. 
F483 I W Testosterone,
dextromethorphan, bufuralol,
MAMC, MDMA
Residue involved in binding and
orientation of substrates, although 
mutation and substrate dependent [111],
(this thesis). 
S486 T Debrisoquine, bunitrolol Known SNP, no effect on metabolism
[105].
 = deletion of residue
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Novel high resolution crystal structures of CYP2C5 with substrates bound [112, 113], made 
it recently possible to further optimize the protein model of CYP2D6 (this thesis and [114]).
This model does not have D301 positioned in the active site anymore, and the active site 
has a more closed conformation, due to incorporation of the F/G-loop, which was not
resolved in the former CYP2C5 crystal structure. Applications of this new CYP2D6 model
show good correlations with experimental data (this thesis and [75, 114]). The new model
could be used to rationalize experimental findings with substrate interacting residues like 
F120, and it could also be used to predict active site residues involved in the mechanism of 
oxidation (this thesis).
Site directed mutagenesis studies of CYP2D6 
Predictions of active site residues crucial for the functioning of CYP2D6, based upon 
substrate and protein models of CYP2D6 were usually validated by site-directed
mutagenesis studies. An overview of these studies is given in Table 3. The residues of 
interest are listed together with the mutations and the postulated functions of the residues. 
As yet, D301 is the most studied residue. It was first indicated as the active site carboxylate 
involved in fixation of the substrate basic nitrogen atom and the first residue subjected to
site directed mutagenesis. Although mutation of this amino acid led to a decreased CYP2D6 
activity, in the latest models it appears not to be in the active site. Instead, another active 
site carboxylate, E216, was suggested to be primarily involved in binding of substrate basic 
nitrogen atom. Besides one or two carboxylates, active site phenylalanines, F120, F481 and
F483, were thought to interact with the aromatic moiety present in most CYP2D6 
substrates. After mutagenesis of any of these, the catalytic activity of CYP2D6 decreased. 
The negative effect on the catalytic activity of mutating D301 is thought to be indirect. D301
is suggested to position the active site substrate aromatic moiety interacting F120, thereby 
affecting substrate binding. Several more distal active site residues are probably also 
interacting with the larger substrates, so more mutagenesis studies are required still (this 
thesis).
Table 4: Biophysical techniques used to study the structure and structural changes of CYPs.
Technique Type of information obtained CYP studied
X-ray 3D structure [46, 115]. 101, 102, 2C5, 
2C9, 3A4 
UV-Vis Spin state, oxidation state, active oxygen species, ligand
binding, active enzyme quantitation [8, 116, 117]. 
101 many 
others
Raman Spin state, oxidation state, coordination number, ligand 
binding, porphyrin conformation [118]. 
101, 102, 1A2, 
3A4
Infrared CO and NO binding, effect substrate binding, active site
conformation [119]. 
101, 102 
Mossbauer Iron electronic stucture [120]. 101
NMR 3D structure and substrate active site orientations [121, 
122].
101, 102, 1A2, 
2C9, 2D6 
EMR Spin state and ligation, oxygenating species lifetimes [123]. 101, 102 
Fluorescence Intraprotein distances, protein to ligand distances, protein
conformational changes [124]. 
101, 11A1, 2B4
AFM/STM Shape and interaction with membrane and other proteins
[125].
101, 2B4
Mass spectrometry Covalent interactions, active site topology [126]. 2C9, 2E1 
Cyclic voltametry Iron electronic stucture [127]. 2C9
Chemical probes Topology of active site cavity [128]. 101, 2D6, 3A4 
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Biophysical studies on cytochromes P450 
Complementary to mutagenesis studies, structural information on CYPs can also be obtained
by using a variety of spectroscopic and other biophysical techniques. The obtained data is 
usually interpreted in combination with a protein model in order to determine the 
mechanism by which the CYP is functioning. The most relevant techniques to study CYPs
are briefly introduced below and an overview is given in Table 4.
Table 5 Overview of the currently available crystal structures of CYP isoforms. modified from de Graaf 
et al (2005) [75]. 
:
CYP Species Ligands mutants PDB



























152A1 Bacilis subtilis Palmitoleic acid 1IZO
154A1 Streptomyces coelicolor A3 4-phenylimidazole 1ODO
154C1 Streptomyces coelicolor A3 1GWI




EpoK Sorangium cellulosum Epothilone B and D 1WIY
1Q5E
OxyB Amycolatopsis orientalis 1LFK
OxyC Amycolatopsis orientalis 1UED



















2A6 Homo sapiens Coumarin, methoxsalen a 1Z10
2C8 Homo sapiens Palmitic acid a 1PQ2
2C9 Homo sapiens S-warfarin, S-flurbiprofen a 1R9O
3A4 Homo sapiens Progesterone, metyrapone a 1TQN
2D6 Homo sapiens 2F9Q
aall mammalian CYPs contain non-active site mutations to improve the crystallization. The PDB codes of 




The common way of obtaining three-dimensional structural information is by using X-ray 
diffraction on crystallized molecules. The bacterial CYPs 101 and 102 are soluble, relatively 
easily expressed and purified, hence these were the first to be crystallized [82, 86, 129]. In 
the absence of crystallized mammalian CYPs, initially the bacterial CYP X-ray structures were 
used as templates for computer homology models of mammalian CYPs (vide supra).  Later
other bacterial and fungal CYPs [130-132], and recently also mammalian CYPs were
crystallized [112, 133]. To make crystallization of mammalian CYPs possible, the membrane-
anchoring N-termini had to be removed and other residues were mutated too. It still needs 
to be determined whether these modifications influence the overall structure. Substrate free
rabbit CYP2B4 crystallized as a dimer, with H226 of the one monomer attached to the heme 
iron atom of the second. This can be an artifact of the crystallization instead of a functional
conformation, which would implicate large conformational changes upon substrate binding 
[134]. Recently, the human CYPs 2C9, 3A4 and 2A6 were crystallized with and without 
substrates [46, 135, 136]. Nevertheless, some skepticism about the resemblance of the 
crystallized protein to the wild-type membrane bound protein still exists, because the 
mutated crystallized CYP2C9 for example, although still active, displayed different kinetic 
behavior compared to the wild-type enzyme [135]. An overview of the currently crystallized
CYPs is presented in Table 5. 
Electronic absorption spectroscopy 
CYPs are brown-red colored enzymes, because of the typical light absorbance of their heme 
prosthetic group [8, 137]. Because of the heme porphyrin and the exceptional 5th ligand 
being a cysteine sulfur atom, CYPs display an absorption spectrum with an intense Soret 
band at about 418 nm, a -band at 385 nm and two Q-bands at about 535 and 560 nm 
(Figure 6) [8]. CYPs can bind CO instead of O2 when the iron is in the ferrous state. This is
not uncommon for heme proteins but due to the cysteine ligand, axial CO binding yields a 
typical absorbance maximum around 450 nm. This characteristic was used to name the 
enzymes, and can also be used to quantify them, as the extinction coefficient was
determined [8, 138]. Other features that can be obtained from the Soret maximum in the
absorbance spectrum are the oxidation state and the spin state of the heme iron atom. The
latter feature can be used to quantify saturation of ligand binding when this competes with 
the binding of the water molecule which is present in the resting state. Thus, dissociation 
constants can be estimated [116].
The optical spectra of CYPs are very sensitive to heme ligation, so UV-vis spectroscopy is 
also an ideal technique to study the oxidized heme intermediates of the catalytic cycle 
(Figure 2). Because these species are very short-lived (microseconds), stop-flow or freeze-
quenching techniques need to be combined with spectroscopy to detect the intermediates 
[139]. This way the primary reduced oxy-P450 species in CYP101 was identified at 77 K as a
superoxo- or hydroperoxo-Fe3+ heme complex. The primary intermediate, a hydroperoxo 
species, was stable below 180 K and converted smoothly to the product complex at 
approximately 195 K. In the course of the thermal annealing, no spectral changes indicating 
the presence of an oxoferryl species (compound I) were observed [117]. Later the oxoferryl 
species was detected, when iron-oxo intermediates of substrate free CYP101 were formed
using peracids [120, 140]. But these studies were contradictory in whether a porphyrin -
cation radical system was formed or a tyrosine radical. Formation of either of these two 
radicals was found to be pH dependent [141]. Furthermore, the structures of the camphor 
analog substrates could influence the physical (spectroscopic) properties of the heme
dioxygen complex and could also affect its reactivity. This indicated that the ability of
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substrates to modulate the reactivity of oxygen intermediates could be a relevant factor in 
explaining the remarkable diversity of reactions catalyzed by the enzyme [142]. So far the 
application of the stop-flow and freeze-quenching techniques combined with electronic 
absorption spectroscopy has been limited to bacterial CYPs. 
Another tool used in combination with absorbance spectroscopy to examine the 
conformation of CYP active sites, is laser driven photodissociation (flash photolysis) of 
heme-bound CO. For instance, this technique was applied to study human CYP2E1. It was 
found that ethanol decreased the rate of CO binding in CYP2E1 whereas arachidonic acid 
completely abolished the photodissociation of CO, confirming the modeled hydrophobic
substrate binding pocket of the enzyme [143].













Figure 6  Absolute absorbance spectra of ferric (black) and ferrous CO-bound (gray) CYP2D6. An
enlarged 500-600 nm region of the ferric enzyme is inserted to show the Q-bands.
:
Vibration spectroscopy 
The two forms of vibration spectroscopy, infrared (IR) and Raman spectroscopy, have been 
used to study CYPs. Although both methods are relatively insensitive, the high light 
absorbance of the heme makes resonance Raman spectroscopy a useful tool to study CYPs
[118, 144-148]. From Raman spectra information on heme iron spin state, oxidation state 
and coordination number can be obtained. Furthermore, vibrations of the porphyrin vinyl
and propionate side chains, and heme bound CO are sensitive to active site conformations.
A resonance Raman spectroscopy study on rabbit CYP2B4 and CYP1A2 revealed that while 
in CYP2B4 the six-coordinated low-spin configuration is predominantly occupied, in CYP1A2 
it is the five-coordinated high-spin form [118, 145]. This was attributed to the structures of 
the active sites. In the low-spin form of CYP2B4 the protein matrix forces the heme into a 
more rigid conformation than in CYP1A2. The vibrational modes of the vinyl groups were 
found to be characteristic markers for the specific structures of the heme pockets in both 
isoforms as they responded sensitively to substrate binding. The resonance Raman
technique can make structural changes visible which are induced by substrate binding in 
addition and independent of the changes associated with the shift of the spin state 
equilibrium: the high-spin states in the substrate-bound and substrate-free enzyme were 
found to be structurally different. The formation of the inactive form, P420, involves a 
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severe structural rearrangement in the heme-binding pocket leading to drastic changes of 
the vinyl group conformations. The conformational differences of the active sites in CYPs
1A2 and 2B4, indicate a structural basis accounting for the substrate specificity of CYPs. An 
advantage of using Raman spectroscopy is the ability to calculate and predict Raman 
frequencies [149, 150], which has not yet been described for the electronic absorption 
spectroscopy.
Fourier transform IR spectroscopy (FTIR) was applied to CYP101 to study the binding of O2
by using the model ligands CO and NO [119, 151]. Thus it was found that sterical 
hindrance, substrate mobility, and protein flexibility determine the position and width of the 
CO-stretching mode signals. The technique is much more insensitive (mM protein needed)
than resonance Raman scattering and the examination of model ligand vibrations can in 
general not be performed in water as this is IR active. Nevertheless, it could also be used to
estimate reduction rates following photoinduced electron transfer from covalently linked 
Ru(bpy)32+ to CYP101 [152].
Mössbauer spectroscopy 
The iron isotope 57Fe can sensitively absorb gamma-radiation by the so-called Mössbauer 
effect. The transmission spectrum obtained can be used to determine the iron electronic 
structure of a CYP which is changing through the catalytic cycle [153]. Mössbauer 
spectroscopy was used to study CYP101 already in 1973 [154], and it has recently gained 
new interests, as a tool to study the heme iron electronic structure in CYPs since fast freeze-
quenching techniques have become available [120, 155]. Thus it was found that 
approximately 10% of freeze quenched 57Fe labeled CYP101 is a FeIV species with a tyrosine
radical (active site Y96 in the wild-type and Y75 in the Y96F mutant) after 8 ms reaction
time in presence of peroxy acetic acid, as assigned by its Mössbauer signature [156]. The
long measuring time to obtain Mössbauer spectra however (up to three weeks) probably 
makes this technique unsuitable for studying mammalian CYPs.
Nuclear magnetic resonance (NMR) 
The heme iron atom of a CYP is paramagnetic when in oxidized state. This is an
experimentally useful characteristic, which can be used to measure orientations of
substrates bound in the active site of the enzyme by measuring spin lattice relaxation NMR
[88, 121, 157, 158]. Hydrogen atoms in a magnetic field will re-align in the direction of this 
field after their orientation has been flipped with a radio-frequency pulse. The velocity of 
this re-alignment, or relaxation back in the lattice, is dependent on the local strength of the 
magnetic field in the direct proximity of the hydrogen atom. So a substrate hydrogen atom 
close to the heme in the active site of a CYP, will relax faster due to the magnetic moment 
of the heme iron atom. The relationship between the iron atom to hydrogen atom distance,
and the rate of relaxation has been established by Solomon and Bloembergen [159], and
can be used to measure substrate orientations in CYP active sites (example of caffeine in
CYP1A2 is shown in Figure 7). A disadvantage of the technique is that high concentrations
of ligands (mM) need to be present to measure NMR spectra and this can be a problem with 
poorly soluble compounds. Furthermore, average substrate active site orientations do not
always match the metabolic profile [158]. An overview of reported spin lattice relaxation 
studies using CYPs is given in Table 6. In most of the cases the catalytic site of the 
substrate was found closest to the heme iron atom, but in many occasions the range of
distances is not as large as the substrate itself. 
NMR methods (1H-15N correlations) have also been used to solve the solution 3D structure
of CYP101. Furthermore, the effects of interactions of CYP101 with its protein partner 
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putidaredoxin [122], and also with substrates [160] were studied using NMR methods. A 
clear advantage of this technique to solve 3D structures is that no crystals are needed and 
that solution structures are probably a better model for physiological conditions. However, a 
disadvantage for using this technique in the study of mammalian CYPs is the millimolar 








Figure 7: NMR inversion recovery spectra of 25 mM caffeine in the absence (A) or presence (B) of 3.5 
M CYP1A2. The glycerol, HDO and C8 hydrogen signals have been deleted. Taken from [158]. 
Table 6: Spin lattice relaxation NMR studies used to determine active site ligand orientations in CYPs.
CYP Ligand Distances (Å)* Major reaction Reference
102 12-Br-lauric acid 7.8 (C1H)-16.3 (C12H) C2-OH [161]
1A Paracetamol 5.9 (phenylH)-6.7 (methylH) Benzoquinone
formation
[121]
1A2 Caffeine 6.5 (N1-methylH)-6.7
(N3 and N7 methylH) 
N1-demethylation [158]




5.4 (C5H of thiophene)-7.1 (phenylH)
6.0 (C4-11H)-6.6 (C2H and C12H)










3.4 (NCH3)- 11.9 (C9H) 










*The minimal and maximal hydrogen atoms to heme on atom measured are given.ir
t t
1Measured in the 
F483I mutant of CYP2D6, the wild-type is inac ive towards tes osterone.
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Electron magnetic resonance (EMR) 
Electron magnetic resonance (EMR) is the generic name for magnetic resonance
spectroscopy involving free or unpaired electrons, and includes electronic paramagnetic
resonance (EPR), electron spin resonance (ESR) and electron nuclear double resonance
(ENDOR). These techniques are successfully applied to CYPs to measure the heme iron spin 
state and ligation [163, 164]. Because the rhombicity of the EPR signal is dependent on the 
ligation of the heme iron, thiolate ligation could be distinguished from thiolate combined 
with distal glutamate ligation in the A264E mutant of CYP102 [147]. 
EPR/ENDOR studies have also been carried out on oxyferrous wild-type and the T252A
mutant of CYP101, after one-electron cryoreduction by gamma-irradiation at 77 K in the
absence of substrate and in the presence of a variety of substrates. The properties and
reactivity of the oxyheme were modulated by the bound substrates. The presence of a 
substrate increased the lifetime of a hydroperoxo iron species in CYP101 about 20-fold. 
Thus these observations showed that substrates influence the properties of the iron-bound 
oxygen intermediates. Furthermore, because of the observed differences between the
T252A and the wild-type enzyme, also the proton-delivery network to the heme appeared to 
be disrupted substrate dependent [41]. 
Fluorescence spectroscopy 
Inter- and intra-protein distances in CYPs have been measured by using various
fluorescence spectroscopy techniques. First of all, fluorescent probes can be (covalently) 
attached to a CYP, thus using the fluorescence intensity as a measure for distances from the 
probe to the quenching heme or to interacting proteins. Thus, by labeling the CPR with a 
coumarin based fluorophore, the interactions of the CPR with CYP2B4 were studied [165]. 
In another study, after labeling of a single lysine residue with a fluorescein isothiocyanate
fluorophore, Förster resonance energy transfer (FRET) quenching was measured in
CYP11A1, enabling to estimate the distance between K338 and the heme group as well as 
the changes in this distance upon substrate binding and interactions with other proteins and 
phospholipids [166]. Also fluorescent ruthenium probes have been attached through a linker 
to a substrate in CYP101, allowing to measure distances, probe-protein interactions and
heme photo-reduction rates (nanoseconds) [167, 168].
An elegant way in which the protein itself is not modified is by measuring the fluorescence
of endogenous tryptophan residues. This way, distances of different parts of the protein to
the quenching heme center have been measured of wild-type and Y96A mutant CYP101 in 
absence and presence of various substrates, leading to insights in the dynamics of the 
enzymes [124, 169]. Furthermore, accessibilities of the tryptophan residues by quenchers 
gave information about their positions in the protein during the binding of a substrate.
Atomic force/scanning tunneling microscopy 
The structure of mammalian CYPs in their native environment of the phospholipid bilayer is 
critical for understanding their activity. Therefore solubilized purified CYP2B4 was 
incorporated into phospholipid bilayer nanostructures (nanodiscs) and oriented on a surface
for visualization by atomic force microscopy (AFM) [125]. Individual CYP molecules were 
shown to be protruding 3.5 nanometers from the bilayer surface, indicating that the 
enzymes are buried deep into the membrane and not only attached through their 
membrane anchor.
Scanning tunneling microscopy (STM) was used to study the complexes of the K344C
mutant of CYP101 and putidaredoxin on a gold surface. STM imaging of a 1:1 mixture of the 
two proteins showed a regular array of pairs of different-sized proteins 20-25 Å apart 
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arranged in rows across the gold surface, which could be attributed to the formation of a 
complex. The redox centers of the two proteins were approximately 20 Å apart, too far for 
rapid intracomplex electron transfer, so whether the observed complex is competent for 
electron transfer or physiologically relevant remains to be elucidated [170]. 
Mass spectrometry 
Mass spectrometry (MS), was successfully employed to study covalent interactions between 
reactive intermediates and the CYP that formed them [126, 171]. Analysis of the tienilic acid
adducts to CYP2C9 after irreversible inhibition with this compound, revealed the active site
residues to which these adducts bound [126].
Rabbit CYP2E1 is irreversibly inhibited by tert-butyl acetylene (tBA), which forms heme-
adducts as observed from the fragmentation patterns in the MS spectrum. The T303A
mutant of the enzyme however, was only reversibly inactivated by tBA, unless the samples 
were pre-acidified, then also the same fragmentation patterns were detected. These results 
suggested a role for the highly conserved threonine 303 residue in proton donation to the 
CYP2E1 active site and thereby stabilizing a reactive intermediate during substrate 
metabolism by CYP2E1 [171]. 
Potentiometry and voltammetry
Substrate binding is thought to trigger electron transfer in CYPs 101 and 102 by inducing a
shift from a low- to high-spin ferric heme and increasing the heme reduction potential [115, 
172]. Whether the combination of change in reduction potential and the change in iron spin 
state is the trigger to start the catalytic cycle, or if either of the two is sufficient, is still 
under debate [30, 31, 173, 174]. Therefore, the changes in reduction potential of CYPs have 
been measured in defined parts of the catalytic cycle, upon substrate binding or after 
mutagenesis [147]. It was found that by mutating F393, the reduction potential of CYP102 
could be modulated, depending on the residue introduced [172]. The potential of the wild-
type enzyme appeared to be optimal for a maximal overall turnover rate. Later it was shown 
by Raman spectroscopy that the size of residue 393 also influences the porphyrin vinyl and 
propionate conformations, which might subsequently influence the heme redox potential
[175].
In some studies CYPs have been immobilized on electrodes to study their redox properties.
For instance, CYP102 could be studied when immobilized in a didodecyldimethylammonium
bromide film cast on an edge-plane graphite electrode [176]. In a setting like this it may 
also be possible to donate electrons to the CYP without the requirement of coenzymes and 
cofactors, which would be beneficial in the development of a CYP based bioreactor [176].
Using CYP2B4 immobilized on clay-modified glassy carbon electrodes in the presence of the 
nonionic detergent Tween 80, it was possible to metabolize several substrates such as 
aminopyrine and benzphetamine [177]. However the turnover rates were slow (aminopyrine
N-demethylation: 0.04 min-1) and high concentrations (mM) of substrates were needed to
measure activity.
Cyclic voltammetry has also been used to study the iron electronic structure of the human 
CYP2C family members in presence of various substrates. The electrochemistry of human 
CYP2C9 was influenced by both pH and ionic strength and a substrate dependent anodic 
shift in the reduction potential was observed. These results suggest alternative mechanisms 
by which CYP2C9 (and by inference other P450 enzymes) may alter the reduction potential




Diazene-containing probes have been used to sample active site cavities of CYPs [106, 128]. 
These probes will label porphyrin nitrogen atoms on the positions where they sense the 
least sterical hindrance from active site residues and can thus be used to give information
on the topology of the CYP active site. In this way, the role of D301 in CYP2D6 was 
examined, and the modeled prediction of charge pairing with the substrate positive charge 
was validated [106].
In another study, the active site topology of CYP3A4 was examined using phenyldiazene. 
After incubation all the four potential N-phenylprotoporphyrin regioisomers were formed. 
Further study using active site mutants, showed that substitution of residues close to the 
heme, caused large changes in regioisomer formation, which reflected the location of these 
amino acid residues in a CYP3A4 homology model. Regioisomer formation was also 
compared in the absence and in the presence of CPR, cytochrome b5, or both. Formation of 
all four regioisomers in CYP3A4 was reduced in the presence of both CPR and cytochrome
b5, mutation dependent, suggesting that conformational changes occur due to protein-
protein interactions between CYP3A4, the CPR, and cytochrome b5 [50].
Scope and objectives of this thesis 
As outlined above, CYP2D6 is one of the most important enzymes in human drug 
metabolism. It is involved in the oxidative metabolism of a large number of clinically 
relevant drugs and furthermore there is a wide variability of the enzyme activity in different
human populations [64, 76, 179]. It would be a great advantage if the metabolism of new 
chemical entities and drug-candidates could be rationalized and predicted in the early stages
of drug discovery and development. Therefore increasing the understanding of the 
structure, dynamics and functioning of CYP2D6 has been the major objective of this thesis. 
This goal was approached, by studying the major factors that may determine the substrate 
binding, the activity, and the regio- and stereoselectivity of CYP2D6. The impact of these 
factors on the functioning of CYP2D6 will subsequently be addressed in this thesis:
(i) First of all, the active site topology may dictate substrate binding and conversion by 
specific interactions with the compound, or by steric restriction. By studying binding and 
metabolism of series of compounds [180], by performing site-directed mutagenesis [99],
and by computer modeling of the CYPs [95], critical interaction points in the active site CYPs 
will be determined.
(ii) At second, the nature of oxygenating species can determine CYP activity and 
regioselectivity. In studies using artificial oxidants to activate CYPs [32], and in studies using
active site threonine mutants of CYPs [37], the existence of multiple oxygenating species
has been evaluated before. In these studies it was found that regioselectivity in catalysis 
could be manipulated, apparently by changing the balance of the reactive oxygen species.
(iii) At third, based on previous studies on other CYPs it is thought that the heme 
configuration can also influence the activity. Originally, changes in the heme iron spin state
were related to substrate binding [30], later it was found that also other porphyrin
characteristics, like sidechain conformations are influenced by the binding of substrates and 
by mutation of active site residues [172, 175].
(iv) Finally, the overall (changes in) conformation of the CYP during the catalytic cycle may 
allow for substrates to enter the active site and substrate active site mobility may determine 
the regioselectivity. Large conformational changes have been proposed for CYP2C9 upon
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substrate binding, based on its crystallized structures in the presence and absence of 
substrates [135]. For CYP101, fluorescence spectroscopy was employed to determine 
conformational changes upon substrate binding [124], indicating that conformational 
changes can be measured, and crystallization of CYPs is not necessary to predict enzyme 
dynamics.
These four factors (i-iv) will be addressed in the following chapters. 
Ad i: At the start of this study in 2001, a new homology model of CYP2D6 was being
developed [95]. This model had good predictive qualities concerning the active site 
orientations of substrates and also predicted positions of residues in the active site.
According to the model, two active site phenylalanine residues were proposed to play an 
important role in substrate interaction in CYP2D6. Therefore, in Chapters 2 and 3 the 
active site residues F120 and F483 are experimentally studied by site-directed mutagenesis. 
Their individual roles in interaction with typical substrates are described in these chapters 
and a comparison between the two is made in Chapter 4. In this chapter, also additional 
active site residues involved in substrate interaction are predicted based upon experimental 
data and computational predictions. The first practical objective for these studies was the 
recombinant expression and subsequent purification of CYP2D6. The human CYP1A2 was 
already expressed in E coli [181], but without the CPR needed to measure activity, nor 
without an affinity tag to ease purification. It was reported that CYP2D6 could be expressed 
and purified in high amounts via a histidine tag [88, 182], and it was also co-expressed with 
CPR [101], but these two aspects were not combined before in a single expression system. 
This is also described in chapters 2,3 and 4. 
Besides determining substrate affinity, the active site topology also influences the 
orientation of the substrate, thereby determining regio- and stereoselectivity. Therefore spin 
lattice relaxation NMR was employed to study active site substrate orientations in CYP2D6, 
in Chapter 6. Spin lattice relaxation NMR was used before to measure differences in the
active site orientation of paracetamol in rat CYPs 1A and 2B [121]. In this study, the active
site orientations of the enantiomers of 3,4-methylenedioxymethylamphetamine (MDMA) in 
the active sites of wild-type and F120A mutant CYP2D6 were determined and compared to
automated docking and molecular dynamics simulations of MDMA in the CYP2D6 homology
model. The experimental data are used to validate computational predictions and to study 
the role of residue F120 in substrate binding. 
Ad ii: CYP2D6 can catalyze several types of reactions; even from one single substrate 
different products can be formed that are apparently formed through different mechanisms 
[33, 183]. Besides the active site topology, determining the substrate orientation, an 
additional explanation for this may be the involvement of different oxygenating species in 
the enzyme. In other CYPs multiple oxygenating species have been suggested, each 
responsible for certain reactions. A conserved active site threonine residue was identified in 
rabbit CYPs 2B4 and 2E1 that could influence the balance of these oxygenating species [39]. 
In Chapter 5 the homologous threonine residue, T309, is studied in relation to the 
mechanism of oxidation by CYP2D6 by performing site-directed mutagenesis studies.
Ad iii: The heme configuration of CYP2D6 was studied in Chapter 7 using resonance
Raman spectroscopy. This technique is used to measure the heme iron spin state, 
coordination number, and oxidation state, information that is complementary to that 
obtained from homology modeling. Furthermore, vinyl and propionate vibrations can be
used to yield information on the active site topology. A resonance Raman microscope was
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build and used to measure anionic dyes [184] and by adapting the instrumental setup and 
the sample presentation it could be used to study CYPs. Notably the influence of the T309V 
mutation on the resonance Raman spectrum of CYP2D6 is studied, in order to rationalize the 
effects of the mutation on the CYP2D6 activity. 
Ad iv: In Chapter 8 conformational changes of CYP2D6 upon binding of the model
substrate 7-methoxy-4-(aminomethyl)-coumarin (MAMC) are examined using fluorescence
spectroscopy. The emission lifetimes of fluorescent endogenous tryptophan residues can be
used to study conformational changes in proteins [185, 186]. External quenching with KI or 
acrylamide can add to the information on relative positions of the tryptophan residues. The 
examination of possible FRET pathways enables to study distances between tryptophan 
residues, the (fluorescent) substrate and the heme prosthetic group. Furthermore, by
measuring the anisotropy of MAMC, its active site mobility is examined. The data obtained 
from all these fluorescence spectroscopy approaches can together, in combination with 
computational studies, be used to study CYP2D6 conformational changes upon substrate
binding.
With the site directed mutations (Part I), and the used spectroscopic techniques (Part II),
substrate binding and metabolism has been studied in relation to the conformation of the
prosthetic group and holoenzyme of wild-type and mutants of CYP2D6. Furthermore, the 
active site orientation and mobility of the substrates was examined. All together, by using 
these approaches in combination with molecular modeling, more insights in the functioning
of CYP2D6 have been gained, which was the aim of this thesis-project. 
Chemistry of complex molecules 
At the start of the study described in this thesis in 2001, at the Vrije Universiteit the
‘Chemistry of Complex Molecules’ (CCM) program was launched (www.chem.vu.nl/ccm). 
This program constituted a collaboration of the departments Biochemistry, Analytical 
Chemistry and Applied Spectroscopy, Organic Chemistry, and LACDR-Pharmacochemistry.
The CCM program focused on the integration of a number of chemical disciplines in order to 
gain novel insights into how complex macromolecular systems, like proteins, function in
space and time. The structure, the dynamics and the functioning of cytochromes P450 was
chosen as one of the main subjects in the CCM program. The work described in this thesis 
was performed within the CCM program. 
References
1. Vermeulen NPE, Role of metabolism in chemical toxicity. In: Cytochromes P450 metabolic and 
toxicological aspects (Ed. Ioannides), pp. 29-53. CRC Press, New York, 1996. 
2. van Bladeren PJ, Glutathione conjugation as a bioactivation reaction. Chem Biol Interact 129:
61-76, 2000. 
3. Klaassen CD, Casarett and Doull's toxicology: the basic science of poisons. McGraw-Hill, New
York, 2001. 
4. Verkade PE, Elzas M, van der Lee J, de Wolff HH, Verkade-Sandbergen A and van der Sande
D, Untersuchen uber den fettstoffwechsel. Proc K Ned Akad Wet 35: 251-66, 1932. 
5. Coon MJ, Cytochrome P450: Nature's most versatile biological catalyst. Annu Rev Pharmacol 
Toxicol 45: 1-25, 2005. 
6. Den H, The biological oxidation of 2,2-dimethyloctanoic acid. Biochim Biophys Acta 98: 462-
9, 1965. 
7. Lu AY and Coon MJ, Role of hemoprotein P-450 in fatty acid omega-hydroxylation in a soluble
enzyme system from liver microsomes. J Biol Chem 243: 1331-2, 1968. 
33
General Introduction
8. Omura T and Sato R, The carbon monoxide-binding pigment of liver microsomes. I. Evidence 
for its hemoprotein nature. J Biol Chem 239: 2370-8, 1964. 
9. Garfinkel D, Studies on pig liver microsomes. I. Enzymatic and pigment composition of 
different microsomal fractions. Arch Biochem Biophys 77: 493-509, 1958. 
10. Omura T, Sato R, Cooper DY, Rosenthal O and Estabrook RW, Function of cytochrome P-450
of micosomes. Fed Proc 24: 1181-9, 1965. 
11. Ortiz de Montellano PR, Cytochromes P450: structure, mechanism, and biochemistry. Kluwer 
Academic, New York, 2005. 
12. Nelson DR, Kamataki T, Waxman DJ, Guengerich FP, Estabrook RW, Feyereisen R, Gonzalez 
FJ, Coon MJ, Gunsalus IC, Gotoh O and et al., The P450 superfamily: update on new
sequences, gene mapping, accession numbers, early trivial names of enzymes, and
nomenclature. DNA Cell Biol 12: 1-51, 1993. 
13. Nelson DR, Koymans L, Kamataki T, Stegeman JJ, Feyereisen R, Waxman DJ, Waterman MR,
Gotoh O, Coon MJ, Estabrook RW, Gunsalus IC and Nebert DW, P450 superfamily: update on
new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 6:
1-42, 1996. 
14. Oscarson M and Ingelman-Sundberg M, CYPalleles: a web page for nomenclature of human 
cytochrome P450 alleles. Drug Metab Pharmacokinet 17: 491-5, 2002. 
15. Nelson DR, Zeldin DC, Hoffman SM, Maltais LJ, Wain HM and Nebert DW, Comparison of
cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature
recommendations for genes, pseudogenes and alternative-splice variants. Pharmacogenetics
14: 1-18, 2004. 
16. de la Torre R, Farre M, Ortuno J, Mas M, Brenneisen R, Roset PN, Segura J and Cami J, Non-
linear pharmacokinetics of MDMA ('ecstacy') in humans. Br J Clin Pharmacol 49: 104-109,
2000.
17. Venkatakrishnan K, von Moltke LL and Greenblatt DJ, Human drug metabolism and the 
cytochromes P450: application and relevance of in vitro models. J Clin Pharmacol 41: 1149-
79, 2001. 
18. Kemp CA, Marechal JD and Sutcliffe MJ, Progress in cytochrome P450 active site modeling.
Arch Biochem Biophys 433: 361-68, 2005. 
19. Shimada T, Yamazaki H, Mimura M, Inui Y and Guengerich FP, Interindividual variations in 
human liver cytochrome P450 enzymes involved in the oxidation of drugs, carcinogens and 
toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J
Pharmacol Exp Ther 270: 414-23, 1994. 
20. Jones BC, Tyman CA and Smith DA, Identification of the cytochrome P450 isoforms involved
in the O-demethylation of 4-nitroanisole in human liver microsomes. Xenobiotica 27: 1025-
37, 1997. 
21. Bertilsson L, Dahl ML, Dalen P and Al-Shurbaji A, Molecular genetics of CYP2D6: clinical 
relevance with focus on psychotropic drugs. Br J Clin Pharmacol 53: 111-22, 2002. 
22. Evans WE and Relling MV, Pharmacogenomics: translating functional genomics into rational
therapeutics. Science 286: 487-91, 1999. 
23. Wormhoudt LW, Commandeur JN and Vermeulen NP, Genetic polymorphisms of human N-
acetyltransferase, cytochrome P450, glutathione-S-transferase, and epoxide hydrolase
enzymes: relevance to xenobiotic metabolism and toxicity. Crit Rev Toxicol 29: 59-124, 1999. 
24. Ingelman-Sundberg M, Pharmacogenetics of cytochrome P450 and its applications in drug 
therapy: the past, present and future. Trends Pharmacol Sci 25: 193-200, 2004. 
25. White RE and Coon MJ, Oxygen activation by cytochrome P-450. Annu Rev Biochem 49: 315-
56, 1980. 
26. Guengerich FP, Common and uncommon cytochrome P450 reactions related to metabolism
and chemical toxicity. Chem Res Toxicol 14: 611-646, 2001. 
27. Groenhof AR, Swart M, Ehlers AW and Lammertsma K, Electronic ground states of iron 
porphyrin and of the first species in the catalytic reaction cycle of cytochrome P450s. J Phys 
Chem A 109: 3411-3417, 2005. 
28. Lange R, Hui Bon Hoa G, Debey P and Gunsalus IC, A thermodynamic-kinetic analysis of the 
cytochrome P-450 heme pocket. Acta Biol Med Ger 38: 143-52, 1979. 
34
Chapter 1 
29. Ortiz de Montellano PR and De Voss JJ, Substrate oxidation by cytochrome P450 enzymes. In: 
Cytochrome P450 struc ure, mechanism, and biochemis ry (Ed. Ortiz de Montellano PR).
Kluwer Academic, New York, 2005. 
t t
30. Sligar SG, Coupling of spin, substrate, and redox equilibria in cytochrome P450. Biochemistry
15: 5399-406, 1976. 
31. Lawson RJ, Leys D, Sutcliffe MJ, Kemp CA, Cheesman MR, Smith SJ, Clarkson J, Smith WE,
Haq I, Perkins JB and Munro AW, Thermodynamic and biophysical characterization of
cytochrome P450 BioI from Bacillus subtilis. Biochemistry 43: 12410-26, 2004. 
32. Guengerich FP, Vaz AD, Raner GM, Pernecky SJ and Coon MJ, Evidence for a role of a 
perferryl-oxygen complex, FeO3+, in the N-oxygenation of amines by cytochrome P450
enzymes. Mol Pharmacol 51: 147-151, 1997. 
33. Hutzler JM, Powers FJ, Wynalda MA and Wienkers LC, Effect of carbonate anion on 
cytochrome P450 2D6-mediated metabolism in vitro: the potential role of multiple
oxygenating species. Arch Biochem Biophys 417: 165-175, 2003. 
34. Sligar SG, Lipscomb JD, Debrunner PG and Gunsalus IC, Superoxide anion production by the 
autoxidation of cytochrome P450cam. Biochem Biophys Res Commun 61: 290-6, 1974. 
35. Goeptar AR, Scheerens H and Vermeulen NPE, Oxygen and xenobiotic reductase activities of 
cytochrome P450. Crit Rev Toxicol 25: 25-65, 1995. 
36. Raag R, Martinis SA, Sligar SG and Poulos TL, Crystal structure of the cytochrome P-450CAM
active site mutant Thr252Ala. Biochemistry 30: 11420-9, 1991. 
37. Vaz AD, Pernecky SJ, Raner GM and Coon MJ, Peroxo-iron and oxenoid-iron species as 
alternative oxygenating agents in cytochrome P450-catalyzed reactions: switching by
threonine-302 to alanine mutagenesis of cytochrome P450 2B4. Proc Natl Acad Sci U S A 93:
4644-8, 1996. 
38. Vaz AD, McGinnity DF and Coon MJ, Epoxidation of olefins by cytochrome P450: evidence
from site-specific mutagenesis for hydroperoxo-iron as an electrophilic oxidant. Proc Natl 
Acad Sci U S A 95: 3555-60, 1998. 
39. Coon MJ, Vaz AD, McGinnity DF and Peng HM, Multiple activated oxygen species in P450
catalysis: contributions To specificity in drug metabolism. Drug Metab Dispos 26: 1190-3,
1998.
40. Chandrasena RE, Vatsis KP, Coon MJ, Hollenberg PF and Newcomb M, Hydroxylation by the
hydroperoxy-iron species in cytochrome P450 enzymes. J Am Chem Soc 126: 115-26, 2004. 
41. Davydov R, Perera R, Jin S, Yang TC, Bryson TA, Sono M, Dawson JH and Hoffman BM,
Substrate modulation of the properties and reactivity of the oxy-ferrous and hydroperoxo-
ferric intermediates of cytochrome P450cam as shown by cryoreduction-EPR/ENDOR
spectroscopy. J Am Chem Soc 127: 1403-13, 2005. 
42. Newcomb M, Hollenberg PF and Coon MJ, Multiple mechanisms and multiple oxidants in
P450-catalyzed hydroxylations. Arch Biochem Biophys 409: 72-9, 2003. 
43. Shaik S, Kumar D, de Visser SP, Altun A and Thiel W, Theoretical perspective on the structure
and mechanism of cytochrome P450 enzymes. Chem Rev 105, 2005. 
44. Shaik S, de Visser SP and Kumar D, One oxidant, many pathways: a theoretical perspective of
monooxygenation mechanisms by cytochrome P450 enzymes. J Biol Inorg Chem 9: 661-8,
2004.
45. Wade RC, Winn PJ, Schlichting I and Sudarko, A survey of active site access channels in 
cytochromes P450. J Inorg Biochem 98: 1175-82, 2004. 
46. Williams PA, Cosme J, Vinkovic DM, Ward A, Angove HC, Day PJ, Vonrhein C, Tickle IJ and
Jhoti H, Crystal structures of human cytochrome P450 3A4 bound to metyrapone and
progesterone. Science 305: 683-6, 2004. 
47. Ludemann SK, Lounnas V and Wade RC, How do substrates enter and products exit the
buried active site of cytochrome P450cam? 1. Random expulsion molecular dynamics
investigation of ligand access channels and mechanisms. Journal of Molecular Biology 303:
797-811, 2000. 
48. Kelley RW, Reed JR and Backes WL, Effects of ionic strength on the functional interactions 
between CYP2B4 and CYP1A2. Biochemistry 44: 2632-41, 2005. 
35
General Introduction
49. Backes WL and Kelley RW, Organization of multiple cytochrome P450s with NADPH-
cytochrome P450 reductase in membranes. Pharmacol Ther 98: 221-33, 2003. 
50. Yamaguchi Y, Khan KK, He YA, He YQ and Halpert JR, Topological changes in the CYP3A4
active site probed with phenyldiazene: effect of interaction with NADPH-cytochrome P450
reductase and cytochrome b5 and of site-directed mutagenesis. Drug Metab Dispos 32: 155-
61, 2004. 
51. Guengerich FP, Cytochrome P450: what have we learned and what are the future issues?
Drug Metab Rev 36: 159-97, 2004. 
52. Allen JG, East PB, Francis RJ and Haigh JL, Metabolism of debrisoquine sulfate. Identification
of some urinary metabolites in rat and man. Drug Metab Dispos 3: 332-7, 1975. 
53. Mahgoub A, Idle JR, Dring LG, Lancaster R and Smith RL, Polymorphic hydroxylation of
Debrisoquine in man. Lancet 2: 584-6, 1977. 
54. Tucker GT, Silas JH, Iyun AO, Lennard MS and Smith AJ, Polymorphic hydroxylation of 
debrisoquine. Lancet 2: 718, 1977. 
55. Boobis AR, Murray S, Kahn GC, Roberts GM and Davies DS, Substrate specificity of the form
of cytochrome P-450 catalyzing the 4-hydroxylation of debrisoquine in man. Mol Pharmacol
23: 474-81, 1983. 
56. Larrey D, Distlerath LM, Wilkinson GR and Guengerich FP, Purification and characterization of 
the rat liver microsomal cytochrome P-450 involved in the 4-hydroxylation of debrisoquine, a
prototype for genetic variation in oxidative drug metabolism. Biochemistry 23: 2787-95,
1984.
57. Distlerath LM, Reilly PE, Martin MV, Davis GG, Wilkinson GR and Guengerich FP, Purification 
and characterization of the human liver cytochromes P-450 involved in debrisoquine 4-
hydroxylation and phenacetin O-deethylation, two prototypes for genetic polymorphism in
oxidative drug metabolism. J Biol Chem 260: 9057-67, 1985. 
58. Eichelbaum M, Baur MP, Dengler HJ, Osikowska-Evers BO, Tieves G, Zekorn C and Rittner C, 
Chromosomal assignment of human cytochrome P-450 (debrisoquine/sparteine type) to
chromosome 22. Br J Clin Pharmacol 23: 455-8, 1987. 
59. Gonzalez FJ, Matsunaga T, Nagata K, Meyer UA, Nebert DW, Pastewska J, Kozak CA, Gillette 
J, Gelboin HV and Hardwick JP, Debrisoquine 4-hydroxylase: characterization of a new P450
gene subfamily, regulation, chromosomal mapping, and molecular analysis of the DA rat
polymorphism. DNA 6: 149-61, 1987. 
60. Gonzalez FJ, Vilbois F, Hardwick JP, McBride OW, Nebert DW, Gelboin HV and Meyer UA, 
Human debrisoquine 4-hydroxylase (P450IID1): cDNA and deduced amino acid sequence and
assignment of the CYP2D locus to chromosome 22. Genomics 2: 174-9, 1988. 
61. Skoda RC, Gonzalez FJ, Demierre A and Meyer UA, Two mutant alleles of the human 
cytochrome P-450db1 gene (P450C2D1) associated with genetically deficient metabolism of
debrisoquine and other drugs. Proc Natl Acad Sci U S A 85: 5240-3, 1988. 
62. Kimura S, Umeno M, Skoda RC, Meyer UA and Gonzalez FJ, The human debrisoquine 4-
hydroxylase (CYP2D) locus: sequence and identification of the polymorphic CYP2D6 gene, a 
related gene, and a pseudogene. Am J Hum Genet 45: 889-904, 1989. 
63. Løvlie R, Daly AK, Matre GE, Molven A and Steen VM, Polymorphisms in CYP2D6 duplication-
negative individuals with the ultrarapid metabolizer phenotype: a role for the CYP2D6*35
allele in ultrarapid metabolism? Pharmacogenetics 11: 45-55, 2001. 
64. Zanger UM, Raimundo S and Eichelbaum M, Cytochrome P450 2D6: overview and update on 
pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch Pharmacol 369: 23-37,
2004.
65. Rendic S, Summary of information on human CYP enzymes: human P450 metabolism data.
Drug Metab Rev 34: 83-448, 2002. 
66. Pirmohamed M and Park BK, Genetic susceptibility to adverse drug reactions. Trends
Pharmacol Sci 22: 298-305, 2001. 
67. Phillips KA, Veenstra DL, Oren E, Lee JK and Sadee W, Potential role of pharmacogenomics in 
reducing adverse drug reactions: a systematic review. Jama 286: 2270-9, 2001. 
68. Du L, Hoffman SM and Keeney DS, Epidermal CYP2 family cytochromes P450. Toxicol Appl
Pharmacol 195: 278-87, 2004. 
36
Chapter 1 
69. Siegle I, Fritz P, Eckhardt K, Zanger UM and Eichelbaum M, Cellular localization and regional
distribution of CYP2D6 mRNA and protein expression in human brain. Pharmacogenetics 11:
237-45, 2001. 
70. Pai HV, Komaddi RP, Chinta SJ, Mori T, Boyd MR and Ravindranath V, A frameshift mutation
and alternate splicing in human brain generate a functional form of the pseudogene
cytochrome P4502D7 that demethylates codeine to morphine. J Biol Chem 279: 27383-9,
2004.
71. Yu A, Idle JR, Byrd LG, Krausz KW, Kupfer A and Gonzalez FJ, Regeneration of serotonin from
5-methoxytrypamine by polymorphic human CYP2D6. Pharmacogenetics 13: 173-181, 2003. 
72. Yu A, Idle JR, Herraiz T, Kupfer A and Gonzalez FJ, Screening for endogenous substrates
reveals that CYP2D6 is a 5-methoxyindolethylamine O-demethylase. Pharmacogenetics 13:
307-319, 2003. 
73. Yu AM, Idle JR and Gonzalez FJ, Polymorphic cytochrome P450 2D6: humanized mouse
model and endogenous substrates. Drug Metab Rev 36: 243-77, 2004. 
74. Kawanishi C, Lundgren S, Agren H and Bertilsson L, Increased incidence of CYP2D6 gene 
duplication in patients with persistent mood disorders: ultrarapid metabolism of 
antidepressants as a cause of nonresponse. A pilot study. Eur J Clin Pharmacol 59: 803-7,
2004.
75. de Graaf C, Vermeulen NPE and Feenstra KA, Cytochrome P450 in silico: an integrative
modeling approach. J Med Chem 48: 2725-55, 2005. 
76. Vermeulen NPE, Prediction of drug metabolism: the case of cytochrome P450 2D6. Curr Top 
Med Chem 3: 1227-39, 2003. 
77. Wolff T, Distlerath LM, Worthington MT, Groopman JD, Hammons GJ, Kadlubar FF, Prough 
RA, Martin MV and P. GF, Substrate specificity of human liver cytochrome P-450 debrisoquine
4-hydroxylase probed using immunochemical inhibition and chemical modeling. Cancer Res
45: 2116-2122, 1985. 
78. Meyer UA, Gut J, Kronbach T, Skoda C and Meier UT, The molecular mechanisms of two 
common polymorphisms of drug oxidation-evidence for functional changes in cytochrome P-
450 isozymes catalysing bufuralol and mephenytoin oxidation. Xenobiotica 16: 449-464,
1986.
79. Koymans L, Vermeulen NP, van Acker SA, te Koppele JM, Heykants JJ, Lavrijsen K, 
Meuldermans W and Donne-Op den Kelder GM, A predictive model for substrates of
cytochrome P450-debrisoquine (2D6). Chem Res Toxicol 5: 211-9, 1992. 
80. de Groot MJ, Bijloo GJ, Hansen KT and Vermeulen NPE, Computer prediction and 
experimental validation of cytochrome P450-2D6 dependent oxidation of GBR 12909 (1-[2-
[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine). Drug Metab Dispos 23:
667-669, 1995. 
81. de Groot MJ, Bijloo GJ, Martens BJ, van Acker FA and Vermeulen NP, A refined substrate
model for human cytochrome P450 2D6. Chem Res Toxicol 10: 41-8, 1997. 
82. Poulos TL, Finzel BC and Howard AJ, High-resolution crystal structure of cytochrome
P450cam. J Mol Biol 195: 687-700, 1987. 
83. Poulos TL and Howard AJ, Crystal structures of metyrapone- and phenylimidazole-inhibited
complexes of cytochrome P-450cam. Biochemistry 26: 8165-74, 1987. 
84. Raag R and Poulos TL, Crystal structure of the carbon monoxide-substrate-cytochrome P-
450CAM ternary complex. Biochemistry 28: 7586-92, 1989. 
85. Koymans LM, Vermeulen NP, Baarslag A and Donne-Op den Kelder GM, A preliminary 3D
model for cytochrome P450 2D6 constructed by homology model building. J Comput Aided
Mol Des 7: 281-9, 1993. 
86. Ravichandran KG, Boddupalli SS, Hasermann CA, Peterson JA and Deisenhofer J, Crystal 
structure of hemoprotein domain of P450BM-3, a prototype for microsomal P450's. Science
261: 731-6, 1993. 
87. Yeom H, Sligar SG, Li H, Poulos TL and Fulco AJ, The role of Thr268 in oxygen activation of
cytochrome P450BM-3. Biochemistry 34: 14733-40, 1995. 
37
General Introduction
88. Modi S, Paine MJ, Sutcliffe MJ, Lian LY, Primrose WU, Wolf CR and Roberts GC, A model for 
human cytochrome P450 2D6 based on homology modeling and NMR studies of substrate
binding. Biochemistry 35: 4540-50, 1996. 
89. Lewis DF, Eddershaw PJ, Goldfarb PS and Tarbit MH, Molecular modelling of cytochrome
P4502D6 (CYP2D6) based on an alignment with CYP102: structural studies on specific
CYP2D6 substrate metabolism. Xenobiotica 27: 319-39, 1997. 
90. de Groot MJ, Vermeulen NP, Kramer JD, van Acker FA and Donne-Op den Kelder GM, A three-
dimensional protein model for human cytochrome P450 2D6 based on the crystal structures
of P450 101, P450 102, and P450 108. Chem Res Toxicol 9: 1079-91, 1996. 
91. de Groot MJ, Ackland MJ, Horne VA, Alex AA and Jones BC, A novel approach to predicting
P450-mediated drug metabolism: Development of a combined protein and pharmacophore
model for CYP2D6. J Med Chem 42: 1515-1524, 1999. 
92. De Rienzo F, Fanelli F, Menziani MC and De Benedetti PG, Theoretical investigation of 
substrate specificity for cytochromes P450 IA2, P450 IID6 and P450 IIIA4. J Comput Aided
Mol Des 14: 93-116, 2000. 
93. de Groot MJ, Ackland MJ, Horne VA, Alex AA and Jones BC, A novel approach to predicting
P450 mediated drug metabolism. CYP2D6 catalyzed N-dealkylation reactions and qualitative
metabolite predictions using a combined protein and pharmacophore model for CYP2D6. J
Med Chem 42: 4062-4070, 1999. 
94. Ekins S, de Groot MJ and Jones JP, Pharmacophore and three-dimensional quantitative
structure activity relationship methods for modeling cytochrome P450 active sites. Drug
Metab Dispos 29: 936-44, 2001. 
95. Venhorst J, ter Laak AM, Commandeur JNM, Funae Y, Hiroi T and Vermeulen NPE, Homology 
modeling of rat and human cytochrome P450 2D (CYP2D) isoforms and computational
rationalization of experimental ligand-binding specificities. J Med Chem 46: 74-86, 2003. 
96. Williams PA, Cosme J, Sridhar V, Johnson EF and McRee DE, Microsomal cytochrome P450 
2C5: comparison to microbial P450s and unique features. J Inorg Biochem 81: 183-90, 2000. 
97. Kirton SB, Kemp CA, Tomkinson NP, St-Gallay S and Sutcliffe MJ, Impact of incorporating the
2C5 crystal structure into comparative models of cytochrome P450 2D6. Proteins 49: 216-31,
2002.
98. Gotoh O, Substrate recognition sites in cytochrome P450 family 2 (CYP2) proteins inferred
from comparative analyses of amino acid and coding nucleotide sequences. J Biol Chem 267:
83-90, 1992. 
99. Ellis SW, Hayhurst GP, Smith G, Lightfoot T, Wong MM, Simula AP, Ackland MJ, Sternberg MJ, 
Lennard MS and Tucker GT, Evidence that aspartic acid 301 is a critical substrate-contact
residue in the active site of cytochrome P450 2D6. J Biol Chem 270: 29055-8, 1995. 
100. Hanna IH, Kim MS and Guengerich FP, Heterologous expression of cytochrome P450 2D6 
mutants, electron transfer, and catalysis of bufuralol hydroxylation: the role of aspartate 301 
in structural integrity. Arch Biochem Biophys 393: 255-61, 2001. 
101. Paine MJ, McLaughlin LA, Flanagan JU, Kemp CA, Sutcliffe MJ, Roberts GC and Wolf CR,
Residues glutamate 216 and aspartate 301 are key determinants of substrate specificity and
product regioselectivity in cytochrome P450 2D6. J Biol Chem 278: 4021-7, 2003. 
102. Guengerich FP, Hanna IH, Martin MV and Gillam EM, Role of glutamic acid 216 in cytochrome 
P450 2D6 substrate binding and catalysis. Biochemistry 42: 1245-53, 2003. 
103. Flanagan JU, Marechal JD, Ward R, Kemp CA, McLaughlin LA, Sutcliffe MJ, Roberts GC, Paine
MJ and Wolf CR, Phe120 contributes to the regiospecificity of cytochrome P450 2D6: 
mutation leads to the formation of a novel dextromethorphan metabolite. Biochem J 380:
353-60, 2004. 
104. Masuda K, Tamagake K, Okuda Y, Torigoe F, Tsuzuki D, Isobe T, Hichiya H, Hanioka N, 
Yamamoto S and Narimatsu S, Change in enantioselectivity in bufuralol 1''-hydroxylation by
the substitution of phenylalanine-120 by alanine in cytochrome P450 2D6. Chirality 17: 37-
43, 2005. 
105. Tsuzuki D, Hichiya H, Okuda Y, Yamamoto S, Tamagake K, Shinoda S and Narimatsu S, 
Alteration in catalytic properties of human CYP2D6 caused by substitution of glycine-42 with
arginine, lysine and glutamic acid. Drug Metab Pharmacokin 18: 79-85, 2003. 
38
Chapter 1 
106. Mackman R, Tschirret-Guth RA, Smith G, Hayhurst GP, Ellis SW, Lennard MS, Tucker GT, Wolf
CR and Ortiz de Montellano PR, Active-site topologies of human CYP2D6 and its aspartate-
301 --> glutamate, asparagine, and glycine mutants. Arch Biochem Biophys 331: 134-40,
1996.
107. Guengerich FP, Miller GP, Hanna IH, Martin MV, Leger S, Black C, Chauret N, Silva JM,
Trimble LA, Yergey JA and Nicoll-Griffith DA, Diversity in the oxidation of substrates by
cytochrome P450 2D6: lack of an obligatory role of aspartate 301-substrate electrostatic
bonding. Biochemistry 41: 11025-34, 2002. 
108. Ellis SW, Hayhurst GP, Lightfoot T, Smith G, Harlow J, Rowland-Yeo K, Larsson C, Mahling J, 
Lim CK, Wolf CR, Blackburn GM, Lennard MS and Tucker GT, Evidence that serine 304 is not
a key ligand-binding residue in the active site of cytochrome P450 2D6. Biochem J 345: 565-
71, 2000. 
109. Ellis SW, Rowland K, Ackland MJ, Rekka E, Simula AP, Lennard MS, Wolf CR and Tucker GT, 
Influence of amino acid residue 374 of cytochrome P-450 2D6 (CYP2D6) on the regio- and 
enantio-selective metabolism of metoprolol. Biochem J 316: 647-54, 1996. 
110. Hayhurst GP, Harlow J, Chowdry J, Gross E, Hilton E, Lennard MS, Tucker GT and Ellis SW,
Influence of phenylalanine-481 substitutions on the catalytic activity of cytochrome P450 2D6.
Biochem J 355: 373-9, 2001. 
111. Smith G, Modi S, Pillai I, Lian LY, Sutcliffe MJ, Pritchard MP, Friedberg T, Roberts GC and Wolf 
CR, Determinants of the substrate specificity of human cytochrome P-450 CYP2D6: design
and construction of a mutant with testosterone hydroxylase activity. Biochem J 331: 783-92,
1998.
112. Wester MR, Johnson EF, Marques-Soares C, Dansette PM, Mansuy D and Stout CD, Structure
of a substrate complex of mammalian cytochrome P450 2C5 at 2.3 A resolution: evidence for
multiple substrate binding modes. Biochemistry 42: 6370-9, 2003. 
113. Wester MR, Johnson EF, Marques-Soares C, Dijols S, Dansette PM, Mansuy D and Stout CD, 
Structure of mammalian cytochrome P450 2C5 complexed with diclofenac at 2.1 A resolution:
evidence for an induced fit model of substrate binding. Biochemistry 42: 9335-45, 2003. 
114. Kemp CA, Flanagan JU, van Eldik AJ, Marechal JD, Wolf CR, Roberts GC, Paine MJ and
Sutcliffe MJ, Validation of model of cytochrome P450 2D6: an in silico tool for predicting
metabolism and inhibition. J Med Chem 47: 5340-6, 2004. 
115. Raag R and Poulos TL, The structural basis for substrate-induced changes in redox potential
and spin equilibrium in cytochrome P-450CAM. Biochemistry 28: 917-22, 1989. 
116. Jefcoate CR, Measurement of substrate and inhibitor binding to microsomal cytochrome P450
by optical-difference spectroscopy. Methods Enzymol 52: 258-79, 1978. 
117. Denisov IG, Makris TM and Sligar SG, Cryotrapped reaction intermediates of cytochrome p450 
studied by radiolytic reduction with phosphorus-32. J Biol Chem 276: 11648-52, 2001. 
118. Hildebrandt P, Garda H, Stier A, Stockburger M and Van Dyke RA, Resonance Raman study of
the cytochrome P-450 LM2-halothane intermediate complex. FEBS Lett 237: 15-20, 1988. 
119. Jung C, Hoa GH, Schroder KL, Simon M and Doucet JP, Substrate analogue induced changes
of the CO-stretching mode in the cytochrome P450cam-carbon monoxide complex.
Biochemistry 31: 12855-62, 1992. 
120. Schunemann V, Jung C, Terner J, Trautwein AX and Weiss R, Spectroscopic studies of 
peroxyacetic acid reaction intermediates of cytochrome P450cam and chloroperoxidase. J
Inorg Biochem 91: 586-96, 2002. 
121. van de Straat R, de Vries J, de Boer HJ, Vromans RM and Vermeulen NPE, Relationship
between paracetamol binding to and its oxidation by two cytochromes P-450 isozymes--a
proton nuclear magnetic resonance and spectrophotometric study. Xenobiotica 17: 1-9, 1987. 
122. Pochapsky TC, Lyons TA, Kazanis S, Arakaki T and Ratnaswamy G, A structure-based model
for cytochrome P450cam-putidaredoxin interactions. Biochimie 78: 723-33, 1996. 
123. Schunemann V, Lendzian F, Jung C, Contzen J, Barra AL, Sligar SG and Trautwein AX, 
Tyrosine radical formation in the reaction of wild type and mutant cytochrome P450cam with
peroxy acids: a multifrequency EPR study of intermediates on the millisecond time scale. J
Biol Chem 279: 10919-30, 2004. 
39
General Introduction
124. Prasad S and Mitra S, Role of protein and substrate dynamics in catalysis by Pseudomonas
putida cytochrome P450cam. Biochemistry 41: 14499-508, 2002. 
125. Bayburt TH and Sligar SG, Single-molecule height measurements on microsomal cytochrome
P450 in nanometer-scale phospholipid bilayer disks. Proc Natl Acad Sci U S A 99: 6725-30,
2002.
126. Koenigs LL, Peter RM, Hunter AP, Haining RL, Rettie AE, Friedberg T, Pritchard MP, Shou M,
Rushmore TH and Trager WF, Electrospray ionization mass spectrometric analysis of intact 
cytochrome P450: identification of tienilic acid adducts to P450 2C9. Biochemistry 38: 2312-
9, 1999. 
127. Johnson DL, Lewis BC, Elliot DJ, Miners JO and Martin LL, Electrochemical characterisation of 
the human cytochrome P450 CYP2C9. Biochem Pharmacol 69: 1533-41, 2005. 
128. Swanson BA, Dutton DR, Lunetta JM, Yang CS and Ortiz de Montellano PR, The active sites of
cytochromes P450 IA1, IIB1, IIB2, and IIE1. Topological analysis by in situ rearrangement of
phenyl-iron complexes. J Biol Chem 266: 19258-64, 1991. 
129. Poulos TL, Perez M and Wagner GC, Preliminary crystallographic data on cytochrome P-
450CAM. J Biol Chem 257: 10427-9, 1982. 
130. Hasemann CA, Ravichandran KG, Peterson JA and Deisenhofer J, Crystal structure and 
refinement of cytochrome P450terp at 2.3 A resolution. J Mol Biol 236: 1169-85, 1994. 
131. Cupp-Vickery JR, Li H and Poulos TL, Preliminary crystallographic analysis of an enzyme
involved in erythromycin biosynthesis: cytochrome P450eryF. Proteins 20: 197-201, 1994. 
132. Park SY, Shimizu H, Adachi S, Nakagawa A, Tanaka I, Nakahara K, Shoun H, Obayashi E, 
Nakamura H, Iizuka T and Shiro Y, Crystal structure of nitric oxide reductase from denitrifying 
fungus Fusarium oxysporum. Nat Struct Biol 4: 827-32, 1997. 
133. Williams PA, Cosme J, Sridhar V, Johnson EF and McRee DE, Mammalian microsomal 
cytochrome P450 monooxygenase: structural adaptations for membrane binding and
functional diversity. Mol Cell 5: 121-31, 2000. 
134. Scott E, He Y, Wester MR, White M, Chin C, Halpert J, Johnson EF and Stout CD, An open 
conformation of mammalian cytochrome P450 2B4 at 1.6-A resolution. Proc Natl Acad Sci U S
A 100: 13196-201, 2003. 
135. Williams PA, Cosme J, Ward A, Angove HC, Matak Vinkovic D and Jhoti H, Crystal structure of 
human cytochrome P450 2C9 with bound warfarin. Nature 424: 464-8, 2003. 
136. Yano JK, Hsu MH, Griffin KJ, Stout CD and Johnson EF, Structures of human microsomal
cytochrome P450 2A6 complexed with coumarin and methoxsalen. Nat Struct Mol Biol 12:
822-3, 2005. 
137. Peterson JA and Coon MJ, Enzymatic omega-oxidation. III. Purification and properties of
rubredoxin, a component of the omega-hydroxylation system of Pseudomonas oleovorans. J
Biol Chem 243: 329-34, 1968. 
138. Omura T and Sato R, The carbon monoxide-binding pigment of liver microsomes. II. 
Solubilization, purification, and properties. J Biol Chem 239: 2379-85, 1964. 
139. Schlichting I, Berendzen J, Chu K, Stock AM, Maves SA, Benson DE, Sweet RM, Ringe D, 
Petsko GA and Sligar SG, The catalytic pathway of cytochrome p450cam at atomic resolution.
Science 287: 1615-22, 2000. 
140. Egawa T, Shimada H and Ishimura Y, Evidence for comppund I formation in the reaction of
cytochrome P450cam with m-chloroperbenzoic acid. Biochem Biophys Res Commun 201:
1464-9, 1994. 
141. Spolitak T, Dawson JH and Ballou DP, Reaction of ferric cytochrome P450cam with peracids. J
Biol Chem 280: 20300-20309, 2005. 
142. Sono M, Perera R, Jin S, Makris TM, Sligar SG, Bryson TA and Dawson JH, The influence of
substrate on the spectral properties of oxyferrous wild-type and T252A cytochrome P450-
CAM. Arch Biochem Biophys 436: 40-9, 2005. 
143. Smith SV, Koley AP, Dai RK, Robinson RC, Leong H, Markowitz A and Friedman FK,
Conformational modulation of human cytochrome P450 2E1 by ethanol and other substrates:
a CO flash photolysis study. Biochemistry 39: 5731-5737, 2000. 
40
Chapter 1 
144. Hildebrandt P, Greinert R, Stier A, Stockburger M and Taniguchi H, Surface enhanced
resonance Raman study of phenobarbital-induced rabbit liver cytochrome P-450 LM2. FEBS
Lett 227: 76-80, 1988. 
145. Hildebrandt P, Greinert R, Stier A and Taniguchi H, Resonance Raman study on the structure
of the active sites of microsomal cytochrome P-450 isozymes LM2 and LM4. Eur J Biochem
186: 291-302, 1989. 
146. Munro AW, Lindsay JG, Coggins JR, MacDonald I, Smith WE and Rospendowski BN,
Resonance Raman spectroscopic studies on intact cytochrome P450 BM3. Biochem Soc Trans
22: 54S, 1994. 
147. Girvan HM, Marshall KR, Lawson RJ, Leys D, Joyce MG, Clarkson J, Smith WE, Cheesman MR
and Munro AW, Flavocytochrome P450 BM3 mutant A264E undergoes substrate-dependent
formation of a novel heme iron ligand set. J Biol Chem 279: 23274-86, 2004. 
148. Wells AV, Li P, Champion PM, Martinis SA and Sligar SG, Resonance Raman investigations of
Escherichia coli-expressed Pseudomonas putida cytochrome P450 and P420. Biochemistry 31:
4384-93, 1992. 
149. Ohta T, Matsuura K, Yoshizawa K and Morishima I, The electronic and vibrational structures
of iron-oxo porphyrin with a methoxide or cysteinate axial ligand. J Inorg Biochem 82: 141-
52, 2000. 
150. Linder DP, Rodgers KR, Banister J, Wyllie GR, Ellison MK and Scheidt WR, Five-coordinate 
Fe(III)NO and Fe(II)CO porphyrinates: where are the electrons and why does it matter? J Am
Chem Soc 126: 14136-48, 2004. 
151. Jung C and Ghosh DK, High pressure fourier transform infrared (FT-IR) spectroscopic studies
on inducible nitric oxide (NO) synthase active site: a comparison to cytochrome p450CAM.
Cell Mol Biol (Noisy-le-grand) 50: 335-46, 2004. 
152. Contzen J, Kostka S, Kraft R and Jung C, Intermolecular electron transfer in cytochrome
P450cam covalently bound with Tris(2,2'-bipyridyl)ruthenium(II): structural changes detected
by FTIR spectroscopy. J Inorg Biochem 91: 607-17, 2002. 
153. Mössbauer R, Kernresonzfluoreszenz von gammastrahlung in Ir191. Z Physik 151: 124-143,
1958.
154. Sharrock M, Munck E, Debrunner PG, Marshall V, Lipscomb JD and Gunsalus IC, Mossbauer 
studies of cytochrome P-450 cam. Biochemistry 12: 258-65, 1973. 
155. Schoneboom JC, Neese F and Thiel W, Toward identification of the compound I reactive
intermediate in cytochrome P450 chemistry: a QM/MM study of its EPR and Mossbauer
parameters. J Am Chem Soc 127: 5840-53, 2005. 
156. Schunemann V, Jung C, Trautwein AX, Mandon D and Weiss R, Intermediates in the reaction 
of substrate-free cytochrome P450cam with peroxy acetic acid. FEBS Lett 479: 149-54, 2000. 
157. Poli-Scaife S, Attias R, Dansette PM and Mansuy D, The substrate binding site of human liver
cytochrome P450 2C9: an NMR study. Biochemistry 36: 12672-82, 1997. 
158. Regal KA and Nelson SD, Orientation of caffeine within the active site of human cytochrome
P450 1A2 based on NMR longitudinal (T1) relaxation measurements. Arch Biochem Biophys
384: 47-58, 2000. 
159. Solomon I and Bloembergen N, Nuclear magnetic interactions in the HF molecule. J Chem 
Phys 25: 261-266, 1956. 
160. Wei JY, Pochapsky TC and Pochapsky SS, Detection of a high barrier conformational change
in the active site of cytochrome P450cam upon binding of putidaredoxin. J Am Chem Soc
127: 6974-6, 2005. 
161. Modi S, Primrose WU, Boyle JM, Gibson CF, Lian LY and Roberts GC, NMR studies of substrate
binding to cytochrome P450 BM3: comparisons to cytochrome P450 cam. Biochemistry 34:
8982-8, 1995. 
162. Modi S, Gilham DE, Sutcliffe MJ, Lian LY, Primrose WU, Wolf CR and Roberts GCK, 1-Methyl-
4-phenyl-1,2,3,6-tetrahydropyridine as a substrate of cytochrome P450 2D6: allosteric effects
of NADPH-cytochrome P450 reductase. Biochemistry 36: 4461-70, 1997. 
163. Stern JO, Peisach J, Blumberg WE, Lu AY and Levin W, A low-temperature EPR study of
partially purified, soluble ferric cytochromes P-450 and P-448 from rat liver microsomes. Arch
Biochem Biophys 156: 404-13, 1973. 
41
General Introduction
164. Dus K, On the structure of putidaredoxin and cytochrome P-450 cam and their mode of
interaction. Adv Exp Med Biol 58: 287-309, 1975. 
165. Davydov DR, Knyushko TV, Kanaeva IP, Koen YM, Samenkova NF, Archakov AI and Hui Bon
Hoa G, Interactions of cytochrome P450 2B4 with NADPH-cytochrome P450 reductase studied
by fluorescent probe. Biochimie 78: 734-743, 1996. 
166. Lepesheva GI, Strushkevich NV and Usanov SA, Conformational dynamics and molecular
interaction reactions of recombinant cytochrome p450scc (CYP11A1) detected by 
fluorescence energy transfer. Biochim Biophys Acta 1434: 31-43, 1999. 
167. Dunn AR, Hays AM, Goodin DB, Stout CD, Chiu R, Winkler JR and Gray HB, Fluorescent 
probes for cytochrome p450 structural characterization and inhibitor screening. J Am Chem 
Soc 124: 10254-5, 2002. 
168. Dunn AR, Dmochowski IJ, Winkler JR and Gray HB, Nanosecond photoreduction of 
cytochrome p450cam by channel-specific Ru-diimine electron tunneling wires. J Am Chem Soc
125: 12450-6, 2003. 
169. Prasad S, Mazumdar S and Mitra S, Binding of camphor to Pseudomonas putida cytochrome
p450(cam): steady-state and picosecond time-resolved fluorescence studies. FEBS Lett 477:
157-60, 2000. 
170. Djuricic D, Hill HA, Lo KK and Wong LL, A scanning tunneling microscopy (STM) investigation 
of complex formation between cytochrome P450(cam) and putidaredoxin. J Inorg Biochem
88: 362-7, 2002. 
171. Blobaum AL, Kent UM, Alworth WL and Hollenberg PF, Novel reversible inactivation of P450
2E1 T303A by tert-butyl acetylene: The role of threonine 303 in proton delivery to the active
site of cytochrome P450 2E1. J Pharmacol Exp Ther, 2004. 
172. Ost TW, Clark J, Mowat CG, Miles CS, Walkinshaw MD, Reid GA, Chapman SK and Daff S, 
Oxygen activation and electron transfer in flavocytochrome P450 BM3. J Am Chem Soc 125:
15010-20, 2003. 
173. Sligar SG, Cinti DL, Gibson GG and Schenkman JB, Spin state control of the hepatic
cytochrome P450 redox potential. Biochem Biophys Res Commun 90: 925-32, 1979. 
174. Munro AW, Leys DG, McLean KJ, Marshall KR, Ost TW, Daff S, Miles CS, Chapman SK, Lysek
DA, Moser CC, Page CC and Dutton PL, P450 BM3: the very model of a modern 
flavocytochrome. Trends Biochem Sci 27: 250-7, 2002. 
175. Chen Z, Ost TW and Schelvis JP, Phe393 mutants of cytochrome P450 BM3 with modified
heme redox potentials have altered heme vinyl and propionate conformations. Biochemistry
43: 1798-808, 2004. 
176. Fleming BD, Tian Y, Bell SG, Wong LL, Urlacher V and Hill HA, Redox properties of 
cytochrome p450BM3 measured by direct methods. Eur J Biochem 270: 4082-8, 2003. 
177. Shumyantseva VV, Ivanov YD, Bistolas N, Scheller FW, Archakov AI and Wollenberger U,
Direct electron transfer of cytochrome P450 2B4 at electrodes modified with nonionic
detergent and colloidal clay nanoparticles. Anal Chem 76: 6046-52, 2004. 
178. Shukla A, Gillam EM, Mitchell DJ and Bernhardt PV, Direct electrochemistry of enzymes from 
the cytochrome P450 2C family. Elec rochem Comm 7: 437-442, 2005. t
179. Ingelman-Sundberg M, Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical
consequences, evolutionary aspects and functional diversity. the Pharmacogenomics Journal
5: 6-13, 2005. 
180. Venhorst J, Onderwater RC, Meerman JH, Commandeur JNM and Vermeulen NPE, Influence
of N-substitution of 7-methoxy-4-(aminomethyl)-coumarin on cytochrome P450 metabolism
and selectivity. Drug Metab Dispos 28: 1524-32, 2000. 
181. Kranendonk M, Mesquita P, Laires A, Vermeulen NP and Rueff J, Expression of human 
cytochrome P450 1A2 in Escherichia coli: a system for biotransformation and genotoxicity
studies of chemical carcinogens. Mutagenesis 13: 263-9, 1998. 
182. Kempf AC, Zanger UM and Meyer UA, Truncated human P450 2D6: expression in Eschirichia
coli, Ni(2+)-chelate affinity purification, and characterization of solubility and aggregation.
Arch Biochem Biophys 321: 277-88, 1995. 
183. Lightfoot T, Ellis SW, Mahling J, Ackland MJ, Blaney FE, Bijloo GJ, De Groot MJ, Vermeulen 
NP, Blackburn GM, Lennard MS and Tucker GT, Regioselective hydroxylation of debrisoquine
42
Chapter 1 
by cytochrome P4502D6: implications for active site modelling. Xenobiotica 30: 219-33,
2000.
184. Seifar RM, Altelaar MA, Dijkstra RJ, Ariese F, Brinkman UA and Gooijer C, Surface-enhanced
resonance Raman spectroscopy as an identification tool in column liquid chromatography.
Anal Chem 72: 5718-24, 2000. 
185. Stortelder A, Buijs JB, Bulthuis J, Gooijer C and van der Zwan G, Fast-gated intensified
charge-coupled device camera to record time-resolved fluorescence spectra of tryptophan.
Appl Spectrosc 58: 705-10, 2004. 
186. Stortelder A, Buijs JB, Bulthuis J, van der Vies SM, Gooijer C and van der Zwan G, Time-
resolved fluorescence of the bacteriophage T4 capsid protein gp23. J Photochem Photobiol B









Influence of phenylalanine 120 on cytochrome P450 2D6 catalytic selectivity and
regiospecificity: crucial role in 7-methoxy-4-(aminomethyl)-coumarin
metabolism
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The polymorphic human debrisoquine hydroxylase, cytochrome P450 2D6 (CYP2D6), is one 
of the most important phase I drug metabolising enzymes. It is responsible for metabolizing 
a large number of compounds that mostly share similarity in having a basic N-atom and an 
aromatic moiety. In homology modeling studies it has been suggested that in fixation of this
aromatic moiety there may be an important role for phenylalanine 120 (F120). In this study,
the role of F120 in ligand binding and catalysis was experimentally examined by mutating it 
into an alanine. Strikingly, this substitution led to a completely abolished 7-methoxy-4-
(aminomethyl)-coumarin O-demethylating activity of CYP2D6. On the other hand, bufuralol
metabolism was hardly affected (Km 1-hydroxylation mutant: 1.2 M, wild-type: 2.9 M, 4-
hydroxylation mutant 1.5 M, wild-type: 3.2 M) and neither was affected
dextromethorphan O-demethylation (Km mutant: 1.2 M, wild-type: 2 M, kcat mutant 4.5 
min-1, wild-type: 3.3 min-1). However, the F120A mutant also formed 3-hydroxymorphinan, 
the double demethylated form of dextromethorphan, which was not detected using wild-
type CYP2D6. 3,4-Methylenedioxymethamphetamine was demethylenated by both mutant 
and wild-type CYP2D6 to 3,4-dihydroxymethamphetamine (Km mutant 55 M, wild-type: 2 
M). In addition the mutant formed two additional metabolites; 3,4-methylenedioxy-
amphetamine and N-hydroxy-3,4-methylenedioxymethamphetamine. Inhibition experiments 
of dextromethorphan O-demethylation showed a decreased affinity of the F120A mutant for
quinidine (IC50 mutant: 240 nM, wild-type 40 nM), while IC50’s for quinine were equal (1 
M). These data indicate the importance of F120 in the selectivity and regiospecificity in 
substrate binding and catalysis by CYP2D6.
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Introduction
Cytochromes P450 (CYPs) are heme containing enzymes capable of oxidizing and reducing a
large variety of endogenous and exogenous substrates in virtually all living organisms [1, 2]. 
In humans one of the most important hepatic phase I drug metabolizing enzymes is 
CYP2D6. It is involved in the metabolism of about 30% of the currently marketed drugs,
including neuroleptics, antidepressants -blockers, opioids and antiarythmics [3, 4]. The
enzyme is known for its genetic polymorphisms, even increasing its clinical relevance [5, 6].
Although some crystal structures of mammalian CYPs have become available in recent years 
[7, 8], so far no crystal structure of CYP2D6 has been resolved. Structural information on
this enzyme still depends on homology modeling and mutagenesis studies.
Recently we have developed a new homology model of CYP2D6 based on the crystal 
structure of rabbit CYP2C5 [9]. This was the first model of CYP2D6 based on a mammalian 
CYP template and is therefore considered an improvement over the existing models. This 
was indicated by the good correlation between experimental data and the modelled protein-
substrate interactions. The model identified some active site key residues. First of all E216
has been shown to be a key ligand binding residue involved in hydrogen bonding with a 
variety of substrates. This residue has been subjected to mutagenesis studies [10, 11], that 
indicated involvement of this residue in fixation of basic nitrogen atoms present in many
CYP2D6 substrates. A second important active site residue in this and other homology 
models is F483 [12], interacting via van der Waals forces with substrates like codeine. 
Earlier mutagenesis of this residue to an isoleucine showed effects on testosterone
metabolism [13]. However, the anchoring of aromatic moieties present in most CYP2D6
substrates, as predicted in pharmacophore models [14-16], cannot be completely ascribed 
to this residue. Therefore other phenylalanine residues contributing to aromatic interactions 
with substrates have to be present in the active site. Mutation of F481 to other non-
aromatic residues led to decreased activities towards model substrates [17], although in the 
model of Venhorst et al. this residue is not considered to be in the active site of CYP2D6. 
Even more interesting is the position of a third phenylalanine at position 120 in the active 
site of CYP2D6 homology models [9, 11, 12]. In these CYP2C5-based models F120 appears 
to be positioned directly above the porphyrin ring. From docking and molecular dynamics
studies this residue seems to be the anchoring residue for the aromatic moiety of ligands 
like quinidine and sparteine via -stacking [9]. In the present study the role of F120 in
ligand binding and metabolism by CYP2D6 is studied experimentally by mutating this residue 
into an alanine. According to computational simulations this mutation will create not only 
more space in the active site, but also eliminates a potentially important aromatic anchoring 
point. By mutating F120 into alanine we are aiming at the elucidation of the role of this
residue in substrate binding and turnover by CYP2D6. 
Materials and Methods 
Materials
The pSP19T7LT plasmid containing human 2D6 with a C-terminal His6-tag bicistronically co-expressed
with human cytochrome P450 NADPH reductase was kindly provided by Prof. Dr. Ingelman-Sundberg.
7-methoxy-4-(aminomethyl)-coumarin (MAMC), 7-hydroxy-4-(aminomethyl)-coumarin (HAMC), 3,4-
methylenedioxymethylamphetamine (MDMA) and 3,4-methylenedioxyamphetamine (MDA) were 
synthesized as described [18, 19]. Bufuralol hydrochloride was obtained from Gentest. N-
methylhydroxylamine hydrochloride, Dextromethorphan hydrobromide and dextrorphan tartrate were






hydroxylaminopropane) was prepared from piperonyl methyl ketone and N-methylhydroxylamine by 
reductive amination with sodium cyanoborohydride [20]. A two-fold surplus of N-methylhydroxylamine
hydrochloride was stirred with piperonyl methyl ketone in methanol at room temperature, sodium
cyanoborohydride was added and stirred for 48 h. After adding water, neutralizing the
cyanoborohydride with 6 M HCl and neutralizing the acid with 6 M NaOH, the product was extracted in 
dichloromethane. 1H NMR (400 Hz, CDCl3):  1.00 (d, 3H, CCH3), 2.38 (dd, 1H, H-1), 2.68 (s, 3H,
NCH3), 2.91 (m, 1H, CHN), 3.10 (dd, 1H, H-1), 5.90 (s, 2H, OCH2O), 6.63 (dd, 1H, H-6’), 6.70 (d, 1H,
H-2’), 6.72 (d, 1H, H-5’). 13C NMR (400 Hz, CDCl3):  14.20 (CH3), 38.82 (CH2), 43.95 (CH3N), 65.35 
(CH), 72.82, 100.83 (OCH2O), 108.17 (C-5’), 109.70 (C-2’), 122.13 (C-6’), 133.29 (C-1’), 145.87 (C-4’),
147.59 (C-3’). MS direct injection: m/z, M+˙ 210, MS/MS: 179 (3), 163 (100), 135 (3). 
Site-directed mutagenesis
The phenylalanine 120 alanine (F120A) mutation was introduced into pSP19T7LT using the
QuickChange XL Site-Directed Mutagenesis kit (Stratagene). The sequences of the forward- and reverse
oligonucleotides, respectively, with the mutated residue in italic, were as follows: 5’-CGT TCC CAA GGG 
GTG GCC CTG GCG CGC TAT-3’ and 5’-ATA GCG CGC CAG GGC CAC CCC TTG GGA ACG-3’. After 
mutagenesis, the presence of the desired F120A mutation was confirmed by DNA sequencing.
Expression and membrane isolation
Both the F120A mutant and the wild-type CYP2D6 containing pSP19T7LT plasmids were transformed
into Escherichia coli strain JM109. Expression was carried out in 3L flasks containing 300 ml TB (Terrific
Broth) medium with additives (1 mM -aminolevulinic acid, 400 l/L trace elements [21], 1 g/ml
thiamine, 100 g/ml ampicillin). Cultures were inoculated with 3 ml frozen E. coli cells containing the 
desired plasmid, and induction was initiated by the addition of 2 mM isopropyl -D-thiogalactoside.
Cultures were grown for 48 h at 28 °C and 125 rpm, before they were harvested. CYP contents were 
determined by CO difference spectra [22].
Harvested cells were pelleted by centrifugation (15 min, 4000 g, 4 °C) and the resulting pellet was
resuspended in TSE buffer (50 mM Tris-acetate pH 7.6, 250 mM sucrose, 0.25 mM EDTA), 35 mg wet
weight cells/ ml. Spheroblasts were prepared by adding 0.1 mg/ml lysozyme and gently shaking the
cells for 30 min on ice. Spheroblasts were pelleted by centrifugation (15 min, 4000 g, 4 °C), and 
resuspended in KPi-glycerol buffer (100 mM potassium phosphate buffer, pH 7.4, 20% glycerol, 0.1 mM
DTT), 0.5 g/ml. The spheroblasts were lysed by passage through a French press followed by sonication
(Branson Sonifier 250, 10 x 20 sec, 70% full power), and the membrane fraction was isolated by
ultracentrifugation (45 min, 120,000 g, 4 °C). Membranes were resuspended in 0.4% of the original
culture volume of TSE buffer and CYP contents were determined with CO difference spectra.
Metabolism and inhibi ion assayst
MAMC O-demethylation [23]: Reactions were carried out in duplicate in a 96 wells plate, in a total
volume of 200 l. The reaction mixture consisted of 50 mM potassium phosphate buffer (KPi) pH 7.4, 5 
mM MgCl2, 0-500 M MAMC (10 concentrations used) and E. coli membranes corresponding to 40 nM 
wild-type or F120A mutant CYP2D6. The reactions were initiated by addition of an NADPH regenerating
system, resulting in final concentrations of 0.1 mM NADPH, 0.3 mM glucose-6-phosphate, and 0.4
units/ml glucose-6-phosphate dehydrogenase. The reaction was monitored for 40 min at 37 °C on a 
Victor2 1420 multilabel counter (Wallac) ( ex= 405 nm, em= 460 nm). The metabolite of MAMC, i.e.
HAMC, was identified and quantified using the synthetic reference compound. HPLC analysis of MAMC
metabolism was performed as described [18], using a C18 column (Chrompack Chromspher 5, 250 x
4.6 mm) with a flow rate of 0.4 ml/min.
Dextromethorphan O-demethylation [10]: Reactions were carried out in 300 l 50 mM KPi pH 7.4, 5 mM
MgCl2 supplemented with 10 concentrations ranging from 0 to 40 M dextromethorphan and E. coli
membranes corresponding to 50 nM wild-type or 25 nM F120A mutant CYP2D6. After 5 min of pre-
incubation at 37 °C, the reactions were initiated with an NADPH regenerating system as described
above. The reaction was allowed to proceed for 5 min before it was stopped by the addition of 15 l
70% HClO4. After centrifugation (10 min, 6800 g), 30 l aliquots of the supernatant were analyzed by 
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HPLC. Metabolites were separated using a C18 column (Chrompack Chromspher 5, 250 x 4.6 mm) with
a flow rate of 1 ml/min. The mobile phase consisted of 30% acetonitrile and 1% triethylamine, set to
pH 3 with 70% HClO4. Metabolites were detected by fluorescence ( ex= 280 nm, em= 311 nm) and 
identified by LC-MS. Inhibition of O-demethylation by various concentrations of quinidine and quinine
was measured under the same conditions using a concentration of 8 M dextromethorphan.
Bufuralol hydroxylation [10, 24]: Reactions were carried out as described above using 9 concentrations
ranging from 0 to 100 M bufuralol and E. coli membranes corresponding to 50 nM wild-type or 25 nM
F120A mutant CYP2D6. Metabolites were separated using a C18 column (Chrompack Chromspher 5, 
250 x 4.6 mm) with a flow rate of 0.6 ml/min. The mobile phase consisted of 30% acetonitrile and 
0.1% triethylamine, set to pH 3 with 70% HClO4. Metabolites were detected by fluorescence ( ex= 252 
nm, em= 302 nm). Metabolites of bufuralol were identified by comparison with other studies [24]. 
MDMA metabolism: Reactions were carried out as described above with 9 concentrations ranging from
0 to 200 M MDMA and E. coli membranes corresponding to 50 nM wild-type or 25 nM F120A mutant
CYP2D6. Metabolites were separated using a C18 column (Phenomenex Inertsil ODS 150 x 4.6 mm) 
with a flow rate of 0.4 ml/min. The mobile phase consisted of 23% acetonitrile and 0.1% triethylamine,
set to pH 3 with 70% HClO4. Metabolites were detected by fluorescence ( ex= 280 nm, em= 320 nm) 
and identified electrochemically (ECD, oxidation mode 0.8 V, for detection of 3,4-OH-MA), by LC-MS
(3,4-OH-MA, MDA, N-OH-MDMA) and using synthesized reference compounds (MDA, N-OH-MDMA).
Peak areas of all metabolites were quantified by Shimadzu Class VP 4.3 and analyzed using Graph Pad 
Prism 4.0. 
LC-MS
To identify the metabolites of MDMA, dextromethorphan and dextrorphan, incubations were carried out
for 10 min as described above with 100 M MDMA, 100 M dextrorphan or 25 M dextromethorphan
respectively and E. coli membranes corresponding to 50 nM 2D6 wild-type or 50 nM 2D6 F120A.
Volumes of 100 µl supernatant were injected and separated using a phenyl column (Waters Novapak 
Phenyl 150 x 4.6 mm) with a flow rate of 0.4 ml/min. The metabolites were eluted using a gradient
starting with a 1% ACN eluens, supplemented with 10 mM ammonium acetate, increasing linearly to 
95% ACN with 10 mM ammoniumacetate in 30 min and analyzed by MS. APCI positive ionisation was
used on a LCQ Deca mass spectrometer (Thermo Finnigan), vaporizer temperature 450 ˚C, N2 as 
sheath (40 psi) and auxiliary gas (10 psi), needle voltage 6000 V, heated capillary 150 ̊ C.
Homology Modeling
A protein homology model of CYP2D6 was constructed based on the crystal structures of
dimethylsulphophenazole and diclofenac bound rabbit CYP2C5, PDB codes 1N6B and 1NR6 respectively
[7, 25]. Homology modeling, model refinement and model validation was performed as described [9].
The final model of wild-type CYP2D6 was used as a template for modeling of the F120A mutant. The 
F120 residue was mutated to alanine using the homology module of InsightII (Biosym), after which an 
energy minimization and a one picosecond position restrained molecular dynamics simulation was
carried out. 
Results
Expression of wild-type and F120A mutant CYP2D6
The F120A mutant had consistently significantly lower expression levels compared to wild-
type CYP2D6. An average culture contained about 70 nM of CYP for the mutant versus 200 
nM for wild-type after 48 hours induction. In the difference spectrum taken from the culture 
of the mutant enzyme a high absorbance was measured at 420 nm, showing the presence 
of large amounts of P420, the inactive form of CYP, indicating that the mutation decreases 
the stability of the enzyme to some extent. 
Metabolism of model compounds 
O-demethylation of the CYP2D6 marker substrate MAMC (Figure 1) showed to be linear for 
over 40 minutes using E. coli membranes containing 40 nM of wild-type CYP2D6. Enzyme 
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kinetics analysis revealed a Km of 49 M and a kcat of 3.7 min-1 (Table 1). Using the F120A 
mutant under the same conditions did not lead to detectable HAMC formation. HPLC 























Fig 1. Structures of the substrates (A: MAMC, B: MDMA, C: bufuralol, D: dextromethorphan) and
ligands (E: quinidine (8R  9S) and quinine (8S, 9R)) used, showing sites of oxidation by wild-type
CYP2D6 ( ) and chiral carbon atoms (*). 
.
,
Dextromethorphan was selectively O-demethylated to dextrorphan by wild-type CYP2D6 (Km
2 M, kcat 3.3 min-1). The F120A mutant also formed dextrorphan be it with a slightly lower
Km and higher kcat than the wild-type. The formation of dextrorphan showed to be linear for 
at least 20 minutes, indicating the mutant to be stable enough for studying the metabolism.
Dextrorphan and other metabolites were identified by LC-MS. The N-demethylated
metabolite of dextromethorphan, i.e. 3-methoxymorphinan (m/z 258, MS/MS: m/z 215), 
was detected for both the wild-type as for the F120A mutant with a tR of 36 min. Because of
overlap with the peak of dextromethorphan (m/z 272, MS/MS: m/z 215) at tR 37 min, N-
demethylation could not be quantified. Interestingly, also a metabolite with m/z 244 (tR 31.1 
min, MS/MS: m/z 147) was detected for the F120A mutant, apparently the double O- and N-
demethylated metabolite of dextromethorphan, i.e. 3-hydroxymorphinan. The 3-
hydroxymorphinan formation could also not be quantified under the conditions used
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because it is a secondary metabolite. When the F120A mutant was incubated with 
dextrorphan again 3-hydroxymorphinan was formed and two other metabolites with m/z
274 were detected (tR 27.5 min, MS/MS: m/z 199 and tR 30.3 min MS/MS: m/z 257 and 
201), indicating hydroxylation of dextrorphan. With the wild-type CYP2D6 no metabolites of 
dextrorphan were detected. 
Table 1: Kinetic parameters of wild- ype and F120A mutant CYP2D6 towards model substrates.t
Wild-type F120ASubstrate Products
Km Vmax Km Vmax
MAMC HAMC 49  2 3.7  0.6 a - b - b
dextromethorphan dextrorphan 2.0  0.2 3.3  0.4 a 1.2  0.4 4.5  0.3 a
3-OH-morphinan - b - b + c + c
dextrorphan 3-OH-morphinan - b - b + c + c
bufuralol 1’-OH 2.9  0.4 54  17 d 1.2  0.2 51  11 d
4-OH 3.2  0.5 2.7  0.8 d 1.5  0.3 2.7  0.6 d
MDMA 3,4-OH-MA 1.9  0.7 3.4  1.0 d 55.4  16 4.6  1.1 d
MDA - b - b 9.0  2.5 6.0  3.3 d
N-OH-MDMA - b - b 11.0  2.8 10.9  3.8 d
All values are the means of at least three independent experiments S.D  as described in the Methods
section. K
.
rm expressed in M, a Vmax expressed in min-1, b not detectable, c p esent but not quantifiable, d
Vmax expressed in 1 x 105 fluorescence units/min/nmol P450.
Upon incubation of bufuralol both with wild-type and F120A mutant CYP2D6 four 
metabolites were detected; 6-OH bufuralol, 1’-OH bufuralol, 4-OH bufuralol and 1’,2’
bufuralol, as identified before by others [24]. Under the conditions used only peak areas of
the metabolites 1’-OH bufuralol and 4-OH bufuralol could be quantified. For both these 
metabolites the F120A mutant showed a two times lower Km than wild-type CYP2D6 with a 
comparable turnover (Table 1). 
Another known CYP2D6 substrate that was subjected to incubations with wild-type and 
F120A mutant CYP2D6 was MDMA [26]. In the case of wild-type CYP2D6 only O-
demethylenenation of MDMA to the catechol 3,4-dihydroxymethylamphetamine (3,4-OH-MA)
was observed with a Km of 2 M and a Vmax of 3.4 x 105 AU. This metabolite was identified
by ECD, LC-MS (measured as the quinone, tR 21.2 min, m/z 180) and it was described 
before by others [26]. The mutant enzyme also formed this catechol with a similar Vmax, but
with a 30-fold higher Km (Figure 2). In addition to demethylenenation, MDMA was also N-
demethylated to MDA by the mutant enzyme, with a Km of 9 M and a Vmax of 6 x 105 AU, 
as identified by LC-MS (tR 21.4 min, m/z 180) and co-elution with the synthetic reference 
(Figure 2). Furthermore, a third metabolite was formed by the F120A mutant with a Km of 
11 M, and a Vmax of 11 x 105 AU. This metabolite was also identified by LC-MS. An m/z of 
210 was observed for this metabolite (tR 21.9 min), indicating hydroxylation of MDMA (m/z
194). MS/MS data showed a mass over charge of 163, suggesting that hydroxylation took 
place on the nitrogen, as the m/z of 163 is the propyl-methylenedioxyphenyl fragment, 
which is also a common fragment of both MDA and MDMA. In order to confirm the identity 
of this new metabolite of MDMA, N-OH-MDMA was synthesized and showed identical mass 
spectroscopic behavior. Direct injection of this compound in the MS gave an m/z 210, with 
as the major MS/MS fragment m/z 163. In addition, the N-OH-MDMA also co-eluted with the
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new metabolite on both the C18 as the phenyl reversed phase columns, when spiked in an 







Fig. 2. Chromatograms of 100 M MDMA incubations with membranes of E coli cells exp essing wild
ype (1) and F120A mutant (2) CYP2D6 with (gray), and without (black) 20 M quinidine (A). 
Metabolites are indicated  ( ) and reference chromatograms of synthesized MDA (3) and synthesized N-





R of the substrate MDMA is 13.2 min, tR metabolites: 3,4-OH-MA 5.5 
min, MDA 10.9 min, N-OH-MDMA 18.8 min. For condi ions used see Methods section. Scheme of MDMA 
metabolism by wild- ype (1) and F120A mutant CYP2D6 in o 3,4-OH-MA (1), MDA (2), and N-OH-MDMA
(3) is shown (B). 
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Inhibition of dextromethorphan metabolism 
Inhibition of dextromethorphan O-demethylation by quinidine and quinine was determined 
for both F120A and wild-type CYP2D6 (Figure 3). In case of both the enzymes, quinine 
inhibited dextrorphan formation with an IC50 of about 1 M (Table 2), whereas quinidine 
was about six-fold less potent in inhibiting the F120A mutant (IC50 200 nM) than the wild-
type enzyme (IC50 40 nM).
Table 2 





quinidine 0.04  0.01 0.24  0.04 
quinine 0.76  0.17 1.3  0.27 
All values are the means of at least two independent experiments  S.D. as described in the Methods
section.
Modeling
In a refined homology model of CYP2D6 used in this study, F120, E216, and F483 are 
positioned at approximately the same location as in the previously reported homology model 
[9]. D301 however, does not point into the active site, but is oriented such that it stabilizes
the B/C-loop by hydrogen bonding to the backbone N-atoms of residues V119 and F120. 
D301 however may also play an electrostatic role in the binding of basic substrates by 
increasing the net negative charge within the active site [12]. Furthermore, the constructed 
homology model used in this study has a more ‘closed’ binding pocket as a result of the fact 
that the substrate-free CYP2C5 crystal structure template used for the old homology model 
is lacking the F/G-loop (unpublished data). 
Discussion
Recently, computer homology modeling studies suggested F120 to be a CYP2D6 active site 
residue involved in the binding of substrates via aromatic interactions [9, 11, 12]. The 
primary aim of this study was to evaluate the role of this residue in the CYP2D6 active site. 
The results presented in this study show that F120 is very relevant in CYP2D6 ligand 
binding, substrate selectivity and regiospecificity in catalysis.
The expression levels of the F120A mutant in E. coli were found to be lower than the wild-
type enzyme, indicating that F120 may have a role in the stability of the enzyme. High levels 
of P420 were seen in the difference spectra, showing that the expression itself was not
hampered, but that a large amount of enzyme formed was not functional as was reported 
before for several other CYP2D6 mutants [10, 27].
Four typical CYP2D6 substrates were selected to characterize the F120A mutant. Compared 
to wild-type CYP2D6 large substrate-dependent differences in metabolism were found after 
introducing a single mutation, not reported before for other CYP2D6 mutants. MAMC was 
not metabolized by the F120A mutant while bufuralol metabolism by the F120A mutant was 
similar to the metabolism by the wild-type enzyme. For both dextromethorphan and MDMA 
there were changes in catalytic regiospecificity after mutating F120 into an alanine. So 
despite the fact that all four substrates show structural similarity in having a basic N-atom at
about 7 Å of the site of oxidation and in having an adjacent aromatic moiety [14], still the 
influence of the mutation differed between these substrates. The only time large substrate
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dependent differences were described for a CYP2D6 mutant was with a Glu216Gln mutant,
using the substrate spirosulfonamide [11], that lacks a basic N-atom and therefore does not 
fit into the classical pharmacophore model [14-16].
A
B
Fig. 3. Rela ive amounts o  dextrometho phan O-demethylation in p esence of various amounts of 
quinine (A) and quinidine (B) by F120A mutant ( ) and wild-type CYP2D6 ( ). Plotted values are the 
means of at least two independent experiments  S.D. as described in the Methods sec ion.
t f r r
t
Neither HAMC nor other metabolites were detected after incubating MAMC with the F120A
mutant so apparently F120 influences either the affinity, or the orientation of this substrate 
with respect to the heme. More experiments with other coumarin derivatives could give 
more information about the underlying mechanisms [28]. 
Bufuralol metabolism by CYP2D6 was studied previously using a series of D301 mutants 
[24], and also mutants of E216 to non-acidic residues were studied using this model 
substrate [10, 11]. Large effects were found on affinity and turnover of the mutants for this 
compound, showing that these acidic residues are more important for bufuralol metabolism 
than F120 as can be concluded from this study. The role of D301 was postulated also to be 
fixation of the B-C loop containing residue F120 [10-12] however the present results do not 
seem to support this role as the F120A mutation hardly shows an effect on bufuralol 
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metabolism. Consequently, the role of D301 does not seem to be merely the fixation of 
F120 into the active site [29], but creation of the net negative charge together with E216 














Fig  4. Binding orientation of dextromethorphan automatically docked in the active site of the homology
models of CYP2D6 using Autodock with standard conditions [30]. In wild-type CYP2D6 the orientation
of dextromethorphan with its O-methyl poin ing towards the heme is favored (A), in the F120A mutant
wo dis inc high ranking o ientations were found, supporting bo h N-demethylation as O-demethylation
(B). A colored version of the figure is shown in the Appendix of this thesis. 
56
Chapter 2 
N-dealkylation of substrates is a possible route in CYP2D6 metabolism and F481 was 
predicted previously to be an important substrate binding residue involved in these reactions 
[15]. However mutating the F481 residue into a Gly did not have a large influence on N-
deisopropylation of metoprolol [17]. Both MDMA and dextrorphan were N-demethylated by 
the F120A mutant implicating a more promiscuous way of orientation of these two 
substrates in the active site of CYP2D6 and the involvement of the F120 residue in binding
substrates undergoing N-dealkylation.
Besides N-dealkylation of MDMA, also N-hydroxylation occurred when MDMA was incubated 
with the F120A mutant. N-OH-MDMA has been described before as a MDMA metabolite in 
horse urine [31], however from this previous study it remained unclear what enzymes were
playing a role in this reaction. Furthermore, aliphatic N-hydroxylation has not been 
described before as a metabolic reaction catalysed by CYP2D6 wild-type or mutants for any
substrate. The co-occurrence of both N-dealkylation and N-hydroxylation of a single
substrate has been reported once before for N-methylbenzamidine by rabbit CYP2C3 [32].
Additional work should give more insights in the mechanism of these transformations by the 
F120A CYP2D6 mutant.
The role of F120 in the active site of CYP2D6 seems to be at least two-fold; firstly, the 
phenyl ring fills the active site cavity causing a reduction of its size and secondly, it may
have a function as an aromatic interaction site. The metabolite 3-hydroxymorphinan is 
detected exclusively in dextromethorphan incubations with the F120A mutant. In Figure 4, it 
is demonstrated how the mutation of the bulky Phe into a smaller Ala-residue allows the 
dextromethorphan N-demethylation binding mode to be accommodated more easily by
creating more space in the CYP2D6 active site. As indicated earlier, F120 is considered 
important for interacting with quinidine via -stacking [9]. The six-fold increase in IC50-value
as determined for the F120A mutant validates the specific anchoring role of this residue. 
This role was confirmed by the inability of the F120A mutant to metabolize MAMC. The two
roles; space filling and aromatic anchoring however only partly explain the substrate specific 
influence, as bufuralol, MDMA and MAMC are structurally similar substrates but showed 
different changes in metabolism when incubated with the F120A mutant.
In the rat isoforms of the CYP2D family, no homologous aromatic residues are present in 
the B-C loop so the F120 is a human CYP2D6 active site specific residue [9]. The data 
presented here introduce F120 as the fourth important residue in the binding of ligands to 
and catalysis by CYP2D6, next to E216, D301 and F483. The effects of removing the F120 
phenyl-moiety are on the affinity, turnover and orientation of substrates, but the effects 
were quite different for structurally similar substrates. To rationalize the large differences 
found with the four chosen substrates advanced molecular modeling is needed. Combined
with molecular dynamics it can give insights where space is a limiting factor or where 
specific interactions play a role in the CYP2D6 active site. 
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The role of phenylalanine 483 in cytochrome P450 2D6 is strongly substrate
dependent
Barbara M.A. van Vugt-Lussenburg, Peter H.J. Keizers, Chris de Graaf, Mats Hidestrand, 
Magnus Ingelman-Sundberg, Nico P.E. Vermeulen, and Jan N.M. Commandeur
adapted from: Biochemical Pharmacology 2005 70:1253-61
The polymorphic cytochrome P450 2D6 (CYP2D6) is involved in the metabolism of 30% of 
the drugs currently prescribed, and is thus clinically relevant. Typical CYP2D6 substrates 
generally contain a basic nitrogen atom and an aromatic moiety adjacent to the site of 
metabolism. Recently, we demonstrated the importance of active site residue F120 in 
substrate binding and catalysis in CYP2D6. On the basis of protein homology models, it is 
claimed that another active site phenylalanine, F483, may also play an important role in the 
interaction with the aromatic moiety of CYP2D6 substrates. Experimental data to support 
this hypothesis, however, is not yet available. In fact, in the only study performed, mutation 
of F483 to isoleucine or tryptophan did not affect the 1’-hydroxylation of bufuralol at all [1]. 
In the present study the role of F483 in ligand binding and metabolism by CYP2D6 was 
examined experimentally using site-directed mutagenesis. Replacement of F483 by alanine 
resulted in a 30-fold lower Vmax for bufuralol 1’-hydroxylation, while the Km was hardly 
affected. The Vmax for 3,4-methylenedioxy-methylamphetamine O-demethylenation on the 
other hand decreased only two-fold, whereas the effect on the Km was much larger. For 
dextromethorphan, in addition to dextrorphan (O-demethylation) and 3-methoxymorphinan
(N-demethylation), two other metabolites were formed that could not be detected for the 
wild-type. The substrate 7-methoxy-4-(aminomethyl)-coumarin was not metabolized at all 
by F483A mutant CYP2D6, a phenomenon that was reported also for F120A mutant 
CYP2D6. The presented data show that next to F120, residue F483 plays a very important 
role in the metabolism of typical CYP2D6 substrates. The influence of F483 on metabolism




The cytochrome P450 (CYP) superfamily constitutes a large group of oxido-reductases that 
are responsible for the oxidation and reduction of many endogenous compounds as well as 
a wide variety of xenobiotics [2-4]. In humans, cytochrome P450 2D6 (CYP2D6) is one of 
the most important enzymes of this family [5]. Despite its low abundance, CYP2D6
represents only 3% of the total amount of CYP in human liver, it metabolizes ~30% of the
drugs currently on the market [6, 7]. Its clinical relevance is even increased by the fact that
CYP2D6 is highly polymorphic; 6% of the European population is classified as a poor
metabolizer, while another 3% has the ultrarapid metabolizer phenotype [7-10], thus 
contributing to large interindividual differences in drug metabolism.
The development of accurate models of the active site of CYP2D6 is useful to identify
potential drug candidates that interact with the enzyme. Because no crystal structure is yet 
available for CYP2D6, the structural information required for such models has to be obtained 
from homology modeling [11, 12] and experimental mutagenesis studies. 
Most substrates of CYP2D6 contain a basic nitrogen at a distance of approximately 5 to 7 Å 
from the site of oxidation, and an adjacent aromatic moiety [13]. Besides the negatively
charged active site residues E216 and D301 that have been shown to play a role in fixation
of the basic nitrogen atom [14-16], pharmacophore and homology models suggest a role for
aromatic residues in the active site to undergo van der Waals interactions with aromatic
moieties of the ligands [17]. Three aromatic phenylalanine residues have been proposed as 
active-site residues, F120, F481 and F483. Recently, it was experimentally underlined that 
F120 is indeed one of the aromatic active site residues playing an important role in
substrate binding and metabolism [18, 19]. In earlier CYP2D6 homology models based on 
bacterial CYP crystal structure templates it was suggested that another aromatic residue 
associated with ligand binding is F481 [17, 20, 21]. Substitution of F481 by non-aromatic
residues reduced the affinity of several typical CYP2D6 substrates [17]. In more recent
homology models based on rabbit CYP2C5, however, F481 is positioned outside the binding
pocket, but in close contact with active site residue F483 [1, 15, 22, 23]. Our model (figure
1) [22] and several others [1, 15, 23, 24] suggest that this aromatic active site residue, i.e. 
F483, is also a potential ligand-contact residue (Figure 1). In a modeling study by Kemp et 
al. phenylalanines 120 and 483 are referred to as important residues in the active site of 
CYP2D6, which are involved in the binding of various compounds from the National Cancer
Institute database [24]. However, experimental data supporting a role for F483 in binding 
known CYP2D6 substrates is not yet available. In fact, in the only experimental study on this 
residue, it was shown that substitution of F483 by isoleucine or tryptophan did not affect 
the 1’-hydroxylation of the typical CYP2D6 substrate bufuralol [1]. Interestingly, the F483I
mutant was able to catalyze the 15 -hydroxylation of testosterone, which is not a substrate 
for wild-type CYP2D6 [23]. Therefore, it is not yet clear whether this residue plays a role in
the binding of typical CYP2D6 substrates. Recently, we demonstrated that the role of 
another active-site phenylalanine residue, F120, is substrate dependent [18, 19]. The F120A 
mutant completely lost the ability to metabolize 7-methoxy-4-(aminomethyl)coumarin
(MAMC), while no significant effect on bufuralol metabolism was observed. 3,4-
Methylenedioxymethamphetamine (MDMA) and dextromethorphan were still metabolized by
F120A, but the regiospecificity of metabolism had changed significantly.
The goal of the present study is to investigate whether the role of phenylalanine F483 in the 
metabolism of typical CYP2D6 substrates is substrate dependent. Using site-directed 
mutagenesis, this phenylalanine residue was substituted by an alanine (F483A), and the 
effect of this mutation on the binding and metabolism of four typical CYP2D6 substrates, 







Figure 1. The ac ive site of the homology model of CYP2D6 [18], showing the ac ive site residues F120,
E216, D301 and F483. The heme i on atom is shown as a sphere, and he subs ate dextromethorphan




Materials and methods 
Materials
7-methoxy-4-(aminomethyl)-coumarin (MAMC), 7-hydroxy-4-(aminomethyl)-coumarin (HAMC), 3,4-
methylenedioxymethylamphetamine (MDMA) and 3,4-methylenedioxyamphetamine (MDA) were 
synthesized as described [25, 26]. Bufuralol hydrochloride was obtained from Gentest.
Dextromethorphan hydrobromide and dextrorphan tartrate were obtained from Sigma. All other
chemicals were of analytical grade and obtained from standard suppliers.
Plasmid and site-direc ed mutagenesis
The pSP19T7LT plasmid containing human CYP2D6 with a C-terminal His6-tag bicistronically co-
expressed with human Cytochrome P450 NADPH reductase (CPR) was constructed as follows: the CPR
was generated by reverse transcription of human genomic DNA using a reverse transcription kit with
oligo dT primers (Clontech, inc, USA). After reverse transcription, the cDNA was amplified with primers
creating restriction enzyme sites. Human CYP2D6 was amplified from a cDNA. During amplification
additional C-terminal histidine residues as well as sites for restriction enzyme cleavage were introduced.
The amplified and digested 2D6 and CPR were subsequently ligated into the expression plasmid
pSP19T7LT [27] in tandem, with a short linker region in-between the two genes. The correct gene
sequence was verified by sequencing.
The phenylalanine 483 to alanine (F483A) mutation was introduced into pSP19T7LT using the
QuikChange XL Site-Directed Mutagenesis kit (Stratagene). The sequences of the forward- and reverse
oligonucleotides, respectively, with the altered nucleotides in italic, were as follows: 5’-AT-GGT-GTC-
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TTT-GCT-GCC-CTG-GTG-AGC-CC-3’ and 5’-GG-GCT-CAC-CAG-GGC-AGC-AAA-GAC-ACC-AT-3’. After
mutagenesis, the presence of the desired F483A mutation was confirmed by DNA sequencing.
Expression and membrane isolation
Both the F483A mutant and the wild-type pSP19T7LT plasmids were transformed into Escherichia coli
strain JM109. Expression was carried out in 3L flasks containing 300 ml TB (Terrific Broth) medium with
additives (1 mM -aminolevulinic acid, 400 l/L trace elements [28], 1 g/ml thiamine, 100 g/ml
ampicillin). Cultures were inoculated with 3 ml frozen E. coli cells containing the desired plasmid, and
expression of CYP2D6 and CPR was initiated by the addition of 2 mM isopropyl- -D-
thiogalactopyranoside. Cultures were grown for 48 h at 28 °C and 125 rpm, before they were 
harvested. CYP contents were determined by CO difference spectra [29].
Harvested cells were pelleted by centrifugation (15 min, 4000 g, 4 °C) and the resulting pellet was
resuspended in 1/20 original culture volume of Tris-Sucrose-EDTA (TSE) buffer (50 mM Tris-acetate pH
7.6, 250 mM sucrose, 0.25 mM EDTA). After the addition of 0.1 mg/ml lysozyme, the cells were 
disrupted using a French Press (1000psi, 3 repeats). To remove remaining undisrupted cells, the lysate
was centrifuged (15 min, 4000 g, 4 °C) and the resulting pellet was discarded. The cytosolic fraction
was separated from the membranous fraction by centrifugation for 45 min at 120,000 g, 4 °C. The 
membrane pellet was resuspended in 1/75 original culture volume of TSE buffer and CYP contents were
determined using CO difference spectra. CPR activity was measured using cytochrome c reduction as
described previously [30, 31]. To convert the CPR activities to CPR concentrations, a specific activity of 
3200 nmol cytochrome c/min/nmol reductase was used [30, 31]. 
For determination of dissociation constants of ligands, the CYP was purified from the membranes.
Enzymes were solubilized by stirring for 2 hrs at 4°C in KPi-glycerol buffer (50 mM potassium phosphate
buffer pH 7.4 with 10% glycerol), supplemented with 0.5% Emulgen 911. Insoluble parts were 
removed by centrifugation (60 min, 120,000 g, 4 °C). Supernatant was incubated, gently rocking, with
Ni-NTA agarose (Qiagen) for 30 min at 4 °C. The column material was retained in a polypropylene tube
with porous disc (Pierce), washed with KPi-glycerol buffer containing 2 mM histidine. CYP2D6 was
eluted with 0.2 M histidine. After overnight dialysis in KPi-glycerol buffer the sample was concentrated
on a Vivaspin 20 filtration tube (10.000 MWCO PES, Sartorius).
Metabolism of model compounds
Before the enzyme kinetic parameters of the four substrates were determined, a series of experiments 
was performed to determine the linearity of the reactions with time and enzyme concentration. Based
on these experiments (data not shown), incubation times and enzyme concentrations were chosen that 
are within the linear range.
MAMC metabolism [25, 32]: Reactions were carried out in triplicate in a black Costar 96 wells plate, in a 
total volume of 200 l. The reaction mixture consisted of 100 mM potassium phosphate buffer pH 7.4 
(KPi) containing 5 mM MgCl2 and 2 mM EDTA, and E. coli membranes containing 40 nM CYP2D6 (wild-
type or F483A mutant CYP2D6), and CPR. 9 Different concentrations of MAMC were used ranging from
0 to 320 M. The reaction was initiated by addition of an NADPH regenerating system, resulting in final 
concentrations of 0.1 mM NADPH, 0.3 mM glucose-6-phosphate, and 0.4 units/ml glucose-6-phosphate
dehydrogenase. The reaction was monitored for 30 min at 37 °C on a Victor2 1420 multilabel counter
(Wallac) ( ex= 405 nm, em= 460 nm). The metabolite of MAMC, i.e. HAMC, was identified and 
quantified using the synthetic reference compound. Samples were also analyzed by high-performance 
liquid chromatography (HPLC) as described previously [25] to determine if other metabolites were
formed that could not be detected on the fluorescence microplate reader.
Dextromethorphan metabolism [16]: The reaction mixture was composed as described for MAMC, with
E. coli membranes containing 25 nM CYP2D6 (wild-type or F483A mutant CYP2D6), and CPR. 10 
Different concentrations of dextromethorphan were used ranging from 0 to 80 M.  After 5 min of 
preincubation at 37 °C, the reaction was initiated by addition of an NADPH regenerating system as 
described above. The reaction was allowed to take place for 10 min at 37 °C before it was stopped with
1/20 volume of 70% HClO4. Precipitated proteins were removed by centrifugation (10 min, 6800 g), and 
the supernatant was analyzed by HPLC (injection volume 25 l). Metabolites were separated using a 
C18 column (Phenomenex Luna 5 , 150 x 4.6 mm) with a flow rate of 0.6 ml/min. The mobile phase
consisted of 30% acetonitrile (ACN) and 0.1% triethylamine, set to pH 3 with HClO4. Metabolites were
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quantified by fluorescence ( ex= 280 nm, em= 311 nm). The metabolite dextrorphan was identified
using co-elution with the reference compound; other metabolites were identified by LC-MS.
Bufuralol metabolism [16, 33]: Reactions were carried out as described above for dextromethorphan,
with 9 concentrations of bufuralol ranging from 0 to 80 M. Metabolites were separated using a C18
column (Phenomenex Luna 5 , 150 x 4.6 mm) with a flow rate of 0.6 ml/min. The mobile phase
consisted of 30% ACN and 0.1% triethylamine, set to pH 3 with HClO4. Metabolites were detected by
fluorescence ( ex= 252 nm, em= 302 nm). Metabolites of bufuralol were identified by comparison with
other studies by comparing retention times and peak areas [33], and 1’-OH bufuralol was identified
using co-elution with a reference compound. LC/MS was used to identify 1,2-bufuralol (data not 
shown).
MDMA metabolism [34]: Reactions were carried out as described above with 9 concentrations of MDMA
ranging from 0 to 220 M. Metabolites were separated using a C18 column (Phenomenex Luna 5 , 150 
x 4.6 mm) with a flow rate of 0.6 ml/min. The mobile phase consisted of 22% ACN and 0.1%
triethylamine, set to pH 3 with HClO4. Metabolites were detected by fluorescence ( ex= 280 nm, em=
320 nm). MDA was identified using the synthesized reference compound (kind gift of Urs Meyer), and
the catechol 3,4-dihydroxy-methylamphetamine (3,4-OH-MA) was identified previously using
electrochemical detection [18]. The peak areas of all metabolites were quantified by Shimadzu Class VP 
4.3. Reaction rates were calculated and plotted against the substrate concentrations to obtain Michaelis 
Menten curves, from the ‘one site binding hyperbola fitting’ module of Graph Pad Prism 4.0, yielding Km
and Vmax values. 
Identification of metabolites using LC-MS 
To identify any unknown metabolites of dextromethorphan, LC-MS was used. For LC-MS measurements, 
incubations were carried out as described above with 40 M substrate, and E. coli membranes 
containing 25 nM CYP2D6 (wild-type or F483A mutant CYP2D6), and CPR. Volumes of 50 l supernatant 
were injected and separated using a phenyl column (Phenomenex Phenyl 150 x 4.6 mm) with a flow
rate of 0.6 ml/min. The metabolites were eluted using a gradient starting with a 5% ACN eluens, 
supplemented with 20 mM ammonium acetate, increasing linearly to 90% ACN with 20 mM
ammoniumacetate in 14 min and analyzed by MS. Positive ion Atmospheric Pressure Chemical 
Ionisation (APCI) was used on a LCQ Deca mass spectrometer (Thermo Finnigan), vaporizer 
temperature 450 ˚C, N2 as sheath (40 psi) and as auxiliary gas (10 psi), needle voltage 6000 V, heated 
capillary 150 ˚C. MS/MS was performed with an activation energy of 30%.
Determination of dissociation constants 
Dissociation constants were determined for dextromethorphan, bufuralol and MDMA in disposable 1 ml
cuvettes. Two cuvettes were prepared containing 1 M of purified CYP (wild-type or F483A mutant
CYP2D6) in a final volume of 500 l 100 mM potassium phosphate buffer (KPi) pH 7.4. Aliquots of 5 l
of a 1 mM substrate solution in KPi buffer were added to the sample cuvette, while the same amount of 
KPi buffer was added to the reference cuvette. Difference spectra from 350 to 450 nm were taken after
every addition. In total, 11 aliquots were added, which corresponds to a substrate concentration 
ranging from 10 M (addition 1) to 104 M (addition 11). Upon type 1 binding of the substrates, a peak
at 390nm and a trough at 420nm appeared. The A390nm-420nm values were plotted against the substrate
concentration, and the ‘one site binding hyperbola fitting’ module of Graph Pad Prism 4.0 was used to
estimate the spectral dissociation constants (Ks).
Results
Expression of wild-type and F483A mutant CYP2D6
Wild-type and F483A mutant CYP2D6 were successfully expressed in E. coli. A typical cell 
culture yielded approximately 400 nM CYP, and the expression levels of CYP were not 
affected by the F483A mutation (Figure 2). The CYP and CPR concentrations in the 
membranes were similar for wild-type and F483A mutant CYP2D6 (Table 1). The purified 
fractions contained 50  5 M of CYP for wild-type and mutant. The CYP content of wild-
type and mutant membranes or purified fractions did not decrease after storage of up to six 
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months at –80 C and repeated cycles of freeze-thawing, indicating that the stability of the 
enzyme was not significantly influenced by the mutation. 
A substantial amount of P420, the inactive form of CYP, could also be detected in the whole 
cell fractions and in the membrane factions. The amount of P420 in wild-type and F483A
mutant CYP2D6 was similar (Figure 2). In the purified fractions, no P420 could be detected.











Figure 2. CO-dif erence spec a of E. coli JM109 cells expressing wild type and F483A mutant CYP2D6.
The cell samples, taken after 48h of exp ession, were diluted two-fold before the spectra were
recorded. Solid line: wild-type CYP2D6; dashed line: F483A mutant CYP2D6. Bo h spectra correspond to





Table 1. CYP and CPR concentrations in membrane fractions. 
Wild-type F483A
[CYP] ( M) 8.1  0.8 7.9  0.7 
[CPR] ( M) 4.7  0.5 4.0  0.5 
[CYP]/[CPR] ratio 1.7  0.3 2.0  0.3 
CPR concentrations were calculated from CPR activities of 15 mM Cyt C/minute for CYP2D6 and 12.9 
mM Cyt C/minute for F483A mutant CYP2D6.
Metabolism of model compounds 
The CYP2D6 marker substrate MAMC was O-demethylated by wild-type CYP2D6 with a Km of 
42 M and a Vmax of 2.0 min-1 (Table 2). In contrast, the F483A mutant CYP2D6 did not 
form any detectable HAMC; re-analysis of the samples using HPLC also showed no
detectable metabolites of MAMC. 
The main metabolite formed upon dextromethorphan metabolism by wild-type CYP2D6 was 
the O-demethylated form, dextrorphan (Table 2) (m/z 258 and MS/MS m/z 201). In 
addition, trace amounts of the N-demethylated compound, 3-methoxymorphinan (m/z 258 
and MS/MS m/z 215), were detected, but the amounts were too low to determine accurate 
enzyme kinetic parameters (Figure 3). The F483A mutant also formed dextrorphan, with a 
15-fold higher Km  and a two-fold higher Vmax than the wild-type resulting in a 7.5-fold lower
Vmax/Km. 3-Methoxymorphinan was formed by F483A mutant CYP2D6 with higher activity
than the wild-type, and Vmax and Km values could be determined (Table 2). In addition, trace 
amounts of two other metabolites were observed (Figure 4). LC-MS analysis showed that
these were the double (O- and N-) demethylated 3-hydroxymorphinan (m/z 244 and MS/MS 
m/z 201), and the monohydroxylated, O-demethylated hydroxydextrorphan (m/z 274 and 
MS/MS m/z 217), respectively.
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Bufuralol was metabolized by wild-type CYP2D6 into three detectable metabolites, 1’-OH-
bufuralol, 4-OH-bufuralol and 1’,2’-bufuralol, as described before [18] (Table 2). Although 
the Km values of wild-type and F483A mutant CYP2D6 for bufuralol 1’-hydroxylation were 
very similar, the Vmax of F483A mutant CYP2D6 was 32-fold lower. Under the conditions 
applied, only 1’-OH-bufuralol and trace amounts of 4-OH-bufuralol could be detected for
















Figure 3. HPLC chromatograms of dextromethorphan incubations with wild- ype (A) or F483A mutant (B
CYP2D6. Incubations were carried out as described in the Methods section. Metabolites indicated by
arrows are 1: hydroxy-dextrorphan; 2: 3-hydroxymo phinan; 3: dextrorphan and 4: 3-
methoxymorphinan. The subst ate dextromethorphan had a retention time of 24 minutes and is no














































































































































































































































































































































































































































































MDMA was converted by wild-type CYP2D6 mainly to the catechol i.e. 3,4-OH-MA, with a Km
of 2.2 M and a Vmax of 1.7 x 105 fluorescence units min-1 nmol-1 CYP. Only trace amounts
of MDA [34] were detected. F483A mutant CYP2D6 formed 3,4-OH-MA with a 13-fold higher 
Km and a 2-fold lower Vmax, resulting in a 26-fold lower Vmax/Km value (Table 2). Like for the 
wild-type, trace amounts of MDA were also observed for F483A mutant CYP2D6. In contrast 
to the F120A mutant, no detectable N-hydroxylation of MDMA was performed by F483A 
mutant CYP2D6 [18]. 
f
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Determination o  dissociation constants
The Ks values of dextromethorphan, bufuralol and MDMA were determined for wild-type and
F483A mutant CYP2D6 (Table 3). For MAMC, no Ks values could be determined because this 
ligand has a high absorbance at 350-450 nm that interfered with the binding spectra. 
Dextromethorphan, bufuralol and MDMA all showed type 1 spectra for wild-type and F483A
mutant CYP2D6, indicating that the ligands bind at the substrate binding site. No large 
differences were found between Ks values for wild-type and F483A mutant CYP2D6. Ks
values of dextromethorphan and bufuralol were both in the range of 20–30 M for wild-type
and F483A mutant CYP2D6, while the Ks values of MDMA were higher for both enzymes
(50–60 M).
Table 3  Optical dissociation constants ( M  of substrates for wild- ype and F483A mutant CYP2D6.
KsSubstrate
wild-type F483A
dextromethorphan 23.9  1.1 21.9  0.7 29.5  1.5 38.1  3.5 
bufuralol 19.4  2.0 15.4  1.2 18.2  1.4 21.8  1.9 
MDMA 34.5  2.1 51.5  3.6 52.4  5.0 60.7  7.1 
Optical dissociation cons ants were determined in two separate experiments as described in the
Methods sec ion. Each value represents an independent experiment. The 11 data points were analyzed
in Graphpad P ism using the ‘one s e binding hyperbola fit ing’ module  The standard errors of he its
are shown in the table. 
t
t
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Discussion
The purpose of this study was to investigate the role of CYP2D6 active site residue F483 in 
ligand binding and metabolism. Aromatic residues in the CYP2D6 active site cavity are 
thought to be particularly important, because of their ability to interact with aromatic
moieties present in many CYP2D6 substrates [13]. Recently, it has been described that
substitution of active site F120 by an alanine has large substrate dependent effects on the 
binding and metabolism of typical CYP2D6 substrates [18, 19]. Homology modeling studies 
have also suggested an important role for residue F483 [1, 15, 22-24], but to date 
experimental evidence supporting this suggestion was not available. The results presented
in this study clearly show that substitution of the phenylalanine moiety at position 483 by an 
alanine (F483A) has marked effects on substrate selectivity and regiospecificity when using 
four typical CYP2D6 substrates (Figure 4). The observed effects of the F483A mutation were
found to be strongly substrate-dependent, as was seen recently for F120A. 
F483A mutant CYP2D6 did not metabolize MAMC, in contrast to wild-type CYP2D6. 
Apparently, residue F483 (this study) and residue F120 [18] are both required for 
metabolism of this substrate. These residues could either provide steric constraints to keep 
the substrate in the orientation required for metabolism, or they could function as aromatic
anchoring points. A possible explanation is that MAMC is kept into position by both
phenylalanines in a ‘sandwich’ configuration.
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Dextromethorphan is believed to bind by electrostatic interactions between its basic nitrogen 
atom and the acidic residues E216 and D301 [16]. Recently, it has been shown that 
aromatic residue F120 also plays a role in dextromethorphan metabolism, since substitution
of this residue resulted in the formation of two novel metabolites [18, 19]. The present 
study shows that residue F483 is also involved in metabolism of dextromethorphan. Wild-
type CYP2D6 performed mainly O-demethylation of dextromethorphan, while F483A also 
formed substantial amounts of N-demethylated product. In addition, two extra metabolites 
were formed (Figure 4) that could not be detected in wild-type CYP2D6 incubations, but
have been described previously for F120A mutant CYP2D6 [18, 19]. The Ks values of 
dextromethorphan were similar for wild-type and F483A mutant CYP2D6 (table 3), indicating 
that the binding affinity of dextromethorphan is not greatly affected by the mutation. The
observed effects on the metabolic ratio may therefore result from the different orientations 
that can be adopted by the large, non-flat substrate dextromethorphan in the active site of 





















Figure 4. Structures of the used CYP2D6 substrates: (A) bufuralol, (B) MDMA, (C) MAMC, (D) 
dextromethorphan, Chiral atoms (*), and sites of oxidation by wild-type CYP2D6 are indicated ( ).
For bufuralol metabolism, the acidic residues E216 and D301 have been shown to be 
important because they are involved in the fixation of the basic nitrogen of bufuralol [15, 
16, 33]. Mutagenesis of aromatic residue F120 to alanine, on the other hand, did not 
significantly affect the metabolism of this substrate [18]. In a previous mutagenesis study, it 
was found that the substitution of F483 by tryptophan or isoleucine also had no influence
bufuralol 1’-hydroxylation [1]. In the present study, however, a significant effect on
bufuralol metabolism was observed when F483 was replaced by the smaller alanine. This 
mutation resulted in a 32-fold lower Vmax for bufuralol 1’-hydroxylation, while the Km value 
was hardly affected. The binding affinity of bufuralol was not significantly influenced by the 
F483A mutation (Table 3). The fact that the more conservative substitutions of F483 by 
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tryptophan and isoleucine have no effect on bufuralol metabolism suggests that these amino
acid residues can compensate for the loss of the phenylalanine-residue, by aromatic, 
hydrophobic, and/or steric interaction with bufuralol.
Previous studies with F120A mutant CYP2D6 showed that for this mutant, regioselectivity of
MDMA metabolism had changed significantly. The amount of MDA produced by this mutant
was greatly increased compared to wild-type CYP2D6. In addition, a novel metabolite was 
formed which could be identified as N-OH-MDMA [18]. In the present study it was shown 
that the effect of a F483A substitution on MDMA did not influence the metabolic ratio, but
only the kinetic parameters of 3,4-OH-MA formation (Table 2). For the formation of the 
major metabolite 3,4-OH-MA, the Km value of F483A mutant CYP2D6 was 13-fold higher
than the wild-type value, while the Vmax value decreased only two-fold (Table 2). The Ks
value of MDMA was similar for the wild-type and F483A mutant CYP2D6 (Table 3). The fact 
that the Km value and the Ks value do not follow the same trend is because Km and Ks values 
represent qualitatively different processes. Whereas the Ks value merely reflects the spin 
shift upon binding of a substrate, the parameter Km is also influenced by catalytic processes
such as product release [35]. 
Residue F120 was shown to be important for MDMA metabolism, but not for bufuralol 
metabolism [18], while for F483A both bufuralol and MDMA metabolism are affected by the 
mutation. For bufuralol, only the Vmax was altered, while for MDMA O-demethylenation 
mainly the Km was influenced by the mutation. These results suggest that these two 
compounds have different modes of binding, despite their high degree of structural
similarity.
In conclusion, the data presented in this study prove that F483 plays an important role in 
CYP2D6 selectivity and activity. Together with acidic residues E216 and D301 and aromatic
residue F120, it defines the ligand binding properties and the regiospecificity of metabolism. 
However, of the at least 25 residues postulated to form the active site of CYP2D6, only eight
have been subjected to experimental studies [36]. Therefore it is possible that in the near 
future additional residues will be identified that contribute to ligand binding and metabolism. 
For E216 and D301, it has been shown that they are important for the fixation of the basic 
nitrogen atom in ligands [14-16]. The strongly substrate dependent effects observed after 
mutagenesis of the aromatic residues F120 and F483 can be attributed either to the change 
in the active site topology upon removal of the phenylalanine residues, or can be due to loss
of aromatic interaction points.
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Metabolism of N-substituted 7-methoxy-4-(aminomethyl)-coumarins by 
cytochrome P450 2D6 mutants indicates additional substrate interaction points
Peter H.J. Keizers, Ben R. van Dijk, Chris de Graaf, Barbara M.A. van Vugt-Lussenburg, Nico
P.E. Vermeulen, and Jan N.M. Commandeur
adapted from: Xenobiotica 2006 in press 
Previous studies have shown the critical roles residues F120 and F483 play in the oxidative
metabolism of 7-methoxy-4-(aminomethyl)-coumarin by cytochrome P450 2D6 (CYP2D6). In 
this study, a series of N-alkyl-7-methoxy-4-(aminomethyl)-coumarins (MAMC-analogs) were 
used as substrates for the F120A and F483A mutants in order to further probe the active 
site of CYP2D6. The F120A and F483A mutants of CYP2D6 displayed significant activity
towards the MAMC-analogs. Automated docking studies of the MAMC-analogs in a CYP2D6 
homology model suggested a distal hydrophobic active site binding cleft for the substrate N-
alkyl chains, consisting of the residues L213 and V308.
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Introduction
One of the most important drug metabolizing phase I enzymes in humans is cytochrome 
P450 2D6 (CYP2D6). Although CYP2D6 accounts for just 3% of all hepatic CYP, it is involved 
in the metabolism of about 30% of currently marketed drugs, and it is well known for its 
genetic polymorphisms [1]. Structural information on the active site of this enzyme is 
beneficial for rational drug development [2]. 
Two active site acidic residues, D301 and E216, have been suggested in computational 
studies to be involved in fixation of the basic nitrogen-atom that is present in most CYP2D6 
substrates [3]. The importance of both residues for CYP2D6 activity was confirmed by site-
directed mutagenesis studies [4, 5]. In modeling studies, D301 appeared to be involved in 
stabilizing the B/C-loop containing F120, rather than binding the substrate [6]. Site-directed
mutation studies on F120 itself indicated that this residue indeed determines catalytic 
selectivity and regioselectivity in CYP2D6 [7, 8]. In addition, F483 was shown to be an 
important residue in metabolism by CYP2D6 [9]. It was suggested that F120 and F483
anchor the substrates, which are typically aromatic compounds [3], by aromatic interactions 
and -stacking. Typically, 7-methoxy-4-(aminomethyl)-coumarin (MAMC) was not
metabolized by the F120A mutant, nor by the F483A mutant, although both mutants did 
metabolize other model CYP2D6 substrates [8, 9]. Apparently, both phenylalanine residues 
are crucial in facilitating MAMC in a reactive conformation in the CYP2D6 active site. 
Previously, a series of MAMC-analogs was evaluated as alternative substrates for CYP2D6 
[10]. It was found that by increasing the N-alkyl chain length, the affinity for the enzyme 
increased substantially, suggesting that additional interaction points play a role in binding of 
the longer N-alkyl chain substrates. In the current study, we have examined the oxidative 
metabolism of this series of MAMC-analogs by the F120A, F483A and D301Q mutants of 
CYP2D6, in order to verify the existence of distal interaction points. Automated docking of 
the MAMC-analogs into the CYP2D6 homology model [11], was employed to rationalize the
experimental findings and to allocate the distal active site residues involved in substrate 
interaction.
Materials and Methods 
Materials
The pSP19T7LT plasmid containing the cDNAs of human cytochrome P450 2D6 with a C- terminal His6-
tag and human NADPH-cytochrome P450 reductase in tandem was used as described before [9]. N-
alkyl-7-methoxy-4-(aminomethyl)-coumarins and N-alkyl-7-hydroxy-4-(aminomethyl)-coumarins (Figure
1) were synthesized before as described [10, 12] and were higher than 98% chemically pure.
Enzyme production
The D301Q mutation was introduced into pSP19T7LT using the QuickChange XL Site-Directed
Mutagenesis kit (Stratagene, La Jolla CA). The sequences of the forward- and reverse oligonucleotides
respectively, with the mutated residue in italic, were as follows: 5’-ATA GTG GTG GCT CAG CTG TTC 
TCT GCC GG-3’ and 5’-CC GGC AGA GAA CAG CTG AGC CAC CAC TAT-3’. After mutagenesis, the
presence of the mutation was confirmed by DNA sequencing. The F483A and F120A mutants were 
obtained as previously described [8, 9]. The mutants and wild-type CYP2D6 containing pSP19T7LT
plasmids were transformed into Escherichia coli strain JM109. Expression and membrane isolation was
carried out as previously described [8]. Membranes were resuspended in 0.5% of the original culture
volume in a 50 mM potassium phosphate buffer, pH 7.4, containing 10% glycerol, 1 mM EDTA and 1
mM DTT, and P450 contents were determined by CO difference spectra [13]. The expression levels of
the D301Q mutant were approximately 200 nM, similar to those of wild-type CYP2D6.
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Analysis of oxidative metabolism
O-demethylation of ten concentrations ranging from 0 to 200 M MAMC and analogs by CYP2D6 was
analyzed by plate reader technology as previously described [8], using the synthesized references for
quantification. N-dealkylation was determined by HPLC. For this, enzyme reactions were carried out in
200 l potassium phosphate buffer, containing 5 mM MgCl2, supplemented with 10 concentrations 
ranging from 0 to 200 M of the MAMC-analogs and E. coli membranes corresponding to 40 nM 
CYP2D6. After 5 min of pre-incubation at 37 °C, the reactions were initiated with an NADPH
regenerating system [8]. The reactions were allowed to proceed for 20 min before they were quenched
by the addition of 20 l 23% HClO4. After centrifugation (10 min, 6800 g), 30 l aliquots of the 
supernatant were analyzed using a C18 column (Phenomenex Inertsil ODS 150 x 4.6 mm) with a flow
rate of 0.6 ml/min. Incubation components were eluted by a linear gradient from 5% acetonitrile in 20
mM ammonium acetate, to 90% acetonitrile in 10 mM ammonium acetate. The products were detected
by fluorescence ( ex= 360 nm, em= 460 nm) and identified and quantified using the synthetic
references. Metabolite peak areas were quantified using Shimadzu Class VP 4.3. Kinetic parameters
were analyzed using non-linear regression in Graph Pad Prism 3.0 (Graph Pad Software Inc. San Diego
CA).
Molecular Modeling
A protein homology model of CYP2D6 was constructed, refined and validated as described before [11].
MAMC and analogs were automatically docked in the CYP2D6 homology model, according to the
method that was previously found optimal in predicting sites of oxidation of substrates in CYP2D6 [14].
In short, preparation of protein and substrate input structures, defining the binding pocket, and the
GRID-based prediction of energetically favorable positions of active site water molecules was performed
as previously described [15]. A total of fifty docking poses were generated per substrate using the










Figure 1: Structure and names of the N-alkyl-7-methoxy-4-(aminomethyl)-coumarins. Sites of oxidation
are indica ed ( ).t
Results and discussion 
The plate reader and HPLC analyses of the enzyme incubations with the MAMC-analogs 
(Figure 1) showed that the O-demethylated and N-dealkylated products were formed 
linearly for at least 30 minutes. Quantification of O-demethylation by HPLC led to similar 
results as quantification by plate reader analysis.
Wild-type CYP2D6 efficiently O-demethylated MAMC and its analogs (Table 1), with Km-
values decreasing with N-alkyl chain length, consistent with previous observations [10]. The 
F120A mutant of CYP2D6, which did not metabolize MAMC at all, as described previously 
[8], O-demethylated all the MAMC-analogs having an alkyl-group on the 4-aminomethyl
position. Similarly to the wild-type enzyme, the F120A mutant displayed a decreasing Km
with increasing N-alkyl chain length. The Vmax-values however, were in all occasions far 
lower than those of the wild-type and were found to substantially increase with N-alkyl
chain length.
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The F483A mutant of CYP2D6 also did not metabolize MAMC, as described previously [9]. 
Furthermore, O-demethylation of MMAMC was not observed. O-demethylation activities 
towards the longer chain MAMC-analogs were similar to that by the F120A mutant. Like in
the wild-type enzyme, the catalytic efficiency of the F120A and F483A mutants towards the 
MAMC-analogs increased with the length of the N-alkyl chain (Figure 2), suggesting that
distal active site residues are involved in substrate binding. To identify these residues, the 
optimal binding configurations of the MAMC-analogs in CYP2D6 were examined by 
automated docking in the homology model. 
A
B
Figure 2: Catalytic efficiencies (Vmax/Km) of the wild type, the F120A, the F483A, and the D301Q mutant
of CYP2D6 towards the substrates MAMC, MMAMC, EMAMC, PMAMC and BMAMC (blank, light gray,
gray, dark gray and black bars respectively), as described in the Methods sec ion. O-demethylation




The highest scoring binding modes of MAMC, MMAMC and BMAMC are shown in Figure 3,
and the optimal orientations of the coumarin ring systems of EMAMC and PMAMC were very 
similar to those of MMAMC and BMAMC. The close contacts between MAMC-analogs and 
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specific CYP2D6 active site residues are summarized in Table 3. MAMC and the analogs have 
approximately the same binding mode, corresponding to O-demethylation, and providing 
electrostatic interactions between their nitrogen atoms and the E216 carboxylate. With the
exception of MAMC, F120 provides -stacking interactions to the substrates aromatic
moiety. An additional difference between the binding modes of the five substrates concerns 
the conformation of the N-alkyl chain. BMAMC and to a lesser extend PMAMC, accommodate 
their relatively long N-alkyl chains in a cleft formed by the apolar sidechains of residues 
L213, V308, and F483, at the top of the binding pocket, providing additional hydrophobic 
interactions with the CYP2D6 active site. Very recently, a crystal structure of CYP2D6 was 
reported [18]. This structure shows high similarity with our homology model, placing F120, 
F483, D301 and L213 in approximately identical positions, therefore confirming the model, 
and supporting the findings in the present study. 
From the series of MAMC-analogs, MAMC is O-demethylated with far the lowest catalytic 
efficiency by wild-type CYP2D6 (Figure 2). In the automated docking studies, MAMC was 
found to have an optimal binding conformation different from its analogs. The conformation
of the MAMC-analogs, stacked to F120, is apparently beneficial for activity. This could 
explain why MAMC is a worse substrate than its analogs and also why mutation of F120 to 
an alanine leads to an enzyme incapable of metabolizing MAMC. Mutating F483 to an 
alanine might lead to binding of MAMC even further away from the heme, because F483 
was found to interact with MAMC by hydrophobic contacts (Table 2). The fact that the
F483A mutant does not metabolize MAMC supports this hypothesis. 
Table 2: Ionic and hydrophobic in eractions between the MAMC analogs and CYP2D6 ac ive site
residues.
t - t
Substrate cResidue Interactiona SRS b
MAMC MMAMC EMAMC PMAMC BMAMC
F120 Hydrophobic 1 - + + + +
L213 Hydrophobic 2 + - - + +
E216 Ionic 2 + + + + +
V308 Hydrophobic 4 + - - + +
V374 Hydrophobic 5 - + + - +
F483 Hydrophobic 6 + - + + +
a Hydrophobic subs ate-protein interac ions are defined as the occurrence o  at least hree close
contacts (within 4 Å) between the carbon atoms of the substrate and the (aromatic or aliphatic) carbon 
atoms of the side chain of a specific amino acid residue. Ionic interactions are defined as at least one 
close contact (within 3.5 Å) between charged groups in the substrate and charged groups in the amino
acid residue. 
tr t f t
r tb Subst ate recogni ion site (SRS) as defined for the CYP2 family members [19]. c + 
indicates interaction, - indicates no interaction.
It has been hypothesized that F120 and F483 function in concert to maintain substrates in 
place by hydrophobic interactions and -stacking, more or less sandwiching the substrate 
into a reactive conformation [20, 21]. In the current study, similar trends in catalytic 
efficiency of O-demethylation of the MAMC-analogs were observed for the F120A and F483A 
mutants of CYP2D6, which could suggest a similar role for the two residues. The N-
dealkylation of the substrates however, was much more significant with the F120A mutant 
than with the F483A mutant (Table 1, Figure 2). Hence the F120A mutant appears to allow 
more for variable orientations of the MAMC-analogs than the F483A mutant does. By 
automated docking of the MAMC-analogs different roles of the two phenylalanine residues
could be distinguished; F120 appeared to be more involved in aromatic interaction, whereas 
F483 more sterically influenced substrate binding (Table 2 and Figure 3).
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The D301Q mutant of CYP2D6 displayed the same trend in catalytic efficiency of O-
demethylation of the MAMC-analogs as the F120A mutant. Furthermore, mutation of D301 
also led to a significant increase in N-dealkylation of the MAMC-analogs. The correlation 
between the effects of mutation of F120 and D301 is consistent with the proposed role of 
D301 in positioning F120 [5, 6]. The differences in reactivity towards the MAMC-analogs 
that were observed for the two mutants may be explained by the nature of the different 
mutations, affecting in one case the removal, and in the other case redirection of the phenyl 
moiety of residue 120, combined with the removal of part of the active site negative charge 
[6].
Figure 3  MAMC and BMAMC (left panel), and MMAMC and BMAMC (right panel), docked into the
CYP2D6 homology model as described in the Methods section. The molecular Connoly surface of the
ac ive site of CYP2D6 is depicted; the surfaces of carboxyl oxygen atoms of D301 and E216, and the
apolar sidechain atoms of L213, V308, and F483 are shown. Amino acid side chains involved in
subs rate binding are shown as s icks. For reasons of clarity, only the loca ions of E216 and V308 are 





In conclusion, the addition and elongation of an N-alkyl chain in the MAMC-analogs restored
the ability of the F120A and F483A mutants of CYP2D6 to catalyze MAMC. Based upon 
automated docking studies a distal hydrophobic active site binding cleft for the N-alkyl
chains is suggested, consisting of L213 and V308, which appear to be as important for 
activity as the two phenylalanine residues. 
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Role of the conserved threonine 309 in mechanism of oxidation by cytochrome
P450 2D6 
Peter H.J. Keizers, Loek H.M. Schraven, Chris de Graaf, Mats Hidestrand, Magnus Ingelman-
Sundberg, Ben R. van Dijk, Nico P.E. Vermeulen, and Jan N. M. Commandeur
adapted from: Biochemical and Biophysical Research Communications 2005 338: 1065-74 
Based on sequence alignments and homology modeling, threonine 309 in cytochrome P450 
2D6 (CYP2D6) is proposed to be the conserved I-helix threonine, which is supposed to be 
involved in dioxygen activation by CYPs.  The T309V mutant of CYP2D6 displayed a strong 
shift from O-dealkylation to N-dealkylation reactions in oxidation of dextromethorphan and 
3,4-methylenedioxymethylamphetamine (MDMA). This may be explained by an elevated
ratio of hydroperoxo-iron to oxenoid-iron of the oxygenating species. In consistence, using
cumene hydroperoxide, which directly forms the oxenoid-iron, the T309V mutant again
selectively catalysed the O-dealkylation reactions. The changed ratio of oxygenating species
can also explain the decreased activity and changed regioselectivity that was observed in 7-
methoxy-4-(aminomethyl)-coumarin (MAMC) and bufuralol oxidation respectively by the 
T309V mutant. Interestingly, the T309V mutant always showed a significantly increased, up 
to 75-fold, higher activity compared to the wild-type when using cumene hydroperoxide. 
These results indicate that T309 in CYP2D6 is involved in maintaining the balance of 
multiple oxygenating species and thus influences substrate and regioselectivity. 
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Introduction
Cytochromes P450 (CYPs) are enzymes responsible for the oxidative biotransformation of a 
large variety of endogenous and exogenous substrates, like steroids, carcinogens and also 
drugs, and can be found in virtually all organisms [1]. In humans, one of the most
important CYPs is CYP2D6. This hepatic drug metabolizing enzyme is involved in the phase I 
metabolism of about 30% of the currently marketed drugs, including neuroleptics,
antidepressants, -blockers, opioids and antiarythmics [2]. The enzyme is known for its 
genetic polymorphisms and gene multiplicities, even increasing its clinical relevance [3]. 
Clearly there is a need for structural data on this enzyme, to understand and predict the
oxidative metabolism of known and new (drug-like) compounds [4-6].
So far, little is known about amino acid residues involved in the mechanism of oxygen 
activation by CYP2D6. In several other CYPs a highly conserved threonine residue in the I-
helix was experimentally shown to have a role in fixation and activation of the heme bound
oxygen [7-9]. In CYP101 (cam), the heme bound oxygen is activated by proton delivery 
mediated by threonine 252 and aspartic acid 251. The latter is forming hydrogen bonds to 
charged residues at the surface, thereby serving as a bridge between solvent trapped in the 
groove of the I-helix and bulk solvent [10]. The threonine 252 hydroxyl group subsequently 
forms a hydrogen bond to a catalytic water molecule which is the ultimate proton donor [11, 
12].  In CYP102 (BM3), a similar proton delivery system is proposed via threonine 268, 
glutamic acid 267, and a catalytic water molecule [13, 14]. It is suggested that in both 
CYP101 and CYP102, dioxygen to heme binding triggers conformational changes in the I-
helix, controlled by the highly conserved threonine residue and its neighboring acidic 
residue, which together enable the transport of a catalytic water molecule into the active
site [12, 14]. In CYP107A (EryF), which is lacking the conserved threonine, the natural 
substrate 6-deoxyerythronolide itself is involved in proton delivery by forming a hydrogen 
bond with the catalytic water molecule [15], or directly with the oxygen [16], and in CYP55A
(nor), which does not have the conserved acidic residue in close proximity to the threonine, 
an alternate proton delivery pathway has been proposed [17]. Obviously, the role of
threonine residues can vary between the CYP isoenzymes [13].
The overall amino acid sequence and structure of the I-helix is highly conserved among 
CYPs in general and the mammalian CYP2 family more specifically [18, 19]. The crystal 
structures of CYPs 2B4, 2C5, 2C8 and 2C9 show a cluster of four conserved threonine
residues in the I-helix above the porphyrin plane [20]. An identical cluster is found in the
sequence of CYP2D6. According to amino acid sequence alignments and based upon protein 
homology modeling [6, 21], T309 is expected to be the conserved threonine involved in 
proton delivery to the catalytic water (Figure 1). The role of the other conserved threonine 
residues in the mammalian CYPs is as yet unknown; they might also have a role in the
proton delivery network.
In this study we have experimentally examined the roles of T309 and T312 by mutating 
these to a valine. These mutations do not significantly alter the size of the residue whereas
the putative proton delivering hydroxyl moiety is removed. T309 was selected because it is
expected to be the ultimate proton donor to the oxygen, T312 because it is one turn of the 
I-helix away but still pointing with its hydroxy-moiety towards the porphyrin plane. The
oxidation of model substrates by the two mutants was examined and compared to that by 
wild-type CYP2D6. Furthermore, the binding of substrates to and the formation of 
uncoupling products by the T309V mutant have been measured. In addition, the oxene
donor cumene hydroperoxide (CuOOH) was used in the substrate oxidation reactions by 
wild-type and the T309V mutant, to distinguish oxidizing species used by the enzymes. It 
has been shown before that by using the oxygen donor CuOOH, formation of the oxenoid-
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iron is mimicked, whereas the other reactive oxygenating species are not formed [22, 23]. 








CYP Species I-helix sequence Last residue














107A S. erythraea ADELTSIALVLLLAGFEASVSLIGIGTYLLLTHP 261
55A1 F. oxysporum KSDAVQIAFLLLVAGNATMVNMIALGVATLAQHP 258
1A2 Rat QEKIVNIVNDIFGAGFETVTTAIFWSILLLVTEP 335
2B4 Rabbi HQNLILTVLSLFFAGTETTSTTLRYGFLLMLKYP 318
2E1 Rabbi LENIAVTVADMFFAGTETTSTTLRYGLLILLKHP 319
2C5 Rabbi LESLVIAVSDLFGAGTETTSTTLRYSLLLLLKHP 314
2D6 Human DENLRIVVADLFSAGMVTTSTTLAWGLLLMILHP 325
B
Figure 1: P o ein model displaying the ac ive site of CYP2D6 wi h dioxygen and S-bufuralol bound,
showing the pos ions of the substrate interac ing residues F120, F483 and E216, he conserved
puta ive oxygen activating T309, and conserved T312 (A). A colored version of the figure is shown in
the Appendix of this thesis. Alignment of the I-helix protein sequences (drnelson.utmem.edu/ 
CytochromesP450.html) showing the conserved threonine residue (in bold) of CYPs of which his
residue was experimentally shown to be involved in oxygen activation (B). The threonine mutants of the 
bacterial CYPs 101, 102A1 and fungal CYP55A1 were c ystallized [10, 13, 17] and so are mammalian
CYPs 2B4 [24] and 2C5 [25], the latter struc ure was used to build the CYP2D6 model. In CYP107A, the
A245T mutant was shown to oxidize alternative subs ates [26], and in CYPs 1A2, 2B4 and 2E1 the
conserved threonine residues were also subjected to mutagenesis studies [7, 27  28].
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Materials and Methods 
Materials
Escherichia coli JM109 were obtained from DSMZ. 7-methoxy-4-(aminomethyl)-coumarin (MAMC), 7-
hydroxy-4-(aminomethyl)-coumarin (HAMC), 3,4-methylenedioxymethylamphetamine (MDMA) and 3,4-
methylenedioxyamphetamine (MDA) were synthesized before as described [29, 30]. Bufuralol
hydrochloride was obtained from Gentest, dextromethorphan hydrobromide and dextrorphan tartrate
were obtained from Sigma, cumene hydroperoxide was obtained from Aldrich, Emulgen 911 was
obtained from Kao chemicals. All other chemicals were of analytical grade and obtained from standard
suppliers.
Cons uc ion of plasmid for bicistronic expression o  CYP2D6 and reduc asetr t f t
r
The cDNA of human NADPH-cytochrome P450 reductase was generated by reverse transcription of
human genomic DNA using a reverse transcription kit with oligo dT primers (Clontech). After reverse 
transcription, the cDNA was amplified with primers creating restriction enzyme cleavage sites. Human
CYP2D6 was amplified from a cDNA. During amplification additional C-terminal histidines as well as sites 
for restriction enzyme cleavage were introduced. The amplified and digested products were
subsequently ligated into the expression plasmid pSP19T7LT [31] in tandem, with a short linker region
in-between the two genes. The correct gene sequence was verified by DNA sequencing.
Site-directed mutagenesis
The threonine 309  valine (T309V) and threonine 312  valine (T312V) mutations were introduced
into pSP19T7LT containing CYP2D6 using the QuickChange XL Site-Directed Mutagenesis kit 
(Stratagene). The sequences of the forward- and reverse oligonucleotides, respectively, with the 
mutated residuein italic, were as follows: 5’-T GCC GGG ATG GTG GTC ACC TCG ACC ACG C-3’ and 5’-A
CGG CCC TAC CAC CAG TGG AGC TGG TGC G-3’ for T309V, and 5’-G GTG ACC ACC TCG GTC ACG CTG 
GCC TGC G-3’ and 5’-C CAC TGG TGG AGC CAG TGC GAC CGG ACC C-3’ for T312V. After mutagenesis,
the presence of the desired mutation was confirmed by DNA sequencing.
Exp ession and Purification of CYP2D6
The pSP19T7LT plasmids containing wild-type and mutants of CYP2D6 cDNAs were transformed into
Escherichia coli strain JM109. Expression and membrane isolation was carried out as described [32].
Membranes were resuspended in 0.5% of the original culture volume of KPi-glycerol buffer (50 mM
potassium phosphate buffer, pH 7.4, 10% glycerol) and stored at –80˚ C after determining CYP
contents by CO difference spectra [33]. The enzymes were purified, first by solubilization from the
membranes by stirring in KPi-glycerol supplemented with 0.5% Emulgen 911 for 2 hrs at 4°C. Insoluble
parts were removed by centrifugation (60 min, 120,000 g at 4 °C). Supernatant (100 ml) was
incubated, gently rocking, with 4 ml Ni-NTA agarose slurry for 60 min at 4 °C. The Ni-NTA agarose was
transferred into a 15 ml polypropylene tube with porous disc (Pierce), and washed with 3 volumes of
KPi-glycerol buffer containing 2 mM histidine. Subsequently, CYP2D6 was eluted with 8 ml 0.2 M
histidine. After overnight dialysis in KPi-glycerol buffer, the sample was concentrated to 2 ml in a
Vivaspin 20 filtration tube (10.000 MWCO PES, Sartorius). The purity of the enzymes was checked by 
SDS polyacrylamide gelelectrophoresis, yielding single bands at approximately 55 kD after Coomassie
staining.
Metabolism assays 
Oxidative metabolism of model substrates by mutants and wild-type CYP2D6 were performed as
described previously [32]. Shortly, MAMC O-demethylation reactions were carried out in duplicate in a
96 wells plate, in a total volume of 200 l. The reaction mixture consisted of 5 mM MgCl2 in KPi buffer,
0-200 M MAMC and E. coli membranes corresponding to 40 nM wild-type or mutant CYP2D6. The 
reactions were initiated by the addition of an NADPH regenerating system, resulting in final
concentrations of 0.1 mM NADPH, 0.3 mM glucose-6-phosphate, and 0.4 units/ml glucose-6-phosphate
dehydrogenase. The reaction was monitored for 30 min at 37°C on a Victor2 1420 multilabel counter




Dextromethorphan O-demethylation reactions were carried out in 200 l KPi buffer containing 5 mM 
MgCl2, with 0-100 M dextromethorphan and E. coli membranes corresponding to 25 nM wild-type or
mutant CYP2D6. After 5 min of pre-incubation at 37°C, the reactions were initiated with an NADPH
regenerating system as described above. The reaction was allowed to proceed for 10 min before it was
stopped by the addition of 20 l 23% HClO4. After centrifugation (10 min, 6800xg), 30 l aliquots of the 
supernatant were analyzed by HPLC, using a C18 column (Phenomenex Inertsil ODS 150x4.6mm) with
a flow rate of 1 ml/min. The mobile phase consisted of 30% acetonitrile and 0.1% triethylamine, set to 
pH 3 with 70% HClO4. Products were detected by fluorescence at ex= 280nm, em= 311nm and 
dextrorphan was quantified using a calibration curve of the commercial reference. 
Bufuralol oxidation reactions were carried out as described above with 0-100 M bufuralol and E. coli
membranes corresponding to 25 nM wild-type or mutant CYP2D6. Analytes were separated using a C18
column (Phenomenex Inertsil ODS 150x4.6mm) with a flow rate of 0.6 ml/min. The mobile phase
consisted of 30% acetonitrile and 0.1% triethylamine, set to pH 3 with 70% HClO4. Products were 
detected by fluorescence at ex=252nm, em=302nm and identified by comparison to a standard in the
case of 1’-OH-bufuralol (kind gift of Dr. Urs Meyer), and previous studies [34]. The product masses 
were verified by LC-MS, using the same conditions as described before [6]. 6-OH-bufuralol eluted at
17.3 min, m/z 278, fragmenting to 260, 242 (100%), 204 and 186. 1’-OH-bufuralol eluted at 18.0 min,
m/z 278, fragmenting to 260 (100%), 221 and 203. 4-OH-bufuralol eluted at 18.2 min, m/z 278, 
fragmenting to 260 (100%) and 204. 1’-2’-bufuralol eluted at 19.6 min, m/z 260, fragmenting to 242 
(100%) and 186. 
MDMA oxidation reactions were carried out as described above with 0-200 M MDMA and E. coli
membranes corresponding to 25 nM wild-type or mutant CYP2D6. Analytes were separated using a C18
column (Phenomenex Inertsil ODS 150x4.6mm) with a flow rate of 0.4 ml/min. The mobile phase
consisted of 23% acetonitrile and 0.1% triethylamine, set to pH 3 with 70% HClO4. Products were 
detected by fluorescence at ex= 280nm, em= 320nm, MDA was quantified using a calibration curve of
the synthetic reference.
The oxidation reactions supported by CuOOH were in presence of 100 M of substrate and initiated by
the addition of 500 M CuOOH. For MAMC oxidation, 25 nM of enzyme was added to the incubation and
the reaction was monitored for 15 min, for the other substrates 2.5 nM of enzyme was added and the
reactions were allowed to proceed for 5 min. Peak areas of all products were quantified by Shimadzu
Class VP 4.3 and analyzed using Graph Pad Prism 3.0 software (GraphPad Software Inc.).
Optical Titrations
Dissociation constants of the substrates to the enzymes were determined by spectral titration, 
according to the method of Jefcoate [6, 35]. Spectra were taken at room temperature on a Pharmacia
Ultrospec 2000 spectrometer. In short, 1 ml of 0.5 M purified enzyme in KPi-glycerol buffer was
divided over two cuvettes, to the first 5 l of a 1 mM solution of compound in the same buffer was 
added, to the second the same volume of just buffer. Difference spectra from 350 to 450 nm were 
taken before, and after each addition of compound. The substrates themselves did not show
absorbance in this spectral range at the concentrations used. The difference between the absorbance at 
390 nm and 425 nm was plotted against the substrate concentration to estimate the dissociation
constant (Ks) using Equation 1 in Graph Pad Prism 3.0 software, where B is the absorbance difference 




max       (1)
Uncoupling of substrate monooxygenation activity 
To determine uncoupling of activity, incubation reactions were carried out as described above in KPi
buffer with 5 mM MgCl2, which was treated with Chelex 100 beads (Biorad) and supplemented with 0.2
mM DETAPAC to remove traces of iron. Substrates (100 M) and E. coli membranes corresponding to
25 nM wild-type or mutant CYP2D6 were added to a total reaction volume of 200 l. To measure the 
total amount of formed hydrogen peroxide and superoxide anion radical, 1870 units of superoxide
dismutase and 40 units of horseradish peroxidase were added together with 3.6 mM para-hydroxy-
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phenyl-acetic acid [36]. Reactions were initiated by adding the NADPH regenerating system described
above and terminated after 10 min by adding 3% HClO4. After centrifugation (10 min, 6800xg), 30 l
aliquots of the supernatant were analyzed by HPLC, using a C18 column (Phenomenex Inertsil ODS 
150x4.6mm) with a flow rate of 0.6 ml/min. Analytes were eluted by a gradient: 5 min of A (20 mM
ammonium acetate containing 5% acetonitrile) followed by an increase to B (10 mM ammonium acetate
containing 90% acetonitrile) over 5 min. After running in B for 5 min the gradient returned to starting 
conditions in 1 min and equilibrated for another 10 min. The product 2,2’-dihydroxybiphenyl-5,5’-
diacetate eluted at 4.6 min and was detected by fluorescence ( ex= 323 nm, em= 400 nm). H2O2 was 
quantified by a calibration curve made by adding various concentrations of 0 to 1 M of H2O2 to 
incubations without substrate.
Results
Expression and spectroscopy of wild- ype and mutants of CYP2D6t
The expression levels of T309V, T312V and wild-type CYP2D6 were approximately 200 nM, 
the same as described before for the wild-type [32]. In the case of T309V, significant 
amounts of P420 (inactive enzyme, observed as an absorbance band at 420 nm in the CO-
difference spectrum) were present in the cells and in the membrane fraction. After 
purification no significant P420 was detected in the CO-difference spectra of the enzymes.
Figure 2: Substrate-velocity plo s for 4-hydroxylation ( ) and 6-hydroxylation ( ) of bufuralol by wild




Oxidation reactions supported by NADPH 
MAMC was linearly O-demethylated by the T309V and T312V mutants for at least 30 
minutes, indicating that the enzymes were stable for at least that time at 37° C. The T312V 
mutant showed an activity approximately equal to that of wild-type CYP2D6 (Table 1). The
T309V mutant showed a similar Km as the wild-type enzyme and a 20-fold decreased
turnover rate.
Bufuralol was oxidized by the T312V mutant similar as by the wild-type, only minor changes, 
up to two-fold, in turnover rates were found. Interestingly, concentration dependence of 6-
hydroxylation of bufuralol by the wild-type and the T312V mutant showed substrate

























































































































































































































































































































































































































































































































































Role of T309 
The turnover rate and Km were estimated from the initial part of the substrate-velocity plots. 
For the 1’-hydroxylation of bufuralol the T309V mutant displayed a Km equal to that of wild-
type CYP2D6, with a turnover rate about 10-fold lower. However, for 4-hydroxylation of
bufuralol both Km and turnover rates were equal for mutant and wild-type. The other 
products of bufuralol formed by wild-type CYP2D6, 6-OH-bufuralol and 1’,2’bufuralol, were 
not detected in incubations with the T309V mutant, indicating that the product ratio of 






























Figure 3: P oduct formation through N-demethylation of 100 M MDMA (A) and 100 M
dextromethorphan (B) by wild- ype, T309V and T312V mutants CYP2D6. Shown are the averages






Similar results were obtained when studying MDMA oxidation. Incubations with the T312V 
mutant yielded only up to two-fold changes in Km and Vmax compared to the wild-type, 
whereas the T309V mutant O-demethylenated MDMA with a 14-fold lower turnover rate. 
Interestingly the T309V mutant also significantly N-dealkylated MDMA, whereas for the wild-
type and the T312V mutant N-dealkylation was a minor pathway (Figure 3).
Dextromethorphan was efficiently O-demethylated by both the mutants, the T309V 
displayed only a two-fold lower turnover rate and the T312V mutant a two-fold higher 
turnover rate, all with similar Km. However, a clear difference was seen in N-demethylation
of dextromethorphan. Although the turnover rates and Km were not quantified, 3-methoxy-
morphinan was formed from 100 M dextromethorphan in 8-fold higher amounts by the
T309V mutant than by wild-type CYP2D6 (Figure 3). So in both cases significantly more N-
demethylation of MDMA and dextromethorphan was observed with the T309V mutant over 
T312V and wild-type CYP2D6. 
Substrate binding 
To study the influence of the T309V mutation on substrate binding affinity, the dissociation 
constants of the used substrates to wild-type and T309V mutant CYP2D6 were determined 
by optical titration (Table 2). Solutions of purified enzymes had to be used, because the 
crude membrane fractions were too turbid for these experiments, due to the relatively low 
expression levels. The addition of bufuralol, MDMA and dextromethorphan to wild-type and 
T309V mutant CYP2D6 all led to a type I change in the absorbance spectrum of both of the 
enzymes, as indicated by an increase of the absorbance at 390 nm and a decrease at 425
nm. It was found that the affinity of the T309V mutant for MDMA was decreased two-fold 
and the affinity for dextromethorphan was increased by 30%. The estimated Ks for bufuralol 
did not change compared to the wild-type enzyme. Binding of MAMC to the enzymes could
not be measured this way because the absorbance of this substrate was too high in this 
spectral range. 
tr -Table 2: Ks values ( M) of the subs ates for wild type and T309V mutant CYP2D6.
KsSubstrate
Wild-type T309V
Bufuralol 26  12 21  4 
MDMA 28  3 47  1 
Dextromethorphan 33  5 20  1 
All values are the means  S.D  o  at leas  two independent experiments as described in the Methods
section.
. f t
Uncoupling of substrate monooxygenation activity 
To investigate whether the loss in turnover of the substrates by the T309V mutant was 
caused by a higher degree of uncoupling of the monooxygenase activity, the formation of 
uncoupling products H2O2 and O2-. was determined in the incubations. Because of the 
turbidity of the membrane fractions, the amount of 2,2’-dihydroxybiphenyl-5,5’-diacetate 
formed  was analyzed by HPLC.  The incubations were performed with 100 M of substrate,
a concentration high enough to reach Vmax conditions for the oxidation of MAMC, bufuralol, 
MDMA and dextromethorphan by wild-type and T309V mutant CYP2D6. Only low amounts 
of uncoupling products were formed by wild-type CYP2D6 when metabolizing MAMC, 
bufuralol, MDMA or dextromethorphan (Table 3). The rate of formation of uncoupling
products is the highest when MAMC is present, i.e. up to 0.5 pmol H2O2/min/pmol CYP, 
compared to a rate of HAMC formation of 3.7 pmol/min/pmol CYP. Similar rates were found 
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when the T309V mutant was used in the incubations, suggesting that decreased product
formation was not due to increased uncoupling of activity. 
tTable 3: Formation of uncoupling produc s by wild-type and T309V mutant CYP2D6.
Reaction rate Substrate
Wild-type T309V
MAMC 0.50  0.19 0.39  0.22 
Bufuralol 0.24  0.06 0.07  0.04 
MDMA 0.03  0.01 0.03  0.02 
Dextromethorphan 0.03  0.01 0.03  0.03 
All values are the means  S.D. o  at leas  three independent experiments as described in the Methods




Table 4: Metabolic oxidation rates of various substrates (100 M) by wild- ype and T309V mutant
CYP2D6 supported by CuOOH.
Substrate Product Wild-type T309V
MAMC HAMC 5.1  0.2 16.5  0.2 
Bufuralol 1’-OH 15.6  2.0 60  7 
4-OH 0.5  0.3 37  10 
6-OH 0.5  0.1 4.8  0.5 
1’,2’ 2.6  0.5 12.4  0.8 
MDMA 3,4-OH-MA 2.2  0.7 5.2  1.1 
Dextromethorphan dextrorphan 122  14 414  70 
3-MOH-Mor - a 0.04  0.01 
3-OH-Mor - a 0.22  0.01 
All values are the means S.D. of at least three experiments as described in the Methods section. Rates
of HAMC and dextrorphan formation are in pmol product/min/pmol CYP2D6, other products in 1 x 106
fluorescence counts/min/pmol CYP2D6, a not detected.
Oxidation reactions supported by CuOOH 
To further investigate the mechanism of oxidation by the T309V mutant of CYP2D6,
incubations were also performed with the oxene donor CuOOH, which directly forms the 
oxenoid-iron in CYPs [23]. MAMC was O-demethylated by both the wild-type and T309V 
mutant CYP2D6 when supported by CuOOH. The reaction rates were linear for at least 15
min and the turnover rate of the T309V mutant was found to be 3-fold higher than that of 
the wild-type (Table 4). Bufuralol was oxidized by wild-type CYP2D6 to the same products 
supported by CuOOH as by O2/NADPH. However, 1’-hydroxylation and 1’-2’ desaturation 
took place with a 2 to 3-fold higher turnover rate when compared to the incubations 
supported by NADPH, whereas the aromatic hydroxylations rates did not change. The same 
observation was described before by others [34]. The T309V mutant formed the same four 
products as wild-type CYP2D6, all of them with a higher turnover rate. The rate of aromatic 
4-hydroxylation was even 70-fold higher, leading to a completely different product ratio 
than wild-type CYP2D6.
O-demethylenation of MDMA was supported by CuOOH in the case of both wild-type and
T309V mutant CYP2D6. The turnover rate of the T309V mutant was two-fold higher than 
that of the wild-type enzyme. N-dealkylation of MDMA was not detected.
Dextromethorphan was O-demethylated by both enzymes, with a 3-fold higher rate by the 
T309V mutant compared to wild-type cyp2d6. Furthermore, low levels of 3-
methoxymorphinan and significant amounts of 3-hydroxymorphinan were formed by the 
mutant, indicating that some N-dealkylation was still taking place.
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Interestingly, the T309V mutant displayed higher turnover rates than wild-type CYP2D6 in
all reactions supported by CuOOH, ranging from two-fold for MDMA O-demethylenation to 
70-fold for bufuralol 4-hydroxylation. 
Discussion
CYPs are enzymes capable of oxidizing and reducing a vast amount of chemically different
substrates by using two electrons donated by NADPH-cytochrome P450 reductase and 
activating molecular oxygen. To bind molecular oxygen CYPs are equipped with an iron
containing porphyrin ring and the protein surroundings of this heme group are thought to
activate the iron bound oxygen by delivering protons as well as to stabilize it to avoid
unwanted side-reactions. A conserved threonine residue in the I-helix overlaying the 
porphyrin is involved in this process, as shown in various mutagenesis and X-ray diffraction 
studies of several CYPs [7, 9-13, 27, 28]. From amino acid sequence alignments and protein 
homology modeling we propose T309 to fulfill this role in CYP2D6.
The results of the present study show that the catalytic behavior of the T309V mutant is 
clearly different from that of wild-type CYP2D6, with significantly decreased turnover rates
of MAMC, bufuralol and MDMA (Table 1). The mutation hardly had an effect on substrate
affinity, as bufuralol, MDMA and dextromethorphan still bound equally well to the enzyme
after mutation (Table 2). Besides changing the substrate affinity, an active site mutation can
lead to alternative orientations of bound substrates [32, 37]. However, because this 
threonine residue is so highly conserved in CYPs with completely different substrate 
preferences, it is unlikely to determine substrate selectivity or metabolic regioselectivity by 
substrate binding. Furthermore, modeling studies did not show involvement of active site 
threonine residues in CYP2D6 substrate interaction [4, 6, 38].
As an explanation for the diminished product formation from MAMC, bufuralol and MDMA by 
the T309V mutant, a higher degree of uncoupling was considered because H2O2 formation 
was previously shown to be increased in the oxidative metabolism by other CYPs of which
this conserved threonine was mutated [13, 27, 28]. However, in this study this was not the 
case (Table 3). An explanation for the lack of increased hydrogen peroxide formation by the 
T309V mutant may be found in the alignment of CYPs (Figure 1). The alignment of the I-
helix of CYPs of which the role of the conserved threonine was studied experimentally, 
shows homology in the conserved threonine residue but also in a highly conserved acidic
residue preceding the threonine. This acidic residue is believed to be of crucial importance 
in the proton delivery to the reactive oxygen species [10, 14]. For CYP55A, which is lacking 
the conserved acidic residue, alternate proton delivery pathways have been proposed based
on its crystal structure [17]. In CYP2D6 there is a valine at position 308 preceding T309 so 
protons are likely to be shuttled different then in CYPs 101, 102, 1A2, 2B4 and 2E1. A
different proton shuttling mechanism will probably change the ease of uncoupling in T309V 
mutant CYP2D6.
The T309V mutant displayed significantly altered product ratio’s of bufuralol, MDMA and 
dextromethorphan metabolism compared to wild-type CYP2D6 (Table 1, Figure 3). Changes
in preference of certain types of reactions like these were observed before for other 
conserved threonine residue mutants of CYPs. For example, the T302A mutant of CYP2B4 
showed a decreased cyclohexane hydroxylation but an increased deformylation of 
cyclohexane carboxaldeyde [27]. The T303A mutant of CYP2E1 showed a reduced 
epoxidation of several model substrates but an enhanced epoxidation of olefins [28]. It was 
hypothesized that CYPs can deploy three different oxygenating species in oxidation 
reactions, namely a peroxo, a hydroperoxo and an oxenoid-iron (shown in Figure 4). These
species have different oxidative properties and therefore prefer certain types of reactions, 
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which can in specific cases each lead to formation of one product [9, 28]. The abundance
and reactivity of these different oxygenating species would thus determine the amount of
product formed. The conserved threonine is thought to be involved in proton delivery to the 
oxygen species and thus a mutation would shift the distribution of these three species. In
this study, the turnover rates of the N-demethylation reactions of dextromethorphan and
MDMA by the T309V mutant were strongly increased compared to wild-type (Figure 3). 
Previously, N-dealkylation reactions were proposed to be mediated predominantly by the
(hydro)peroxo-iron, whereas O-dealkylation reactions were proposed to be mediated by the 
oxenoid-iron in CYP2D6 [23]. Our observation that the T309V mutant N-dealkylates rather 
than to O-demethylates or O-demethylenates dextromethorphan and MDMA respectively, 
might therefore be explained by an increased ratio of (hydro)peroxo-iron to oxenoid-iron. To
test this hypothesis, we used CuOOH to support the T309V mutant CYP2D6 mediated
reactions, instead of NADPH with molecular oxygen. CuOOH is a model oxidant, known to 
short-circuit the catalytic cycle of CYP and directly form the oxenoid-iron [22, 23, 34, 39]. 
Indeed, in presence of CuOOH the T309V mutant was again well capable to O-demethylate
MAMC and dextromethorphan and to O-demethylenate MDMA (Table 4). This suggests that 
the changed regioselectivity of the T309V mutant may be caused by its incapability to form 
the oxenoid-iron. Consistent with these findings it was recently proposed, based upon
crystallographic data of the dioxygen complex of the T252A mutant of CYP101, that T252 
accepts a hydrogen bond from the hydroperoxo-iron promoting the second protonation
leading to O-O cleavage and oxenoid-iron formation [40]. 
Bufuralol is widely used as a CYP2D6 model substrate [34, 41], however, several interesting 
changes were observed in CYP2D6 mediated bufuralol oxidative metabolism in this study. 
The formation of 1’-OH-bufuralol and 1’,2’bufuralol by the T309V mutant was decreased 
supported by NADPH and O2 compared to wild-type CYP2D6. Like the O-demethylation
reactions these activities could be restored with CuOOH, suggesting that also the aliphatic 
hydroxylation and the desaturation reaction are predominantly mediated through the 
oxenoid-iron. The fact that both these activities were also relatively increased by the wild-
type when supported by CuOOH strengthens this hypothesis. The active oxygen species 
involved in aromatic hydroxylations of bufuralol are more difficult to assign. The aromatic 
hydroxylations of debrisoquine by CYP2D6 were previously suggested to be determined by 
the mechanism of oxidation rather then the orientation of the substrate in the active site 
[42]. Several mechanisms have been proposed for aromatic hydroxylation reactions by 
CYPs. Firstly, epoxidation may occur, followed by spontaneous rearrangement restoring
aromaticity. Secondly, aromatic hydroxylation may result from initial electron abstraction, 
yielding the hydroxylated product via a radical cation intermediate. Finally, in case a benzylic 
hydrogen atom is present this can be abstracted, followed by spin-delocalization, and then 
via oxygen rebound leading to the hydroxylated product [43-45]. The T309V mutant 
displayed equal 4-hydroxylation and decreased 6-hydroxylation of bufuralol compared to the 
wild-type when supported by NADPH and O2, whereas when supported by CuOOH the 
mutant displayed highly increased aromatic hydroxylations compared to the wild-type 
(Tables 1 and 4). This suggests the oxenoid-iron has a part in the aromatic hydroxylations, 
probably as the electrophilic oxidant, abstracting the electron, or inserting the O-atom in the
epoxidation reaction. However, the high turnover of 4-OH-bufuralol by the T309V mutant
supported by NADPH and O2, implies that also the (hydro)peroxo-iron may be involved in
aromatic hydroxylation of bufuralol. The currently general accepted idea is that the 
hydroperoxo-iron effects oxidation by insertion of OH+ into a C-H bond [46-48]. The
mechanism of aromatic hydroxylation of bufuralol by the hydroperoxo-iron would be via
epoxidation, as the hydroperoxo-iron is an effective electrophilic epoxidizing agent [49]. The 
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reaction types determined in this study and the oxygenating species suggested to be 























Figure 4: Schematic showing the oxygenating species in CYP, adapted from Vaz et al. [28]. 
Table 5  Involvement of oxygenating species (shown in Figure 4) in reactions catalyzed by CYP2D6
measured in this study.
:
Oxygenating species (Hydro)peroxo-iron Oxenoid-iron
Reactions N-dealkylation O-dealkylation




In the current study peroxo-iron and hydroperoxo-iron were not distinguished. The aromatic
hyd oylation occurs via r 1epoxidation or via 2epoxidation, electron abstraction or proton abstraction.
The reason that the T309V mutant formed more 4- then 6-OH-bufuralol, might have to do 
with sterical hindrance of the 1’-ethyl. A striking observation was the fact that 4- and 6-
hydroxylation of bufuralol by the T309V mutant supported by CuOOH are respectively 75- 
and 10-fold higher than the turnover rates by the wild-type enzyme. Although CuOOH has
been used to support reactions by conserved threonine mutants of CYPs, to study 
mechanism based inactivation [50, 51], such strong increases in product formation have not
been described yet. Apparently, the T309 hydroxy moiety has a negative influence on the 
mechanism leading to aromatic hydroxylations of bufuralol. Possible explanations for this 
might be hydrogen bond interactions of the threonine hydroxy moiety with the CuOOH, 
leading to less oxenoid-iron formation, or destabilization by the threonine hydroxy moiety of
the bufuralol radical cation intermediate after electron abstraction.
The formation of 6-OH-bufuralol displayed substrate inhibition, while formation of the other
three bufuralol products displayed Michaelis-Menten kinetics (Figure 2). Atypical kinetics of
only one of several products of a substrate have been described before for the metabolism 
of midazolam and verapamil by CYP3A4 [52, 53]. These effects were explained by steric 
interaction of substrates in a two binding-site model. Several recent observations suggest 
that also CYP2D6 may contain two substrate binding sites. Potentiation of MAMC O-
demethylation by sparteine and phenformine was observed previously [21],  biphasic 
kinetics were observed in MDMA O-demethylenation by the polymorphic variant CYP2D6*17 
[54], and an additional binding site for MAMC was observed in wild-type CYP2D6 [55].
Besides T309 (Figure 1A), three other threonine residues are present in the I-helix at
positions 310, 312 and 313 (Figure 1B). The latter three threonine residues are also highly 
conserved in mammalian CYPs but with unknown function. In the homology model of
CYP2D6, T312 is one turn of the I-helix further away from the heme and seems to be 
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stabilizing a distortion in the I-helix by providing hydrogen bonds to the carbonyl group of 
V308. Mutating T312 to a valine in this study however, did not result in changes in 
expression levels, nor in the metabolic activity towards MAMC, bufuralol, MDMA or
dextromethorphan, suggesting that the role of T312 in the oxidative metabolism by CYP2D6 
is limited. 
In summary, the present study suggests T309 in CYP2D6 to be the conserved I-helix
threonine involved in oxygen activation. Retrieving the lost activities of the T309V mutant 
with CuOOH, indicated that T309 is a key determinant in maintaining the balance of reactive 
oxygen species. Interestingly, supported by CuOOH the T309V mutant displayed even
higher activities than wild-type CYP2D6 of which the mechanism remains to be resolved. 
Furthermore, atypical enzyme kinetics in the metabolism of bufuralol by wild-type CYP2D6 
was observed, which might indicate a second substrate binding place in CYP2D6.
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Metabolic regio- and stereoselectivity of cytochrome P450 2D6 towards 3,4-
methylenedioxy-N-alkyl-amphetamines: in silico predictions and experimental 
validation
Peter H.J. Keizers*, Chris de Graaf*, Frans J.J. de Kanter, Chris Oostenbrink, K. Anton 
Feenstra, Jan N.M. Commandeur, and Nico P.E. Vermeulen *contributed equally 
adapted from: The Journal of Medicinal Chemistry 2005 48: 6117-27 
A series of 3,4-methylenedioxy-N-alkylamphetamines (MDAAs) were automatically docked
and subjected to molecular dynamics (MD) simulations in a cytochrome P450 2D6 (CYP2D6) 
protein model. The predicted substrate binding orientations, sites of oxidation, and relative 
reactivities were compared to experimental data of wild-type and F120A mutant CYP2D6. 
Automated docking results were not sufficient to accurately rationalize experimental binding 
orientations of 3,4-methylenedioxy-N-methylamphetamine (MDMA) in the two enzymes as 
measured with spin lattice relaxation NMR. Nevertheless, the docking results could be used 
as starting structures for MD simulations. Predicted binding orientations of MDMA and sites 
of oxidation of the MDAAs derived from MD simulations matched well with the experimental 
data. It appeared the experimental results were best described in MD simulations 
considering the nitrogen-atoms of the MDAAs in neutral form. Differences in regioselectivity 
and stereoselectivity in the oxidative metabolism of the MDAAs by the F120A mutant 
CYP2D6 were correctly predicted and the effects of the F120A mutation could be 
rationalized as well.
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Introduction
Cytochromes P450 (CYPs) are heme containing enzymes which can be found in virtually all
organisms. This large family of enzymes is capable of oxidizing and reducing a broad range
of endogenous and exogenous substrates, such as steroids, carcinogens and drugs [1, 2]. 
In humans one of the most relevant drug metabolizing CYPs is CYP2D6. Although the 
expression levels of CYP2D6 are only 3% of all hepatic CYPs, following CYP3A4, it is the
second most important drug metabolizing enzyme, involved in the metabolism of about 30% 
of the currently marketed drugs, including -blockers, neuroleptics, antidepressants and 
antiarythmics [3-5]. Large interindividual differences exist in CYP2D6 activity, due to gene
multiplicity and polymorphisms, thus further increasing its clinical importance [6, 7]. The 
rationalization and prediction of potential CYP2D6 substrates is therefore advantageous in 
the discovery and development of new drugs. Nowadays the first crystal structures of 
mammalian CYPs are becoming available [8-10]. However, so far a crystal structure of
CYP2D6 remains to be resolved and any structural information on this enzyme still depends
on homology modeling, mutagenesis and spectroscopic studies.
CYP2D6 is one of the CYP isoforms studied most extensively using molecular modeling [11].
Several homology model structures of CYP2D6 have been built, refined and validated 
experimentally. The homology models of CYP2D6 suggest substrates to interact with two or
three aromatic/hydrophobic residues, F120 and F483 and a carboxylic acid residue, E216 or 
D301 [12, 13]. The relevance of these residues was supported by site-directed mutagenesis 
studies [14-18]. These interactions are consistent as well with those derived from
pharmacophore models of inhibitors and substrates [19, 20]. Molecular modeling can
provide information on active site characteristics and the importance of specific amino acid 
residues in enzyme-substrate interactions, but it can also be used to rationalize and predict 
regio- and stereoselectivity in metabolism by CYPs. It has recently also been shown that 
automated docking can successfully be applied to predict sites of oxidation in substrates 
using CYP crystal structures [21]. Molecular Dynamics (MD) simulations in addition can 
account for distributions of multiple binding conformations and thus give a more 
comprehensive description of multiple sites of oxidation in substrates catalyzed by CYPs [22-
25].
In this study a molecular modeling approach has been used to study the binding orientation
and the sites of oxidation of a series of 3,4-methylenedioxy-N-alkylamphetamines (MDAAs), 
or XTC analogues, by CYP2D6. The primary aim was to evaluate an integrated molecular 
modeling approach to rationalize and predict substrate binding and metabolism by CYP2D6.
When regioselectivity and stereoselectivity in drug metabolism, and the effect of active site 
mutations can be rationalized for a series of closely related compounds, such an approach 
can be considered as accurate and reliable. The molecular modeling predictions were based 
on a homology model of CYP2D6. Reactive substrate poses were generated using 
automated docking and were obtained from MD simulations of wild-type and mutant 
CYP2D6 protein containing all three MDAAs. Two different protonation states of the basic
nitrogen-atom were studied, as it is known that this can drastically influence the oxidation
by CYP2D6 [26]. These computational predictions were validated experimentally. The 
effects of mutating F120 into alanine on the binding modes and metabolic products were 
studied for five MDAAs, i.e. 3,4-methylenedioxy-N-methylamphetamine (MDMA) and its 
stereoisomers, 3,4-methylenedioxy-N-ethylamphetamine (MDEA) and 3,4-methylenedioxy-
N-propylamphetamine (MDPA). For the recently described F120A mutant large effects on 
the regioselective oxidation of MDMA were demonstrated [16]. Dissociation constants for
the three MDAAs were determined by spectral titration. The metabolic products were 
analyzed and furthermore, the binding orientations of MDMA in the wild-type and mutant 
104
Chapter 6 
active sites were explored experimentally by NMR spin lattice relaxation rate measurements, 
a technique previously used to determine hydrogen atom to heme distances in CYPs [27-
30].
Materials and Methods 
Materials
The pSP19T7LT plasmid containing human 2D6 with a C- terminal His6-tag bicistronically co-expressed
with human NADPH-cytochrome P450 reductase was kindly provided by Prof. Dr. Ingelman-Sundberg.
3,4-methylenedioxy- N-alkylamphetamines (MDAAs) were synthesized as described before [31, 32]. S-
and R-MDMA.HCl were obtained from the division of Neurioscience and Behavioral Research of the 
National Institute on Drug Abuse (Bethesda, MD USA). Emulgen 911 was obtained from KAO Chemicals
(Tokyo, Japan). Ni-NTA-agarose was from Qiagen (Westburg, Leusden, The Netherlands). All other 
chemicals were of analytical grade and obtained from standard suppliers.
Expression and purifica ion of CYP2D6t
Both the F120A mutant and the wild-type pSP19T7LT plasmids were transformed into Escherichia coli,
strain JM109. Expression and membrane isolation was carried out as described [16]. Membranes were 
resuspended in 0.4% of the original culture volume of KPi-glycerol buffer (50 mM potassium phosphate
buffer, pH 7.4, 10% glycerol) and CYP contents were determined by CO difference spectra [33].
Enzymes were solubilized from membranes by stirring in KPi-glycerol supplemented with 0.5% Emulgen
911 for 2 h at 4°C. Insoluble parts were removed by centrifugation (60 min, 120,000 g at 4 °C). The
supernatant was incubated, gently rocking, with Ni-NTA agarose for 30 min at 4 °C. The Ni-NTA
agarose was retained in a polypropylene tube with porous disc (Pierce, Perbio Science, Ettenleur, The 
Netherlands), washed with KPi-glycerol buffer containing 2 mM histidine. CYP2D6 was eluted with 0.2 M 
histidine. After overnight dialysis in KPi-glycerol buffer the sample was concentrated on a Vivaspin 20
filtration tube (10.000 MWCO PES, Sartorius, Nieuwegein, The Netherlands). For NMR spin lattice
relaxation rate measurements the buffer was exchanged for deuterated KPi-glycerol buffer by repeated
rounds of adding a larger volume of deuterated buffer and concentrating. Deuterated KPi-glycerol
buffer was made by repeated rounds of evaporating water or D2O from a KPi buffer and dissolving the
residue again in D2O. Then 5% of glycerol was added and traces of iron were removed with Chelex 100 
(Biorad, Richmond CA). 
Optical titrations
Dissociation constants of substrates to the enzymes were determined by spectral titration, according to 
the method of Jefcoate [34, 35]. Spectra were taken at room temperature on a Pharmacia Ultrospec 
2000 spectrometer. In short, 1 ml of 0.5 M purified enzyme in KPi-glycerol buffer was divided over
two cuvettes, to the first 5 l of a 1 mM solution of compound in the same buffer was added, to the
second the same volume of just buffer. Difference spectra from 350 to 450 nm were taken before, and
after each addition of compound. The difference in absorbance at 390 and 425 was plotted against the
substrate concentration to estimate the dissociation constant (Ks) using Equation (1) in Graph Pad Prism 






max       (1)
Metabolism of MDAAs
Metabolic reactions were carried out in 200 l 50 mM KPi pH 7.4, 5 mM MgCl2 supplemented with 10 
concentrations ranging from 0 to 200 M of one of the MDAAs and E. coli membranes corresponding to
25 nM wild-type or F120A mutant CYP2D6. After 5 min of pre-incubation at 37 °C, the reactions were
initiated with an NADPH regenerating system, resulting in final concentrations of 0.2 mM NADPH, 0.3 
mM glucose-6-phosphate, and 0.4 units/ml glucose-6-phosphate dehydrogenase. The reaction was
allowed to proceed for 10 min before it was stopped by the addition of 20 l 23% HClO4. After 
centrifugation (10 min, 6800 g), 30 l aliquots of the supernatant were analyzed by HPLC. To measure 
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O-demethylenation, analytes were separated isocratically using a C18 column (Phenomenex Luna 5u 
150 x 4.6) with a mobile phase consisting of 22% acetonitrile (ACN) and 0.1% triethylamine, set to pH 
3 with HClO4 at a flow rate of 0.6 ml/min. Other oxidation products were found using the same column 
with a gradient (A: 5% ACN with 20 mM ammonium acetate, B: 90% ACN with 10 mM ammonium
acetate). All oxidation products were detected by fluorescence ( ex= 280 nm, em= 320 nm) and 
identified by LC-MS. Peak areas of all products were quantified by Shimadzu Class VP 4.3 software and
analyzed using non linear regression with one site binding in Graph Pad Prism 3.0.
LC-MS
To identify the metabolic products of the MDAAs, incubations were carried out for 15 min as described
above with 100 M of MDMA, MDEA or MDPA and E. coli membranes corresponding to 50 nM wild-type 
or F120A CYP2D6. Volumes of 100 l supernatant were injected and separated using a C18 column
(Phenomenex Luna 5u 150 x 4.6) with a flow rate of 0.6 ml/min and analyzed by MS. The analytes
were eluted using a gradient starting with a 5% ACN eluens, supplemented with 20 mM ammonium
acetate for 7 min, then increasing linearly to 90% ACN with 10 mM ammonium acetate in 14 min and 
kept there for 5 min. APCI positive ionization was used on a LCQ Deca mass spectrometer (Thermo
Finnigan, Breda, The Netherlands), vaporizer temperature 450 °C, N2 as sheath (40 psi) and auxiliary
gas (10 psi), needle voltage 6000 V, heated capillary 150 °C.
Products of MDMA metabolism: 3,4-OH-MA (tR: 9.5 min., m/z 182, MS/MS: m/z 151), MDA (tR: 17.0 
min., m/z 180, MS/MS: m/z 163) and N-OH-MDMA (tR: 20.4 min., m/z 210, MS/MS: m/z 163). Products
of MDEA metabolism: 3,4-OH-EA (tR: 13.0 min., m/z 196, MS/MS: m/z 151), MDA (tR: 17.0 min., m/z
180, MS/MS: m/z 163) N-OH-MDEA (tR: 21.6 min., m/z 224, MS/MS: m/z 163) a fourth product was
detected for the mutant (tR 18.5 min., m/z 222, MS/MS: m/z 163). Products of MDPA metabolism: 3,4-
OH-PA (tR: 16.0 min., m/z 210, MS/MS: m/z 151), MDA (tR: 17.0 min., m/z 180, MS/MS: m/z 163), N-
OH-MDPA (tR: 23.4 min., m/z 238, MS/MS: m/z 163) a fourth product was detected for the mutant (tR:
19.2 min m/z 254, no fragmentation observed).
NMR spin lattice relaxation rate measurements
Distances from substrate hydrogen atoms to the enzyme heme iron atom were calculated from their
longitudinal relaxation rates determined using 1H NMR [27-30]. 1H NMR measurements were performed 
on a Bruker Avance 400 MHz spectrometer, signals were referenced to HDO at 4.75 ppm. Longitudinal
relaxation times (Tl) of substrate hydrogen atoms were measured with a standard inversion recovery 
sequence of 180°- -90°. The spectra were recorded with 20 values of , ranging from 0.1 to 12.5 s and 
a relaxation delay of 5-10 x Tl. The temperature was kept at 300 K, except for the variable temperature
experiments. Tl was determined by plotting peak areas against delay times  and exponential fitting (It
= A +Be- / Tl) with Bruker XWINNMR software. The measured Tl was transformed into the longitudinal





)(T)(TR 23      (2)
Where is the relaxation time of substrate hydrogen atoms in the presence of ferric enzyme, and
is the relaxation time in the presence of ferrous CO-bound enzyme. The hydrogen atoms to 





NMR can be calculated from RlP using the simplified Solomon and Bloembergen
equation [27, 36] (Equation 3). 
1/6
clP
NMR ))F(RC(r      (3)
Where C is a constant taking into account the spin state as well as other nuclear and electronic factors, 
with a value of 813 for high spin CYP, [30]  is the fraction of enzyme bound substrate, determined as 
the ratio of the concentration of enzyme and the sum of the substrate concentration and its spectral
dissociation constant (Ks). F( c) is a function of the correlation time c, for which the value of 3x10-10 s is 
taken, as determined for CYP2D6 by others [28]. In the calculations of hydrogen atoms to heme
distances, according to eqs. 2 and 3, the assumption has been made that on the NMR time-scale there 
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is a fast exchange between substrate molecules in solution and in the enzyme active site. This was
verified by measuring the temperature dependence of 1/Tl, which should show a linear increase with
the reciprocal value of the temperature [29, 30].
In a typical experiment 5 M of enzyme and 20 mM of substrate was used in a volume of 500 l.
Recording the spectra for relaxation times determination with oxidized enzyme took about an hour,
then sodium dithionite was added and the sample was treated for 30 sec with CO to do the
measurements with the reduced CO-bound enzyme.
Homology modeling
A protein homology model of CYP2D6 was constructed based on the crystal structures of
dimethylsulphophenazole derivative and diclofenac bound rabbit CYP2C5 (PDB codes 1N6B and 1NR6,
respectively) [37, 38]. Homology modeling, model refinement and model validation was performed
according to the approach described previously [12]. In short, a hundred CYP2D6 models were 
generated with the restraint-based comparative modeling program Modeller [39], using the same amino
acid alignment as before [12]. Subsequently, three models were selected with the best loop
conformations as determined by visual inspection, stereochemical parameters using PROCHECK [40], 
and side-chain environment using Errat [41], and Verify3D [42]. Homology models had approximately
the same protein quality check scores as the crystal structure templates. Finally, one single model was
selected which could accommodate codeine best in the experimental binding orientation [28]. This final 
model was validated on its ability to reproduce substrate binding orientations corresponding to 
metabolic profiles with AutoDock [43], FlexX [44], and GOLD [45] automated docking studies (de Graaf,
unpublished results). The final model of wild-type CYP2D6 was used as a template for modeling of the 
F120A mutant. The Phe residue at position 120 was mutated to Ala using the homology module of
Insight II (Biosym. San Diego, USA), after which an energy minimization and a 1 ps MD simulation with
position restraints on the protein backbone was carried out as described under “MD Simulations”.
Automated docking s udiest
The R-, and S-enantiomers of MDMA, MDEA and MDPA in their neutral (basic) and charged (acidic) 
forms were docked into the active site of the CYP2D6 homology model using AutoDock and GOLD.
Active site water molecules, predicted using a protocol based on the program GRID [46], and a ligand-
based cut off were included. The preparation of enzyme and substrate structures in the automated
docking studies were performed using default settings and predicted water molecules as described
before [21]. For each substrate, 50 independent AutoDock and GOLD docking runs were performed
using default parameter values. Docking poses generated by both docking algorithms were clustered
(maximum root-mean square differences between members of the cluster of 1 Å) and re-scored with
the SCORE scoring function [47]. The three energetically most favorable, distinct docking poses of each
MDAA species were selected as starting structures for MD calculations, yielding in total 12 (3 docking
poses times 2 enatiomers, times 2 protonation states) simulations for each substrate in both wild-type
and F120A mutant CYP2D6.
MD simulations
Substrate conformations selected from the automated docking studies were used as starting structures 
for MD simulations, using the GROMACS molecular simulation package [48] and the GROMOS-96 force
field, parameter set 43A1 [49, 50]. Heme parameters were taken from this parameter set, and 
additionally, a covalent bond was defined between the heme iron atom and the sulfur atom of C443 
with an ideal bond distance of 0.240 nm. The enzyme including substrate and heme, was energy 
minimized in vacuum using the steepest descent method, first with harmonic position restraints using a
force constant of 1000 kJ mol-1 nm-2 on all non-hydrogen atoms, then without position restraints. 
Subsequently, pre-equilibrated water was added in a dodecahedral box with a minimum distance of 1
nm between the enzyme and box edges, followed by minimization. The water was allowed to relax for 1 
ps, while the whole enzyme was position restrained. Then, first only the side chains of the residues not 
involved in substrate binding were released for 1 ps, next also the backbone of these residues for 10 
ps. Finally, only the backbone of the binding residues were restrained for 100 ps. The equilibration
scheme was followed by an unrestrained 10 ns MD production run. MD simulations were carried out 
with a time step of 2 fs, a twin range cut-off of 0.8/1.4 nm and a relative dielectric constant of 1.0. The
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LINCS algorithm was used to constrain the length of all covalent bonds [51]. Pressure was maintained
at 1 bar and temperature at 300° K by weak coupling to an external bath [52], with relaxation times of
0.1 and 1.0 ps respectively. Coordinates were saved at a 1.0 ps interval for subsequent analysis. 
Enzyme-substrate interactions were estimated using the SCORE scoring function and averaged over the
trajectories.
Analysis of MD simulations
Hydrogen atoms to iron atom distances rMD for different protonation states of the MDAA enantiomers 
were derived from MD simulations by averaging distances (r) observed in the three independent
simulations with different starting positions as: 
rMD = ( r -6 )-1/6 (4)
These distances could directly be compared to the experimentally obtained distances rNMR, (Equation 3). 
Sites of oxidation were predicted based on enzyme-substrate conformations generated by automated
docking and MD simulations. Distances of 6.0 Å or less between the heme iron and an atom in the 
substrate (e.g. corresponding to O-demethylenation, N-dealkylation, N-hydroxylation, or -
hydroxylation) were considered as reactive in the sense that activation of the C-H bond by the heme-
Fe-O moiety is possible [53]. Site of oxidation predictions were performed to determine both substrate
reactivity (expressed in the number of reactive MD configurations out of the total) and regioselectivity.
The catalytic regioselectivity was calculated by determining which site of oxidation was closest to the 
heme iron atom for each reactive docking pose or MD configuration. Enzyme-substrate interactions 
during the MD simulations were monitored in terms of the occurrence of atom-atom distances of 3.5 Å
or less between the F/A120 side-chain and the MDAA ring system (representing aromatic/van der Waals
interactions) and hydrogen bonds between the E216 carboxylate oxygen atoms and the MDAA N-atom.
Substrate reactivity, regioselectivity and enzyme substrate interactions were calculated for any given 
protonation state, stereo- and regio-isomer, as a Boltzmann weighted average over the three
independent MD simulations with different substrate starting orientations. The average of an individual 
simulation i was weighted by a relative probability pi, which was calculated from the average enzyme 
substrate interaction estimates as obtained from the program SCORE (EiSCORE). In this equation, kB is the 









Expression and purification of wild-type and F120A mutant CYP2D6
The expression levels of both wild-type and F120A mutant CYP2D6 were similar as 
described previously [16]. The enzymes which contained a C-terminal 6 x histidine tag were 
purified using Ni-NTA-agarose. Eluting the enzymes from the Ni-NTA-agarose using 
imidazole led to a shift of the Soret absorbance band to 422 nm, apparently due to heme 
ligation of the imidazole. Even after overnight dialysis, the Soret peak remained shifted to 
the red. Therefore 0,2 mM L-histidine was preferred as eluting agent over imidazole, 
because it did not cause a change in spin state after dialysis, yielding pure enzymes which 
were stable for at least four hours at 24° C in the presence of 5% glycerol and 100 M of
substrate as assessed by CO-difference spectroscopy. Hardly any P420 (i.e. inactive CYP
detected as an absorbance maximum at 420 nm in the CO-difference spectrum) was present
in the batches of purified enzyme. 
Spectral titration of substrates to the enzymes
The addition of all MDAAs to purified wild-type or F120A mutant CYP2D6 led to a type I 
change in the visible absorbance spectrum. By titration of the compounds to the solutions of 
enzyme the spectral dissociation constants Ks could be estimated (using Equation 1, data 
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shown in Table 1). While there were minor differences in affinity between the wild-type and 
the mutant, for both enzymes a slightly lower Ks was found for MDEA and MDPA than for 
MDMA. The enantiomers of MDMA had about equal affinity for the wild-type, but a slight 
preference towards S-MDMA was observed for the mutant enzyme.
t
/
t , ) t
Figure 1: Scheme of 3,4-methylenedioxy-N-alkylamphetamines (MDAAs) oxidation by F120A mutant
CYP2D6. The MDAAs are O-demethylenated to 3,4,-dihydroxy-N-alkylamphetamine (1), N-dealkylated 
o 3,4-methylenedioxyamphetamine (2), N-hydroxylated to 3,4-methylenedioxy-N-hydroxy-N-
alkylamphetamine (3) or -1-hydroxylated to 3,4-methylenedioxy- / -1-hydroxy-N-alkyl-
amphetamine (4). The C3 methyl is indicated, R is methyl, ethyl and propyl for MDMA, MDEA and MDPA
respectively.




R/S-MDMA 28  3 28  2 
R-MDMA 43  6 53  2 
S-MDMA 40  5 38  4 
MDEA 19  2 15  4 
MDPA 18  1 12  2 
All values are the means  S.D  o  at leas  two independent experiments as described in the Methods
section. R S-MDMA refers to the racemic mixture of 3,4-methylenedioxy-N-methylamphetamine
(MDMA , R MDMA and S-MDMA to the pure R  and S-isomer of MDMA respectively. For the
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Metabolism o  MDAAsf
r t
As reported previously [16], MDMA is oxidized by the F120A mutant to MDA and N-OH-
MDMA, in addition to 3,4-OH-MA, the only product formed by the wild-type enzyme (Figure 
1). Elongation of the N-methyl chain to an ethyl or propyl yielded the corresponding
products after incubation with both enzymes. MDEA was O-demethylenated by wild-type 
and mutant CYP2D6 and additionally the mutant N-dealkylated and N-hydroxylated MDEA. A 
fourth oxidation product of MDEA by the mutant was detected at tR 18.5 min, with a m/z of 
222, fragmenting to m/z 163. This product could be the aldehyde- or keto-form of - or -
1-hydroxylation respectively.
Table 2: P oduct formation of MDAAs oxidation by wild- ype and F120A mutant CYP2D6.
Wild-type F120ASubstrate Product         Structure
Km Vmax Km Vmax
R/S-MDMA 3,4-OH-MA 1 1.9  0.5 1.2  0.4a 11.8  3.8 2.2  0.0a
MDA 2 - c - c 14.5  2.4 3.5  0.1b
N-OH-MDMA 3 - c - c 11.2  1.4 7.1  0.5a
R-MDMA 3,4-OH-MA 1 2.7  0.4 1.2  0.2a 13.2  0.6 2.4  0.1a
MDA 2 - c - c 26.1  3.3 5.9  0.7b
N-OH-MDMA 3 - c - c 20.6  2.5 10.7  1.3a
S-MDMA 3,4-OH-MA 1 3.3  0.5 1.2  0.0a 4.9  0.1 2.4  0.0a
MDA 2 - c - c 10.3  0.6 3.8  0.1b
N-OH-MDMA 3 - c - c 6.9  0.6 8.4  0.4a
MDEA 3,4-OH-EA 1 1.1  0.1 1.2  0.2a 3.3  0.0 2.9  0.2a
MDA 2 - c - c 4.5  0.8 4.2  0.1b
N-OH-MDEA 3 - c - c 5.7  0.3 1.4  0.1a
MDPA 3,4-OH-PA 1 1.0  0.1 1.3  0.1a 5.2  0.6 7.5  0.6a
MDA 2 - c - c 9.1  0.5 7.3  1.8b
N-OH-MDPA 3 - c - c 28.0  6.5 3.0  0.2a
All values are the means of at least two independent experiments  S.D. as described in the Methods
section. Structure numbers refer to products drawn in Figure 1, Km expressed in M, a Vmax expressed in
1 x 105 fluorescence units/min/nmol CYP, b Vmax expressed in min-1, c not observed.
MDPA was O-demethylenated by wild-type and the mutant CYP2D6, the latter enzyme also 
N-dealkylated and N-hydroxylated this substrate. A peak with m/z of 254 was found at 19.2 
min with the mutant, indicating a double hydroxylation. No fragmentation took place so the 
positions of the hydroxyl groups remain unknown.
Product formation from all substrates was linear for at least 10 min for both enzymes under 
the conditions used, and the kinetic parameters were determined for the major products 
(Table 2). The overall rate of oxidation by the F120A mutant was higher than that of wild-
type CYP2D6 for all MDAAs. The rates for O-demethylenation were two to five-fold higher
for the mutant and the fact that more products are formed indicate an even higher increase 
in oxidation rates. To quantify the turnover rates, synthetic reference compound was only




Because the fluorescence peak areas of equal concentrations of MDA, MDMA, MDEA and 
MDPA are equal, it is likely that the N-alkyl chain has no influence on the fluorescence yield 
of the compounds, and therefore it is reasonable this holds true for the O-demethylenated 
and N-hydroxylated products of the MDAAs as well.
The turnover rates of MDMA, MDEA and MDPA were equal for wild-type CYP2D6 (Table 2).
The catalytic efficiency (Vmax/ Km) indicated that MDPA is oxidized most efficient and MDMA
the least efficient (Figure 2A). The mutant showed a higher catalytic efficiency in O-
demethylenating MDPA over MDMA and MDEA, while the efficiency in N-hydroxylation was 
the highest for MDMA (Figure 2B-D). MDEA and MDPA were N-dealkylated more efficiently 
than MDMA. So elongation of the N-alkyl chain leads to an altered catalytic regioselectivity 
by the mutant enzyme.
Stereoselectivity in MDMA oxidation by wild-type CYP2D6 was hardly found (Figure 3).
However, the mutant enzyme showed at least two-fold lower Km values for all three 
products of S-MDMA when compared to R-MDMA, while the Vmax values for the products of 
both enantiomers did not differ (Table 2). Eventually these changes lead to a different
product ratio for the enantiomers: O-demethylenation is more prominent for S-MDMA then






























































Figure 2: Vmax / Km product ratio’s (min-1 · µM-1 for N-dealkylation, AU for the other p oducts) for the O-
demethylenation by wild type (grey lef ), and O-demethylenation (grey right), N-dealkylation (blank)































max / Km ) over R-MDMA catalytic efficiency (Vmax / Km ) 
by wild-type (in gray), and by F120A mutant CYP2D6 (in black) for the products 3,4,-dihydroxy-N




Figure 4: 1H NMR spec rum of 20 mM R-MDMA in deuterated Kpi-glycerol in presence of 5 µM F120A
mutant CYP2D6 showing the resonance assignments.
NMR spin lattice relaxation rate measurements
Enzyme bound MDMA hydrogen atom to heme iron distances were determined by spin 
lattice relaxation NMR to validate the computationally predicted distances. The 1H-NMR
spectrum of MDMA in presence of glycerol and each of the two enzyme was well resolved, 
all signals of the different hydrogen atoms were clearly visible (Figure 4). Because the 
doublet of the C3 methyl (  1.18 ppm), and the singlets of the N-methyl (  2.61 ppm), and 
methylene ( 5.89 ppm) hydrogen atoms could be best quantified and are the most distal 
groups in MDMA, these were used to determine the substrate orientation in the active site 
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of the two enzymes. An increase in Tl of the MDMA hydrogen atoms was found after 
reducing the enzymes with dithionite, indicating that the paramagnetic effect of the 
enzymes was diminished. From the Tl the distances from the methylene, C3 and N-methyl
hydrogen atoms to the heme iron atom were calculated (using Equation 2) and tabulated (in
Table 3). The fast exchange condition (see Methods section) was validated, by measuring 
the temperature dependence of RlP from 281° K to 307° K (Figure 5). For the three groups 
of hydrogen atoms studied, there was a linear increase of RlP with the reciprocal 
temperature (1/T), showing that the exchange between substrate molecules in the enzyme 
active site and in solution is fast on the NMR timescale. Only minor differences were
observed for the hydrogen atoms to iron distances, between the enantiomers of MDMA and 
each of the two enzymes. The measured hydrogen atoms to iron distances indicate that the 
methylene moiety is closest to the heme iron, at about 6.4 Å, the N-methyl is the most 
distal to the heme at about 7.3 Å and the C3 hydrogen atoms are at a distance of about 6.7 
Å.












Figure 5: Temperature dependence o  Tf r
/
.
l relaxation rates for the hyd ogen atoms of N-methyl (  2.61) 
of + - MDMA in wild-type CYP2D6. The positive slope indicates that the fast exchange condition is
satisfied
Automated docking studies 
All automatically docked poses of the MDAAs, in two protonation states and in both enzymes 
were found to be predominantly within a reactive distance of 6 Å from the heme iron atom 
(69% and higher, Table 4A). Of these reactive poses, the large majority corresponded to O-
demethylenation (62-100%). The relative occurrence of docking poses corresponding to N-
dealkylation (0-38%) and N-hydroxylation (0-13%) of the MDAAs was found to be enzyme,
stereoisomer, and protonation state dependent. In both enzymes, the neutral forms of the 
compounds showed the widest range of reactive substrate orientations, whereas the wild-
type allowed for more diversity. This observation is in contrast with the experimental finding 
that wild-type CYP2D6 only catalyzes O-demethylenation, while the F120A mutant allows for 
alternative product formation. 
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Three distinct, energetically most favorable automatically docked poses were selected of all
MDAAs as starting conformations for MD calculations, an example of charged R-MDMA being 
shown (Figure 6). These three distinct docked poses could be generally described as one 
binding orientation corresponding to O-demethylenation, with the substrate nitrogen atom
in close contact with E216 (pose 1, generated by AutoDock), another corresponding to O-
demethylenation, with the substrate nitrogen atom placed between E216 and D301 (pose 2,
generated by GOLD) and one corresponding to N-dealkylation or N-hydroxylation (pose 3, 
generated by AutoDock). In cases where pose 3 was not observed for the substrate in the
charged form (see Table 4A), the corresponding pose of the neutral state was protonated 
and taken as starting conformation for MD simulations.
t
Table 3: Hydrogen atom to heme iron distances (Å) of the MDMA enantiomers to wild-type and F120A
mutant CYP2D6 as determined by NMR spin lattice relaxation rate measurements and by molecular
dynamics (MD) simula ions of neutral and charged MDMA.
wild-type F120APosition
R-MDMA S-MDMA R-MDMA S-MDMA
NMR 6.4 6.3 6.4 6.5
MD (charged) 3.5 3.6 4.6 3.1
Methylene
(  5.89 ppm) 
MD (neutral) 4.3 4.5 5.0 5.5
NMR 7.3 7.2 7.5 7.2
MD (charged) 11.0 10.1 10.1 9.4
N-methyl
(  2.61 ppm) 
MD (neutral) 5.9 6.5 8.4 6.0
NMR 6.9 6.7 6.6 6.7
MD (charged) 11.8 11.0 8.7 11.5
C3
(  1.18 ppm) 
MD (neutral) 5.3 6.6 6.9 6.5
NMR derived values are the means of at least two independent measurements with S.D. less then 5%,
as described in the Materials and Methods. MD simulations derived values are averaged over time and
or three individual runs  starting f om different docking poses, according to equation 4.f , r
MD simulations
Simulations of the enzymes with substrates bound in the active site, starting from the three 
different automatically docked poses, remained stable during 10 ns unrestraint MD at 300° 
K, with final atom-positional root-mean-square deviation values of 1.3 to 3.8 Å. Throughout
the simulations structure determining hydrogen-bonds were observed and the majority of 
the orientations of the substrates in the enzymes were within a reactive distance to the iron
atom (74% and higher, Table 4B). The substrates appeared to have considerable freedom 
within the binding site. Complete reorientation from the initial coordinates was frequently 
observed, indicating that the unrestrained MD simulations sampled the substrate 
conformational space sufficiently. The distances between substrate hydrogen atoms and the 
heme iron atom of wild-type and F120A mutant CYP2D6 were derived for the two different 
protonation states of the MDMA enantiomers, by averaging the distances over the three 
simulations (using Equation 4) and these were subsequently compared to experimentally 
determined distances (Table 3). Relatively large differences in averaged hydrogen atom to 
iron distances were found within individual MD simulations starting from different substrate
docking poses. However, averaged distances of individual MD simulations of the same 
protonation state and starting from the same docking pose, were approximately equal. 
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Table 4: Distributions of substrate orientations corresponding to specific sites of oxidation (in %),
according to automated docking studies (A) and MD simula ions (B).t
A
wild-type F120ASubstrate
reactive ODM NDM NOH OH reactive ODM NDM NOH OH
MDMA R H+ 100 100 0 0 - 100 100 0 0 -
n 88 86 10 4 - 93 90 3 7 -
S H+ 92 100 0 0 - 100 100 0 0 -
n 99 73 14 13 - 80 99 0 1 -
MDEA R H+ 91 99 1 0 0 100 99 1 0 0
n 100 91 9 0 0 100 98 2 0 0
S H+ 69 99 1 0 0 100 99 1 0 0
n 99 78 22 0 0 100 93 7 0 0
MDPA R H+ 70 79 21 0 0 99 99 1 0 0
n 92 62 38 0 0 100 97 3 0 0
S H+ 74 100 0 0 0 95 62 38 0 0
n 82 99 1 0 0 100 73 27 0 0
B
wild-type F120ASubstrate
reactive ODM NDM NOH OH reactive ODM NDM NOH OH
MDMA R H+ 97 100 0 0 - 89 100 0 0 -
n 77 83 3 12 - 96 69 3 28 -
S H+ 99 100 0 0 - 100 100 0 0 -
n 80 88 1 11 - 92 64 23 13 -
MDEA R H+ 74 99 0 0 1 64 99 0 0 1
n 95 85 2 2 11 93 71 18 9 2
S H+ 100 100 0 0 0 76 100 0 0 0
n 82 92 2 6 0 79 61 32 5 2
MDPA R H+ 97 100 0 0 0 99 100 0 0 0
n 97 100 0 0 0 100 58 22 1 20
S H+ 100 100 0 0 0 98 100 0 0 0
n 100 100 0 0 0 98 99 1 0 0
-
t t
The columns ‘reactive’ indicate the percentage of all binding orientations that displayed a site of 
oxidation within 6 Å of the heme iron. The subsequent columns show the distribution of the reactive 
conformations for the different sites of oxidation, corresponding to O-demethylenation (ODM), N
demethylation (NDM), N-hydroxylation (NOH), and ‘omega-hydroxylation’ ( OH). The automated
docking s udies are based on 50 independent AutoDock and GOLD docking runs, the MD simula ions
are Boltzmann weighted averages over three independent simulations, starting from three different
docking poses. Substrates were simulated in neutral (n) and charged (H+) form.
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An exception was the difference in averaged distance of the methylenedioxy hydrogen
atoms of both neutral MDMA enantiomers in simulations starting from pose 3 
(corresponding to N-demethylation/hydroxylation) in wild-type CYP2D6 (~ 7.5 Å) compared
to the F120A mutant (~ 11.0 Å). Also the averaged distances derived from all three 
simulations of individual protonation states were approximately the same for the different
MDMA enantiomers in wild-type and F120A mutant CYP2D6. The averaged hydrogen atom 
to heme iron distances of the neutral MDMA enantiomers agreed well with the distances 
determined by NMR spin lattice relaxation rate measurements. Apparently, considering the 
substrates to be neutral describes the experimental situation best. With the exception of the 
N-methyl and C3 hydrogen atoms of R-MDMA in the F120A mutant, all hydrogen atom to 
heme iron distances calculated from MD simulations of neutral MDMA enantiomers were 
shorter than the experimentally derived distances. The methylenedioxy hydrogen atom to
heme iron distances were slightly lower than those of the N-methyl and C3 hydrogen atoms. 
In contrast, the averaged N-methyl and C3 hydrogen atom to heme iron distances of the
charged MDMA enantiomers violated the experimental distances consistently.
For all MDAAs, differences between the averaged enzyme-substrate interaction energies 
calculated using SCORE, were within 3 kJ/mol (~kT) for all three MD simulations of the 
same protonation states and within 5 kJ/mol for all six MD simulations. The relative weights 
of the MD simulations of the three starting orientations used in the Boltzmann averaging 
(Equation 5, see Methods section) over the simulations ranged between 0.11 and 0.54. 
Already during the equilibration time, or soon after the start of the MD simulations with 
charged MDAAs, reorientation of pose 3 (corresponding to N-demethylation) into pose 1
(corresponding to O-demethylenation) occurred. In the case of MDEA, this led to non-
reactive binding orientations outside of the binding pocket, forming a hydrogen bond
between its protonated nitrogen and the carboxylate group of E216 (Table 4B and Figure 6). 
Relatively high probabilities of O-demethylenation poses were found for neutral MDAAs
(>58%), although orientations corresponding to N-demethylation/hydroxylation were also
observed, except for MDPA in wild-type CYP2D6. N-demethylation or N-hydroxylation of 
neutral MDAAs had significant higher probabilities in the F120A mutant than in wild-type 
CYP2D6. Furthermore, substrate dependent catalytic regioselectivity was observed for the 
mutant: elongation of the N-alkyl chain led to a decreased N-hydroxylation efficiency with
an optimal N-dealkylation efficiency for MDEA (Table 4B). These trends were equal to those 
found experimentally and became even more pronounced when the MDAAs were averaged 
over enantiomers, over protonation states and Boltzmann weighted (Figure 7).
Significant stereoselective differences in the probabilities of O-demethylenation vs. N-
demethylation/hydroxylation were not observed for wild-type CYP2D6. The F120A mutant
however, did in all cases discriminate the enantiomers of the neutral MDAAs. Differences
between the probabilities of N-demethylation and N-hydroxylation of MDMA enantiomers
were found and R-MDPA was found in orientations leading to N-demethylation and -
hydroxylation more often than S-MDPA (Table 4B).
Enzyme-substrate interactions observed in the MD simulations of neutral MDAAs showed a 
significant decrease in van der Waals / aromatic interactions with residue 120 in the F120A 
mutant compared to wild-type CYP2D6 (Table 5). Furthermore, a small decrease in 
hydrogen-bond interactions with the carboxylic acid of E216 was observed for the F120A 
mutant as a direct result of the relatively high probability of binding orientations 
corresponding to N-dealkylation or N-hydroxylation. In both wild-type and F120A mutant
CYP2D6 however, hydrogen-bond interactions were found to be significantly decreased for 
neutral MDAAs (up to 23% on average for each enantiomer) when compared to charged 
MDAAs (up to 92% on average for each enantiomer). During the MD-simulations, water 
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molecules were primarily observed to fill the part of the active site which is connected with a 
so called “water channel” [54], which was already partially occupied by predicted water 
molecules in the automated docking starting structures (Figure 6). These water molecules 
were found to form H-bonds with the substrate. At most, one water molecule was observed
in other regions of the active site. 
A
B
Figure 6: Molecular dynamics (MD) simula ions starting o ientations o  charged R-MDMA  generated by
automated docking studies in wild-type (A) and F120A mutant (B) CYP2D6 homology models. Two 
orientations are corresponding to O-demethylenation, with the substrate nitrogen-atom either in close
contac with E216 (pose 1) or placed between E216 and D301 (pose 2). A third orientation is
corresponding to N-demethylation o N-hydroxylation (pose 3). Water oxygen atoms, as predicted by
GRID (see Materials and Methods section), are depicted as spheres. A colored version of the figure is 
shown in the Appendix of this thesis. 
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Table 5: Enzyme-substrate interactions (%) during MD simulations.
Enzyme-substrate interactions during the MD simulations were monitored in terms of the occurrence of 
atom-a om dis ances of 3.5 Å or less between the F A120 side-chain and the MDAA ring system,
representing aromatic/van der Waals in erac ions and hydrogen bonds between the E216 carboxylate
oxygen atoms and the MDAA nitrogen-atom. Values of neutral and charged substrates were averaged.
Wild-type F120ASubstrate
VdW/arom. F120 H-bond E216 VdW/arom. A120 H-bond E216 
MDMA R 81 65 12 54
S 80 69 23 47
MDEA R 55 51 2 46
S 66 70 1 57
MDPA R 71 74 5 52




The primary aim of this study was to develop an integrated molecular modeling approach to
analyze substrate oxidation by CYP2D6. When regioselectivity and stereoselectivity in
metabolic oxidation and the effect of enzyme active site mutations can be visualized and 
quantified using a series of related compounds, such an approach could be a useful tool in
the rationalization and prediction of metabolism. Using this approach the experimentally 
determined binding modes and the product formation of a series of MDAAs by wild-type and
F120A mutant CYP2D6 could be rationalized. 
Substrate binding orientations
In the present study, molecular modeling was used to explain the apparent discrepancy
between experimentally observed differences in regioselective oxidation and the
stereoselective preference by the F120A mutant towards MDMA (Figure 1) and the average
substrate orientation in the mutant and wild-type active sites as determined by NMR spin 
lattice relaxation rate measurements (Table 3). The average hydrogen atom to iron 
distances calculated from the Tl of the MDMA enantiomers in both enzymes were equal, with
the methylene moiety in both cases closest to the heme iron atom. Although the distances
between the hydrogen atoms at potential sites of oxidation in MDMA and the heme iron 
atom were somewhat larger than comparable distances found in CYP X-ray structures (4-6 
Å) they were within the ranges of distances determined in other NMR studies [27-30]. This 
difference can be explained by the fact that experimentally determined distances are
averages of all possible substrate orientations during access to, residence in and exit from 
the active site. As a result they contain more information then just that of a reactive 
substrate orientation. NMR spin lattice relaxation rate measurements have been used before 
to determine the orientation of codeine in CYP2D6, where the measured hydrogen atoms to 
iron atom matched the orientation expected from codeine’s metabolic profile [28]. Codeine
is a more rigid and bulky substrate than MDMA, which may explain the good match.
Caffeine, a small and low affinity substrate of CYP1A2 was also subject of NMR spin lattice 
relaxation rate measurements, but the orientation found of caffeine did not match the 
metabolic profile [30]. From other experimental studies it is known that substrates can be 
quite mobile in CYP active sites [55], and the existence of multiple substrate binding modes 
and substrate mobility in CYP2D6 is clearly supported by our molecular modeling studies. 
Averaged distances derived from the present studies, considering three distinct 
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automatically docked substrate binding modes of the MDAAs in combination with long MD 
simulations, were in good agreement with the experimentally determined metabolic profiles 
when considering the MDAAs to be in their neutral form (Table 3). Still, this does not explain 
the experimentally observed change in regioselective oxidation and stereoselective 
preference of the F120A mutant towards MDMA compared to wild-type. So it is likely that a 
small substrate like MDMA is very mobile in the CYP2D6 active site and that the reactivity of 

















































Figure 7: Probabilities (%) of reactive binding orientations corresponding to O-demethylenation (grey),
N-dealkylation (blank), N-hydroxylation (diagonal stripe), and -hydroxylation (black), of the MDAAs in 
wild- ype (A) and in F120A mutant (B) CYP2D6, as derived from 12 MD simula ions. Shown are the
Boltzmann weighted averages o  two di ferent protonation s ates and three di ferent docking poses
(examples in Figure 6), and assuming a 1:1 ratio between R- and S-enantiomers.
t t
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Regioselectivity and stereoselectivity in oxidation
Experimentally observed trends in regioselectivity in the oxidation of the MDAAs by wild-
type and F120A mutant CYP2D6 (Table 2) were in good agreement with the relative
probabilities of different binding modes of the MDAAs observed in the MD simulations (Table
4B). In the wild-type enzyme, only O-demethylenation was observed experimentally, while 
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in the F120A mutant also N-demethylation and N-hydroxylation occurred. The molecular 
modeling studies showed that N-demethylation/hydroxylation probabilities for neutral 
MDAAs were significantly higher in F120A mutant than in the wild-type enzyme (Table 4B). 
Both the experimental and modeling studies showed a decreased N-hydroxylation efficiency 
with elongation of the N-alkyl chain and the highest MDA formation efficiency for MDEA.
Stereoselectivity in oxidation of MDMA by wild-type CYP2D6 was hardly found
experimentally neither predicted by molecular modeling. However, the experimentally 
observed preference for S-MDMA by the F120A mutant could not be rationalized by
molecular modeling. This may be due to the fact that the stereoselectivity is predominantly 
caused by a difference in Km and not in Vmax, while affinities of the substrates to the 
enzymes were not predicted in a rigorous manner in this study. On the other hand, the
small violations of the calculated to the experimentally determined hydrogen atom to iron 
distances for neutral R-MDMA bound to the F120A mutant do indicate that this enantiomer 
experiences more difficulties to find its optimum orientation in the binding pocket.
Influence of F120A mutation on oxidation reactions
By removing the phenyl ring of F120 more space is created in the active site of CYP2D6 and
a specific aromatic interaction point is eliminated [16]. From the MD simulations it became
clear that this space was not occupied by the MDAAs or by water molecules, but that critical 
substrate interactions were lost after mutating F120 into an alanine (Table 5). This 
observation and the fact that the stereo- and regioselectivity of the mutant enzyme differed
from wild-type shows that F120 is important for specific interactions with the MDAAs in
CYP2D6. There is not sufficient space in the active sites of wild-type or the F120A mutant 
CYP2D6 to accommodate two molecules of the MDAAs at the same time. However, it could 
be possible that two substrate molecules bind simultaneously to different parts of the
protein e.g. in the active site and in substrate access channels [54], or in a peripheral 
binding site [9]. 
Combination of automated docking and MD simulations
In earlier studies it was shown that automated docking can successfully be applied to 
predict sites of oxidation by CYPs. [21] In contrast, the current study shows that automated 
docking alone is not suitable for accurate determination of relative probabilities of different 
substrate binding modes and for discrimination between substrates and enzymes of high 
similarity, such as regio/stereoisomers and mutants of enzymes. In order to reproduce the
experimental data, which are an average over many different substrate and enzyme 
orientations in time, a dynamic treatment of both  substrate and enzyme is required. Only 
when averaging over different positions and orientations was taken into account,
experimentally determined substrate hydrogen atoms to heme iron atom distances could be 
reproduced accurately. The experimentally observed differences in substrate oxidation by 
wild-type and F120A mutant CYP2D6 could only be explained from the different binding 
modes observed in the MD simulations. Multiple and extensive MD simulations are needed 
to catch these subtle differences between substrates, enzyme structures and their dynamics.
Substrate protonation states
The molecular modeling was performed with neutral and charged substrates because this 
markedly influenced the binding and mobility of the MDAAs in the active site of the two
enzymes. Even though the MDAAs in physiological solution will occur predominantly in their 
charged form, the preferred protonation state within the binding pocket can differ 
significantly, thus reductions of apparent pKa values for substrates upon binding to CYP2D6 
120
Chapter 6 
of up to 2 pH units have been reported [26]. From a direct comparison between the 
experimentally derived hydrogen atom to heme iron distances and the computationally 
determined values it became clear that the MD simulations reproduced the experimental 
data best when the MDAAs were represented in their neutral form. 
Conclusions
The approach of combining automated docking and MD simulations in a protein model was
a successful way to rationalize the oxidative metabolism of a series of 3,4-methylenedioxy-
N-alkylamphetamines (MDAAs) by CYP2D6. Differences in oxidative metabolism of these
closely related substrates could be predicted in details like regioselectivity and 
stereoselectivity. Furthermore, the effects of the active site F120A mutation on the substrate 
selectivity could be rationalized. The presented integrated modeling method is a promising 
tool in the prediction of the metabolic properties of new (drug-like) compounds by CYP2D6
and might be applicable for other drug metabolizing enzymes as well.
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The conserved threonine 309 influences spin state equilibrium in cytochrome 
P450 2D6: a resonance Raman scattering study
Peter H.J. Keizers, Alois Bonifacio, Gert van der Zwan, Cees Gooijer, Nico P.E. Vermeulen,
and Jan N. M. Commandeur
The polymorphic cytochrome P450 2D6 (CYP2D6) is one of the major drug metabolizing 
enzymes in humans. Its active site residue T309 was shown to be of crucial importance for 
the enzyme activity, probably by determining the ratio of multiple oxygenating species [1]. 
In this study, the heme prosthetic group, and its environment, of wild-type and the T309V 
mutant of CYP2D6 have been studied using resonance Raman spectroscopy. It was found
that T309 is involved in maintaining a 5-coordinated high spin species in presence and 
absence of substrates. Binding of dextromethorphan to wild-type CYP2D6 led to a change in 
the polarity of the heme environment, as observed by a shift of the Fe-CO stretching 
frequency, whereas in the T309V mutant this effect was less apparent. Dextromethorphan
binds similar to the mutant as to the wild-type and the T309V mutation has no direct effect
on the polarity of the heme environment. These data suggest that T309 is involved in the 
hydrogen-bonds network in the active site of CYP2D6, but the residue is too far from the 
heme to be directly interacting with iron-bound water or molecular oxygen. The observed 
effects of the T309V mutation on the heme and its environment can be an additional 
explanation for the changed reactivity of the mutant, besides its effect on the balance of
oxygenating species.
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Introduction
Cytochromes P450 (CYPs) are enzymes responsible for the oxidative biotransformation of a 
large variety of endogenous and exogenous substrates, like steroids, carcinogens and drugs, 
and can be found in virtually all organisms [2]. In human drug metabolism, one of the most
important CYP isoforms is CYP2D6. This hepatic enzyme is involved in the phase I oxidative
metabolism of about 30% of the currently marketed drugs, including much prescribed 
antidepressants, -blockers, opioids and antiarythmics [3]. The enzyme is known for its 
genetic polymorphisms and gene multiplicities, even increasing its clinical relevance [4]. 
Structural studies on CYP2D6 are of crucial importance to understand the functioning of the 
enzyme and to be able to predict the metabolism of new (drug-like) compounds [5].
Previously, we demonstrated the critical role of residue T309 in the mechanism of oxidation 
by CYP2D6 [1]. The T309V mutant displayed a decreased O-dealkylation activity towards 
model substrates and when possible, N-dealkylation reactions were preferred. These 
observations were explained by a decreased ability to form the oxenoid-iron species 
(compound I), the presumed dominant oxygenating species involved in O-dealkylation
reactions [6]. This was confirmed by the fact that by using cumene hydroperoxide as
oxygen donor, the O-dealkylating activities were restored. Cumene hydroperoxide is known
to short-circuit the catalytic cycle and directly forms the oxenoid iron [7]. Apparently,
without T309 the oxygenating species preceding the oxenoid iron in the catalytic cycle, the 
hydroperoxo-iron accumulates, leading to a changed reactivity pattern of the enzyme. 
Similar results were found after mutation of the homologous threonine residues in other CYP 
isoforms, like T302 and T303 in rabbit CYP2B4 and CYP2E1 respectively [8, 9]. The I-helix 
threonine is highly conserved in CYPs and seems to be involved in proton donation to the 
heme bound oxygen [10]. Based on crystal structures of the ferrous dioxygen complex of 
the wild-type and the T252A mutant of CYP101, it was proposed that T252 accepts a 
hydrogen bond from the hydroperoxo-iron intermediate, thereby promoting the second
protonation on the distal oxygen atom, which leads to O-O bond cleavage and compound I 
formation [11]. Resonance Raman (RR) spectroscopy can be used to obtain information
about several properties of the heme prosthetic group. The iron oxidation state, the spin
state, the coordination number, and also conformational changes of the vinyl and
propionate side chains of the heme can be studied [12]. Furthermore, the Fe-CO stretching 
mode is sensitive to the polarity of the heme environment [13, 14]. By choosing the 
excitation wavelength in resonance with the Soret absorbance band, RR is a sensitive 
spectroscopic technique to study CYPs [15]. Most bands in RR spectra of CYPs have been
assigned to heme vibrational modes and are in many cases well resolved [12]. The
technique offers great selectivity and can thus be more sensitive for small changes in the 
heme than UV-visible absorbance spectroscopy. RR was successfully employed before to 
study the effects of active site mutations in CYPs [16-18], including those of the conserved
I-helix threonine [19, 20]. In this study, we have chosen RR spectroscopy to probe the
heme characteristics of wild-type and the T309V mutant of CYP2D6 in order to find out 
whether the mutation influences the heme properties, correlated with the altered catalytic 
activity of the mutant.
Materials and Methods 
Materials
The pSP19T7LT plasmid containing in tandem the cDNAs of human CYP2D6 with a C- terminal His6-tag
and the human NADPH-cytochrome P450 reductase, was used as described before [1]. Escherichia coli 
JM109 were obtained from DSMZ (Braunschweig, Germany). Dextromethorphan hydrobromide was




Expression and puri ica ion of the enzymesf t
The pSP19T7LT plasmids containing wild-type or the T309V mutant of CYP2D6 cDNA were transformed
into E. coli strain JM109. Expression and membrane isolation was carried out as described [1]. 
Membranes were resuspended in 0.5% of the original culture volume of KPi-glycerol buffer (50 mM
potassium phosphate buffer, pH 7.4, 10% glycerol) and the enzymes were purified, using nickel affinity
chromatography as described [21]. CYP concentrations were determined by CO-difference absorption
spectra on a Pharmacia Ultrospec 2000 spectrometer, using = 91 cm-1mM-1 according to Omura and 
Sato [22]. 
Resonance Raman spectroscopy
Spectroscopic measurements were conducted using a home-built Raman microscope in a backscattering
configuration. A Zeiss microscope (D-7082 with 40x objective, NA 0.85, working distance 0.3 mm) was
coupled to a single monochromator (Instruments SA Inc., Metuchen, NJ) with a mounted 2400 g/mm 
grating and a CCD camera (Andor Technologies DV-420OE, Belfast, N.Ireland). The 413.1 nm line of a 
continuous wave Kr ion laser (Coherent Innova 300c, Coherent Inc., Santa Clara CA) and the 457.9 nm 
of a continuous wave Ar ion laser (Spectra Physics 2000-336, Newport corp., Mountain View CA) were
used for excitation and the Rayleigh scattered light was removed using 3rd Millenium edge long pass 
filters (Omega Optical, Bratleboro, VT). Laser powers of 10-15 mW (at 413.1 nm) and 1 mW (at 457.9 
nm) were used on the sample throughout the experiments. The sloping background of the spectra was 
subtracted using a baseline fitted to the experimental data with the Andor CCD camera software. The 
fitting of experimental data with Lorentzian functions was performed with PeakFit 4.12 (SeaSolve 
Software Inc., Richmond CA). For RR measurements, a 1 mm-diameter glass capillary was filled with 10 
µl of varying concentrations (1-50 µM) CYP2D6 in KPi-glycerol buffer and put in a spinning capillary
holder under the microscope objective. To measure substrate binding, substrate concentrations of 5-10
mM were used, leading to a 500-1000 fold excess of substrate with respect to the enzyme (saturating
conditions, as indicated by the Ks reported for the substrates [1]). No further spectral changes were 
detected upon increasing substrate concentration, indicating that all the CYP2D6 in the sample was
bound to the substrate [23]. To obtain the ferrous CO-complexes, oxygen was removed from the 
CYP2D6 samples (with or without substrate) by stirring under a nitrogen atmosphere, reduced by 
adding 5 µl of a 25 mg/ml sodium dithionite in KPi-glycerol buffer, to 20 µl of enzyme in the same
buffer, and exposed to CO for 2-3 minutes while stirring. During all measurements the capillary
containing the sample was kept spinning to minimize local heating and photodissociation of the iron 
bound CO. Before and after every RR measurement, CYP integrity was monitored by CO difference
absorption spectroscopy.
Results
Expression and purification of the enzymes 
Recombinant expression followed by affinity chromatography purification yielded 
approximately 60 nmoles CYP2D6 per liter of cultured E coli, in case of the wild-type and the 
T309V mutant of CYP2D6. The enzymes were pure, as judged by the observation of a single 
band of 55 kD on a Coomassie brilliant blue stained SDS-polyacrylamide gel. The absolute 
absorbance spectra of oxidized, and reduced CO-bound, wild-type CYP2D6 are shown in
Figure 1. There were no significant differences between the spectra of the wild-type and the 
T309V mutant of CYP2D6. A small amount of P420 (inactive CYP, observed as a shoulder at 
420 nm in the CO-difference spectrum) was present in the both the wild-type and T309V 
mutant samples.
Resonance Raman spectroscopy
The low- and high-frequency regions in the RR spectra of the wild-type and T309V mutant 
of CYP2D6 in the resting state (i.e. without substrate), are at first sight rather similar
(Figure 2). In both cases, the most intense band at 1372 cm-1 is attributed to the 4
vibrational mode, indicative for an oxidized heme iron atom, and the band at 675 cm-1 is 
attributed to the 7 vibrational mode [12].
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The wild-type enzyme high-frequency region spectrum (Figure 3a), is indicative for a
predominantly six-coordinated low-spin (6cLS) oxidized heme. The bands at 1501, 1582 and
1637 cm-1 are attributed to the 3, 2 and 10 vibrational modes for a 6cLS heme 
respectively [12]. However, a weak shoulder of 3 suggests the presence of another band at 
lower wavenumbers, characteristic of a five-coordinated high-spin (5cHS). In consistence, a 
better fit of the spectral data for wild-type CYP2D6 was obtained when including bands at 
1486, 1567 and 1623 cm-1, for respectively the 3, 2 and 10 vibrational modes of a 5cHS 
heme species in addition to the 6cLS bands (Figure 3a).













Figure 1: Absolute absorbance spectra of 1 M puri ied wild- ype CYP2D6 before, and af er addi ion o
sodium di hionite and CO (dashed line).
f t t t f
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Although the high-frequency region RR spectrum of the T309V mutant seemed similar to 
that of the wild-type, the difference spectrum of the two enzymes (Figure 3), shows an
intensity increase for the bands characteristic of a 6cLS species, and a concomitant decrease 
of the 3, 2 and 10 vibrational modes, typical for a 5cHS heme. Therefore, in the T309V 
mutant the content of 5cHS is decreased compared to the wild-type, with a concomitant 
increase of the 6cLS fraction. 
In the presence of saturating amounts of the substrate dextromethorphan, the bands 
distinctive of the 5cHS species ( 3 and 2 at 1486 cm-1 and 1567 cm-1 respectively) increased 
in intensity, whereas the intensity of the corresponding bands for the 6cLS species ( 3 and 
2 at 1501 and 1582 cm-1 respectively) diminished, for both the wild-type and the T309V
mutant of CYP2D6 (Figures 3 and 4). A difference between the two enzymes was found in
the intensity ratio between the 6cLS/5cHS 3 bands (at 1501 and 1486 cm-1 respectively),
which was higher in the T309V mutant than in wild-type CYP2D6 (Figure 3).
The Fe-CO stretching ( Fe-CO) frequency is known to decrease with increasing polarity of the 
heme environment [13, 24]. In both the CO-bound wild-type and T309V mutant CYP2D6, 
the band attributed to Fe-CO was observed at 476 cm-1. In the RR spectrum of wild-type 
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CYP2D6 in the presence of saturating amounts of dextromethorphan, the Fe-CO was
increased by 5 cm-1. In the spectrum of the CO-bound T309V mutant in the presence of 
saturating amounts of dextromethorphan, the shift of Fe-CO was less evident, although the
band broadened towards higher wavenumbers (Figure 5).


























Figure 2. High- and low-frequency RR spect a of wild type and T309V mutant CYP2D6. Spec a were 
taken as described in the Methods section, the vib ational modes are assigned to the most intense







Conserved I-helix threonines in CYPs play an important role in the mechanism of oxidation
by these enzymes. Apparently, these residues are involved in the process of proton donation
to the heme-bound molecular oxygen, thereby activating it to the ultimate oxygenating
species. Recently, T309 was shown to fulfill this role in CYP2D6. In this study we have 
employed resonance Raman (RR) spectroscopy to examine the impact of the T309V 
mutation on the porphyrin prosthetic group properties, and the polarity of its environment.
In the absence of a substrate, the CYP heme iron atom is generally observed as oxidized
(Fe3+), and mainly in the 6cLS state with a water molecule (or hydroxyl ion) as the sixth 
distal ligand trans to the endogenous cysteinate ligand [25]. In this study, the 6cLS state 
was indeed found predominant for wild-type CYP2D6. In addition, a minor presence of the
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5cHS state was observed (Figure 3). The presence of the 5cHS species in the resting state 
RR spectrum has been reported for other CYPs as well; a mixed spin state with a 5cHS 3
mode at 1488 cm-1 and a 6cLS 3 mode at 1502 cm-1 was observed for substrate free rabbit 
CYP1A2 [26], while for substrate free human CYP1A2 only one 3 band at 1487 cm-1 was 
reported, indicating the exclusive presence of an HS resting state [27]. Also in the cases of 
bacterial CYP121 and CYP152, mixed LS/HS spin states have been reported in the absence 
of substrates [28, 29].


















































































Figure 3. Spin-marker bands region of the RR spect a of 30µM CYP2D6 wild- ype (a), T309V mutant (b)
and their difference spectrum (b)-(a) are shown in the le t panel  Spin-marker bands region of the RR 
spectra of CYP2D6 wild type (c), and T309V mutant (d) in presence of dextromethorphan and their
di ference spectrum (d)-(c) are shown in the right panel  Excita ion wavelength 413.1 nm, power 10 
mW, accumula ion ime 600 s. The Lorentzian functions used to f  the spec rum (a) (see Methods
section) are represented as solid (high-spin marker bands  o  dotted (low-spin marker bands) peaks
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The apparent equilibrium of spin states may be disturbed by active site conformational 
changes. In the 5cHS state, the heme is no longer ligated to an axial water molecule. This is 
often observed when a substrate is present in the heme-pocket, perturbing the iron bound
water molecule directly, or through inducing conformational changes in the enzyme. In the
presence of dextromethorphan, the 5cHS content of CYP2D6 was found significantly
increased (Figures 3 and 4). In recent studies on synthesized CYP heme mimetic models
[30] and QM/MM calculations on CYP101 [31, 32], it was suggested that the axial water 
ligand is involved in a hydrogen-bonds network due to a cluster of water molecules in the 
binding pocket. Changes in this network will directly modulate the properties of the distal 
water-ligand and thus the relative stability of the 6cLS versus the 5cHS state. In the resting 
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state of the T309V mutant of CYP2D6 the 5cHS content is decreased, with a concomitant 
increase of the 6cLS content. This higher stability of the 6cLS in the T309V mutant with
respect to wild-type CYP2D6 is preserved in the presence of dextromethorphan (Figures 3 
and 4). The substrate itself perturbs the wild-type and mutant spin-equilibria to the same 
extent (Figure 4). This strongly suggests that the difference in the 6cLS/5cHS ratio between 
the substrate-bound wild-type and mutant enzyme is not due to different binding modes of
dextromethorphan, but rather to a difference caused by the T309V mutation. Apparently the 
T309 residue is involved in the hydrogen-bonds network involving the cluster of active site
water molecules. 
To further investigate the role of T309 in CYP2D6, the spectra of the reduced CO-bound
wild-type and T309V mutant enzymes were analyzed (Figure 5). The ferrous CO-heme 
complex has an electronic structure similar to the oxygenated complex but it is stable, and
therefore a convenient model to mimic the Fe-O2-complex [12, 33]. Moreover, CO can be
used as a vibrational probe of the heme pocket polarity, since changes in the water content
of the pocket cause a variation of the local electromagnetic field and induce a shift in the 
Fe-CO vibrational frequencies [13, 14, 24]. 





























Figure 4. The difference spectra between the dextromethorphan bound and the subst ate-free enzyme
(Figure 3), for the wild- ype (a) and the T309V mutant (b) of CYP2D6. Excita ion 413.1 nm, power 10




In the absence of substrate no differences were detected between the wild-type and the 
T309V mutant CYP2D6 Fe-CO frequencies, suggesting that T309 does not interact directly 
with CO and has no relevant effect on the polarity of the binding pocket localized directly 
above the heme. This observation is consistent with RR data from CO-adducts of the T252A 
mutant of CYP101 [20], and the T243V mutant of CYP55A [34], whereas the T301V mutant 
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of rabbit CYP4A6 displayed a 3cm-1 increase of the Fe-CO compared to the wild-type [19]. 
On the other hand, binding of dextromethorphan caused a 5 cm-1 increase of Fe-CO in wild-
type CYP2D6, indicating a diminution in local polarity due to a decrease of water content in 
the binding pocket [13, 24]. A similar but smaller effect is observed for the T309V mutant, 
showing a broadening of the Fe-CO peak towards higher wavenumbers, which indicates that 
the electrostatic field variation caused by dextromethorphan in the two enzymes do not 
differ substantially. The affinity of the two enzymes for dextromethorphan is similar as well, 
as was judged from optical titration experiments, which yielded type I binding spectra with
spectroscopic dissociation constants (Ks) of 33 and 20 M for wild-type and mutant 
respectively [1]. 

















Figure 5. Low-frequency RR spectra of CO-bound CYP2D6 wild- ype (a,b) and T309V mutant (c,d), in
absence (a,c) and in presence (b,d) of dextromethorphan. Excita ion 457.9 nm, power 1 mW,




Also, modeling studies do not indicate T309 to be involved in substrate binding in CYP2D6 
[35]. To summarize, there is no direct effect of T309 on the hydrophobicity of the heme-
bound CO environment and the residue does not significantly influence the effects of 
dextromethorphan binding in the active site. According to our CYP2D6 homology model 
[36], the T309 hydroxy moiety is at approximately 5 Å from the heme iron atom, depending 
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on its rotameric state (Figure 6). This distance is too large for T309 to be directly involved in
hydrogen bonding with a heme-bound water molecule or with iron-oxygen species, unlike
T252 in CYP101, where the distance from the heme iron atom to the T252 hydroxy moiety 
is 3.5 Å [11]. Therefore, T309 in CYP2D6 is believed to have an indirect influence on the 
heme bound axial ligand, via hydrogen bonding with other active site water molecules. In a 
previous study we have shown that T309 affects the proton delivery to the heme-bound 
oxygen [1], while the present investigations indicate that T309 is involved in the network of
hydrogen-bonds in the active site. It is arguable whether there is a relation between a 
change in spin state and the activity of a CYP, because upon mutation of W97 in CYP102
the spin state also changed, while mutant activities remained high [37]. But the loss of the 
T309 hydroxy moiety in CYP2D6 does change the active site conformation of the water 
cluster to some extent, in addition to its role in activating heme-bound oxygen.
T309
Figure 6: Protein model displaying the ac ive site of CYP2D6 with dextromethorphan bound [36]. The 
porphyrin is shown wi h Fe as a sphere, the Fe coordinating C443 is shown and he putative oxygen
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Binding of 7-methoxy-4-(aminomethyl)-coumarin to wild-type and W128F 
mutant cytochrome P450 2D6 studied by time-resolved fluorescence
spectroscopy
Peter H.J. Keizers*, Aike Stortelder*, Chris Oostenbrink, Chris de Graaf, Petra de Kruijf, Nico
P.E. Vermeulen, Cees Gooijer, Jan N.M. Commandeur, and Gert van der Zwan *contributed
equally
adapted from: The Biochemical Journal 2006 393: 635-43 
Enzyme structure and dynamics may play a main role in substrate binding and the
subsequent steps in the cytochrome P450 catalytic cycle. In the present study, changes in 
the structure of human cytochrome P450 2D6 (CYP2D6) upon binding of the substrate are 
studied using steady-state and time-resolved fluorescence methods, focusing not only on 
the emission of the tryptophan residues, but also on emission of the substrate. As a 
substrate 7-methoxy-4-(aminomethyl)-coumarin (MAMC) was selected, a compound 
exhibiting native fluorescence. Next to the wild-type enzyme the W128F mutant of CYP2D6 
was studied. After binding, a variety of energy transfer possibilities exist, therefore 
molecular dynamics simulations were performed to calculate distances and relative
orientations of donors and acceptors. Energy transfer from W128 to heme appeared to be
important, its emission was related to the shortest of the three average tryptophan 
fluorescence lifetimes observed for CYP2D6. MAMC to heme energy transfer was very 
efficient as well: when bound in the active site, the emission of MAMC was fully quenched. 
Steady-state anisotropy revealed that besides the MAMC in the active site, another 2.4% of 
MAMC was bound outside of the active site to wild-type CYP2D6. The tryptophan residues in 
CYP2D6 appeared to be less accessible for the external quenchers iodide and acrylamide in 
presence of MAMC, indicating a tightening of the enzyme structure upon substrate binding. 
However, the changes in the overall enzyme structure were not very large, since the 
emission characteristics of the enzyme were not very different in the presence of MAMC.
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Introduction
Among the large variety of cytochromes P450 (CYPs), one of the most important phase I 
drug metabolizing enzymes in humans is CYP2D6. Although the hepatic expression levels 
are low - about 3% of the total amount of CYP - it is involved in the oxidative metabolism of 
about 30% of the currently marketed drugs, including -blockers, neuroleptics,
antidepressants and antiarythmics [1, 2]. In addition, this enzyme is clinically relevant 
because of the large interindividual differences that exist in CYP2D6 activity, due to gene 
multiplicity and polymorphisms [3]. The scientific challenge is to rationalize why and how 
substrates are metabolized and to predict the metabolism of newly found or synthesized 
(drug-like) compounds. For this purpose, detailed structural information on CYP2D6 is 
essential, but so far no crystal structure of CYP2D6 has been resolved and any structural 
information on this enzyme still depends on homology modeling.
This paper focuses on some structural features of the enzyme, in particular the 
conformational changes induced by binding of the substrate. Since homology models as
such cannot be used for this purpose, we will make use of molecular dynamics and docking 
studies, as has been successfully employed for other CYPs [4]. Furthermore, both time-
resolved and steady-state fluorescence spectroscopy will be used, as has been applied 
before to CYP101 [5, 6]. In these studies by Prasad et al. on the dynamics of substrate 
binding to CYP101, the attention was focused on the emission of the five available 
tryptophan residues. Tryptophan residues are good endogenous probes since both lifetimes 
and emission wavelengths may be influenced when the conformation of (parts of) the
protein changes [7-9]. Analysis of the tryptophan fluorescence lifetimes data for CYP101 
indicated substrate dependent dynamic behavior of W42 in the wild-type and Y96A mutant 
enzymes. CYP2D6 contains seven tryptophan residues. Based on the homology model, the
fluorescence of W128 in CYP2D6 is expected to be sensitive to substrate binding as well. 
Although it is not located close to the substrate access channel – like W42 in CYP101 – it is 
close to the heme group. Moreover, it is thought to be bound to the propionate of pyrrole
ring D of the porphyrin via hydrogen bonds, as are the homologous tryptophan residues in
the crystal structures of mammalian CYPs 2C5, 2C9, 2B4 and 3A4 (PDB codes 1N6B, 1OG2, 
1PO5 and 1TQN respectively) [10-13].
A useful feature of tryptophan fluorescence in heme proteins is resonance energy transfer to
the heme prophyrin ring [14, 15], which generally leads to a low tryptophan fluorescence
quantum yield [16]. In the presence of substrates, other possible energy transfer pathways 
need consideration as well, i.e. from tryptophan to substrate and from substrate to heme. 
The CYP2D6 substrate 7-methoxy-4-(aminomethyl)-coumarin (MAMC) is a fluorescing,
moderate affinity substrate [17, 18]. Its long-wavelength absorption band overlaps with the 
tryptophan emission, so when bound to CYP2D6 energy transfer is expected. Furthermore,
it can also be excited selectively, allowing for investigation of its properties even when 
bound to CYP2D6.
In this study, the binding of MAMC to CYP2D6 was studied by steady-state and time-
resolved fluorescence experiments on the tryptophan residues and MAMC, both for wild-type 
and W128F mutant CYP2D6. Quenching experiments with acrylamide and potassium iodide 
(KI) provide information about the accessibility of the tryptophan residues and the dynamics 
of the protein structure [19-21]. Experimental results will be compared to molecular
dynamics (MD) simulations that are performed on a homology model [22]. The relative 
locations and orientations of the tryptophan residues, the heme group and MAMC during the 
simulations can be related to the Förster resonance energy transfer (FRET) efficiency 
between the individual pairs of FRET partners and are used to support the interpretation of 
the intricate fluorescence signals. 
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Materials and Methods 
Materials
The pSP19T7LT plasmid containing human C- terminal His6-tagged CYP2D6 bicistronically together with
human NADPH-cytochrome P450 reductase was kindly provided by Prof. Dr. Ingelman-Sundberg. 7-
methoxy-4-(aminomethyl)-coumarin (MAMC) and 7-hydroxy-4-(aminomethyl)-coumarin (HAMC) were
synthesized as described before [17]. Emulgen 911 was obtained from KAO Chemicals (Tokyo, Japan).
Ni-NTA-agarose was from Qiagen (Westburg, Leusden, The Netherlands). All other chemicals were of 
analytical grade and obtained from standard suppliers.
t
Mutagenesis and expression
The tryptophan 128 phenylalanine (W128F) mutation was introduced into pSP19T7LT using the
QuickChange XL Site-Directed Mutagenesis kit (Stratagene). The sequences of the forward- and reverse
oligonucleotides, respectively, with the mutated residue in italic, were as follows: 5’-C TAT GGG CCC 
GCG TTT CGC GAG CAG AGG C-3’ and 5’-G ATA CCC GGG CGC AAA GCG CTC GTC TCC G-3’. After 
mutagenesis, the presence of the desired W128F mutation was confirmed by DNA sequencing. Both the
W128F mutant and the wild-type pSP19T7LT_2D6 plasmids were transformed into Escherichia coli,
strain JM109. Expression and membrane isolation was carried out as described [23]. 
Enzyme purifica ion and sample preparation
Enzymes were purified as described before [22]. Shortly, membranes were resuspended in KPi-glycerol 
buffer (50 mM potassium phosphate buffer, pH 7.4, 10% glycerol). Enzymes were solubilized by stirring
in KPi-glycerol supplemented with 0.5% Emulgen 911 for 2 hrs at 4°C. Insoluble parts were removed by 
centrifugation (60 min, 120,000 g at 4 °C). The supernatant was incubated, gently rocking, with Ni-NTA
agarose for 60 min at 4 °C. The column material was filtered out and washed with 10 volumes of KPi-
glycerol buffer containing 2 mM histidine. CYP2D6 was eluted with 0.2 M histidine. After overnight
dialysis in KPi-glycerol buffer the sample was concentrated on a Vivaspin 20 filtration tube (10.000 
MWCO PES, Sartorius, Nieuwegein, The Netherlands). The amount of CYP was quantified by taking CO-
difference absorbance spectra [24]. Samples of 1 µM purified enzyme were used for fluorescence
measurements. MAMC concentration was 2 µM; at this concentration the emission intensities of CYP2D6
and MAMC were almost equal, the one signal did not overwhelm the other. For the quenching
experiments, KI was added to obtain final concentrations in the range from 0 M to 0.5 M. To avoid
formation of I2, 10 mM Na2S2O3 was added, the ionic strength was kept constant by addition of KCl.
Enzyme activity 
MAMC O-demethylation reactions were carried out in duplicate in a 96 wells plate, in a total volume of
200 l as described before [23]. The reaction mixture consisted of 50 mM KPi buffer containing 5 mM
MgCl2, 0-200 M MAMC and E. coli membranes corresponding to 40 nM wild-type or W128F mutant
CYP2D6. The reactions were initiated by addition of an NADPH regenerating system, resulting in final
concentrations of 0.1 mM NADPH, 0.3 mM glucose-6-phosphate, and 0.4 units/ml glucose-6-phosphate
dehydrogenase. The reaction was monitored for 30 min at 37°C on a Victor2 1420 multilabel counter
(Wallac Oy Finland) ( ex=405nm, em=460nm). The metabolite of MAMC, i.e. HAMC, was quantified
using the synthetic reference compound. 
Fluorescence instrumentation 
Time-resolved fluorescence experiments were performed using a laser system combined with time-
resolved photon counting detection. The laser system used was a Mira 900-P laser (Coherent, Santa 
Clara CA, USA), emitting 3 ps pulses at a repetition rate of 76 MHz, pumped by a Verdi-8 diode laser
(Coherent). The Mira 900-P is a mode-locked titanium-sapphire laser, tunable from approximately 700 
to 1000 nm. The laser emission was led through a pulse picker (Coherent), which reduced the repetition
rate to 4.75 MHz in order to avoid double excitation of molecules. The output wavelength of 290 nm 
was generated by means of a frequency tripler (Coherent). This light was used to excite the protein
sample in a cell with 1 cm pathlength (type 104F, Hellma GmbH &Co KG, Müllheim, Germany). For the
time-correlated single-photon counting (TCSPC), a SPC-630 (Becker &Hickl GmbH, Berlin, Germany)
system with a time-resolution of about 15 ps was used. A laser pulse focused on a photodiode provided
the synchronization signal. Fluorescence emission was collected at 90º, dispersed by a monochromator 
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(TVC JarrellAsh Monospec 18, Grand Junction CO, USA) and detected by a photomultiplier tube. Decays
were recorded at wavelengths between 330 and 440 nm in 10 nm steps. Quenching experiments were 
performed using TCSPC detection at two wavelengths, 340 and 430 nm. Steady-state fluorescence
emission and excitation spectra were recorded on a LS-50B instrument (PerkinElmer Inc., Wellesley, 
MA, USA). Steady-state anisotropy measurements were conducted using a Fluorolog-tau2 system
(HORIBA Jobin Yvon Inc., Edison, NJ, USA). 
Data analysis
Fluorescence decay curves were analyzed using a fit procedure based on the Levenberg-Marquardt
algorithm. This procedure uses the instrument response signal (obtained by recording scattered laser-
light) for deconvolution of the recorded decays and determination of lifetimes and wavelength





The quality of the fit (“goodness of fit”) was assessed on the basis of 2, the covariance matrix and the
distribution of residuals. The set of time-constants was kept as low as possible; normally not more than 
three constants were needed to obtain a fit of sufficient quality. For measurements at a series of 
detection wavelengths, a global fit procedure was used, based on the method described above.
Lifetimes are assumed to be constant for the decays included, while the amplitudes were varied. This
assumption is correct for proteins in many cases [25].
Decay-associated spectra (DAS) provide information on the fluorescence emission per lifetime
component. DAS are constructed by distributing the total intensity per decay-curve over the lifetimes
that make up the total intensity according to their ratio (amplitudes are obtained by global fit). The 
relative fluorescence intensity of lifetime component j, at wavelength  with amplitude A, can be
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Förster resonance energy transfer (FRET) 
FRET is radiationless transfer of excitation energy from a donor to an acceptor chromophore, controlled
by long range dipole-dipole interactions [26, 27]. It can be used for estimation of intermolecular
distances, because the efficiency of energy transfer ( T) is dependent on the distance r between a 
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, kD is the emission 
rate constant of the donor and 0D its lifetime in the absence of energy transfer; R0 is the Förster radius,
the distance at which transfer and spontaneous decay of the donor are equally probable. R0 can be
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where 2 is the orientation factor of the donor and acceptor transition dipole moments, 0D the 
fluorescence quantum yield of the donor in absence of energy transfer, NA Avogadro’s number, n the 
average refractive index of the medium, and  the overlap integral of the




DI ) and acceptor absorption spectra ( A ).
The distance dependence of energy transfer makes FRET useful to study structural changes. A
complicating feature is the dependency of the FRET efficiency on the orientation of donor and acceptor
transition dipoles via 2. This orientation factor varies between 0 and 4, and can be calculated from
atomic coordinates. Because of the dynamics of the protein, the exact orientations of the dipole
transition moments are not constant, and values of 2 (and also the distance r) will fluctuate in time.
Anisotropy
Steady-state anisotropy experiments were performed on a Fluorolog FL3-11-Tau3 system (Jobin-Yvon
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in which Ivv and Ivh are the intensities of the vertically and horizontally polarized components of the 
fluorophore emission, respectively, and is the angle between absorption and emission transition
dipole moment. Equation 5 can be adapted to an equation giving the ratio of concentrations of
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the (measured) anisotropy for the unbound substrate being 0. A solution of 50 M MAMC in glycerol
was used to determine the limiting anisotropy r0.
Computer simulations
The substrate MAMC was docked into the active site of the homology model with the programs
Autodock and GOLD [28, 29]. Five molecular dynamics simulations were performed in explicit Simple
Point Charge water [30]: four with different initial orientations of the substrate and one with the wild-
type CYP2D6 protein without substrate. Interatomic interactions were calculated from the GROMOS
force field parameter set 43A2 [31-33]. All five simulations were performed for ten nanoseconds using
the GROMACS simulation package [34]. Simulation parameter settings were chosen as described before
[22].
The value of 2/r6 for individual pairs of fluorescent groups is directly proportional to the FRET efficiency
of the pair (eq. 3 and 4). In order to relate the structural dynamics to the FRET efficiency, dipole
transition moments were chosen as follows. For tryptophan the transition moment 1La lies in the plane
of the indole ring at an angle of -46 degrees with respect to the indole molecular frame [35]. Only the 
1La transition dipole moment of tryptophan was included, since it is the only emitting state (internal
conversion from 1Lb is on a much faster timescale than fluorescence). For the heme moiety, two
degenerate dipole transition moments in the plane of the heme were considered, one pointing from N1
to N3 and another perpendicular to this [15]. For the substrate MAMC a transition dipole moment was
estimated in analogy to previous studies on coumarin-type compounds point from atom 3 to atom 7 
(Figure 1) [36]. 2/r6 was calculated for every pair of trp-heme, trp-MAMC and MAMC-heme transition
moments and averaged over the simulations.
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Solvent accessible surface areas of all tryptophan residues have been calculated from the MD simulation 
data according to the algorithm of Lee and Richards [37], for all tryptophan residues, using a probe size











 indicates the transition dipole moment; for tryptophan and heme two transitions are 
possible, as indicated.
Results and discussion 
Expression, purification and activity of mutant W128F 
The expression levels of the W128F mutant CYP2D6 were about 200 nM in an average 
culture, which is equal to those of the wild-type enzyme. P420 (inactive form of P450, 
determined as a peak at 420 nm in CO-difference spectrum) was present in the crude
membranes but was lost during the purification of the W128F mutant. The turnover rate of
MAMC O-demethylation by the W128F mutant is about two-fold lower than that of wild-type 
CYP2D6, Vmax 3.5  0.7 vs. 6.7  0.1 min-1, whereas the Km remained constant, Km 29.8 
0.1 vs. 30  1 µM for mutant and wild-type respectively. From these similar kinetic 
parameters W128 does not appear to be crucial for MAMC O-demethylating activity, nor for 
the CYP2D6 stability. This is in agreement with MD simulations, showing that W128 is not 
the only residue forming hydrogen bonds to the propionate of pyrrole ring D of the
porphyrin; R101 forms H-bonds to the same atoms.
142
Chapter 8 
Fluorescence properties of CYP2D6 and MAMC
The fluorescence emission spectra of wild-type and W128F CYP2D6 in the presence and 
absence of MAMC, as well as for MAMC alone, are depicted in Figure 2. The corresponding
excitation and emission maxima together with the fluorescence lifetimes are listed in Table 
1.
Figure 2  Emission spectra of 1 M of the W128F mutant (A) and of wild type CYP2D6 (B), and mixtures
of W128F mutant and wild- ype CYP2D6 with 2 M MAMC (C and D, respectively). Also the emission of
2 M of MAMC is shown (E).
: -
t
The emission maximum at 335-340 nm indicate moderately buried tryptophan residues [38]. 
The emission spectrum of the W128F mutant is 2 nm red-shifted compared to wild-type 
CYP2D6 and is about 22% lower in intensity. In the presence of MAMC, excitation- and 
emission maxima of wild-type and W128F mutant CYP2D6 do not shift, indicating that no 
large conformational change of the enzyme is needed to accommodate the substrate, but 
their intensities decrease about 6%. A notable decrease in the MAMC emission intensity is 
seen in the presence of enzyme, which is the same for the mutant W128F (35%) and for 
wild-type CYP2D6 (35%), indicative of some form of energy transfer or quenching. Also, in 
presence of both CYP2D6 enzymes a blue shift in MAMC emission of about 6 nm is
observed. This shift is most likely the result of a smaller Stokes-shift (the excitation
spectrum does not change), and indicates a less polar environment for MAMC in presence of 
CYP2D6 than for pure MAMC in aqueous solution, which is of course expected.
Fitting of the fluorescence intensity decay curves yielded three tryptophan lifetimes for wild-
type and W128F mutant CYP2D6 and two for MAMC, as shown in Table 1. The origin of this 
double exponential decay of MAMC fluorescence is not trivial; it may be caused by a charge 
transfer state, as described for coumarin-type molecules [26, 39]. The fluorescence lifetimes 
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of both wild-type and W128F mutant CYP2D6 do not change dramatically upon addition of 
MAMC. The tryptophan DAS of wild-type CYP2D6 and W128F mutant are shown in Figure 3. 
Table 1: Fluorescence maxima (nm , relative intensities (peak area, AU) and emission lifetimes (ns) for 
wild- ype and W128F mutant CYP2D6 and MAMC. For the lifetimes the rela ive contributions to the to al
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Figure 3: Decay-associated spec ra of wild type CYP2D6 (A) and W128F (B) and the corresponding
lifetimes ( total spectrum,
t -
1, 2, x 3).
For the wild-type enzyme all three components have similar relative intensities and their 
emission maxima are close as well. Interestingly, the spectrum associated with 1 of the 
W128F mutant has a three-fold lower intensity than that of 2 and 3. This suggests that
W128 contributes predominantly to the shortest lifetime (of 130 ps) component of the 
overall tryptophan emission. This tryptophan residue was expected to have such a short 
fluorescence lifetime, since its location at position 128 is close to the heme and its emission 
will therefore be quenched (by a FRET mechanism) more strongly than the other residues. 
On the other hand, the remaining signal indicates that the shortest lifetime is not solely due
to W128 and in fact is even shorter than in wild-type CYP2D6. The shorter 1 for W128F 
compared to wild-type CYP2D6 was unexpected: the tryptophan closest to heme is 
removed, so at first sight the residual lifetime should be longer. However, in view of the 
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large number of possible relaxation times of the six tryptophan residuess in W128F, this 
seemingly shortened lifetime may be the result of a shift in the distribution of all tryptophan 
lifetimes over the three lifetimes obtained from the fit of the data. In addition, lifetimes 
shorter than 100 ps are not uncommon in proteins, even in cases when no heme or other 
energy transfer mechanism is present [40, 41], and may be caused by close-lying quenching 
amino acids such as tyrosine, cysteine or histidine [42]. The decay times of MAMC do not 
change significantly when either wild-type CYP2D6 or W128F mutant is present. Although a
change would be expected due to interactions with the protein, it seems that these
interactions do not influence the lifetimes or that the changes are too small to be observed 
in the overwhelming emission of the unbound MAMC. A more feasible explanation may be 
that the fluorescence quantum yield of bound MAMC is negligible due to quenching by the 
close-lying heme. To assess the latter explanation, the FRET “network” in the 
CYP2D6/MAMC system was evaluated, which will be discussed later. 
Quenching experiments 
The accessibility of the tryptophan residues was studied using acrylamide and iodide as 
dynamic quenchers. In both cases quenching only takes place if the quencher and the 
fluorescing tryptophan residue are in physical contact; long range quenching does not
occur. Acrylamide is a small and uncharged molecule that can diffuse into the protein; its 
quenching behaviour provides information on the overall accessibility of the tryptophan 
residues in the protein [19]. Iodide is a charged ion, which cannot enter the protein interior,
and will quench only exposed tryptophan residues on the periphery of the protein [21]. The
fluorescence intensity quenching experiments using acrylamide yielded linear Stern-Volmer
curves for both wild-type and W128F CYP2D6. Apparently, static quenching in ground-state 
tryptophan-acrylamide complexes is negligible. Using iodide as a quencher, slightly 
downward curved Stern-Volmer curves were obtained, indicating that some tryptophans are 
unattainable to iodide [19]. For MAMC emission, upward curving Stern-Volmer graphs are 
observed in the case of iodide quenching, indicating a static component. However, analysis 
of the data using a modified version of the Stern-Volmer equation which allows for the 
separation of the static and dynamic part of the observed quenching, showed that 
quenching in this case is not caused by ground-state complexes, but rather by close 
proximity of quencher and fluorophore, resulting in almost 100% quenching probability [20], 
presumably caused by iodide being attracted to the positive charge of the substrate. The 
quenching constants for all compounds are collected in Table 2. 
The acrylamide quenching constants for tryptophan are similar for the two enzymes, so no 
large differences in permeability exist between wild-type and W128F CYP2D6. In both cases, 
the quenching rates are somewhat smaller in the presence of MAMC (12.5 and 13.0 vs. 9.7
and 10.5 M-1ns-1), indicating a slightly more compact structure. The structure of CYP2D6 is 
less compact compared to CYP101, which quenching constant is three times lower (4.5 and
1.45 M-1, respectively) [6]. The accessible fraction of tryptophan emission for quenching by 
acrylamide is, as expected, around 100%. The smaller accessible fraction of wild-type 
CYP2D6 in the presence of MAMC – some 20% lower - might be caused by MAMC blocking
the pathway for acrylamide in the substrate access channel, in line with the somewhat
decreased quenching constant found in this case. This effect was not observed for the 
W128F mutant, which indicates that indeed the access channel to the active site is blocked:
apparently it is W128, which lies in the active site, that cannot be reached anymore by
acrylamide when MAMC is present.
As expected, the tryptophan residues in both W128F and wild-type CYP2D6 are less easily 
accessible to iodide than to acrylamide, and the fraction of the total emission accessible to 
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quenching is accordingly smaller (30-40%). This is somewhat higher than for, for example, 
the 16% accessible for substrate-free CYP101 [6], but also the quenching constants for 
CYP2D6 are about five times larger, indicating a higher degree of exposure of the
tryptophan residues in CYP2D6 than in CYP101. The quenching constant of W128F is slightly 
higher than that of wild-type CYP2D6 (0.9 vs. 0.7 M-1). Its structure may be different, 
and/or the remaining tryptophan residues are relatively more exposed, resulting in a 
somewhat higher accessible fraction (0.4 instead of 0.3). In the presence of MAMC, the
quenching rate is slightly lower, as was the case with acrylamide. This supports the 
explanation that the substrate-bound enzyme has a less accessible structure. Calculation of
the solvent accessible surface areas (SASA) revealed that W152, W262 and especially W75 
were accessible to bulk solvent, while W128, W316 and W409 were not found to interact 
strongly with water. Consequently, we expect the iodide quenching to be mostly acting on
W75. Therefore, it is not surprising that the accessible fraction of emission of W128F found 
with the quenching experiments is not much different from the wild-type. In the presence of 
the substrate MAMC the SASA do not change much, confirming the fluorescence quenching
results. Also in that case, W75 is the most accessible residue and the accessibilities of the
other residues are maximally 10%. As acrylamide is much smaller and may penetrate the 
protein, it is likely to interact with all tryptophan residues and calculations of the SASA will 
not yield useful results for this probe.
t fr
Table 2: Fluorescence quenching parameters (Ksv in M-1, kq in 109·M-1s-1, av in ns) of wild-type CYP2D6,




KSV kq av fa KSV kq av fa
WT 4.5 12.5 0.36 1.1 0.7 1.8 0.40 0.3
WT+MAMC 3.8 9.7 0.39 0.8 0.6 1.5 0.40 0.3
W128F 3.9 13.0 0.30 1.1 0.9 3.0 0.30 0.4
W128F+MAMC 4.1 10.5 0.39 1.0 0.8 2.1 0.39 0.3
MAMC 2.7 1.5 1.76 0.9 14.1 17.2 0.82 1.1
MAMC+WT 3.1 1.9 1.55 0.8 15.2 10.3 1.47 1.1
MAMC+W128F 2.9 1.8 1.59 0.9 18.4 11.6 1.59 1.1
FRET efficiencies 
In CYP2D6 three chromophoric groups are present; the porphyrin, the tryptophan residues 
and the coumarin substrate, all are absorbing, and the coumarin and tryptophan residues
also emitting, in generally the same spectral range. The spectral overlap may give rise to
energy transfer pathways, in particular of the Förster-type. The location and orientation of 
MAMC in the active site of CYP2D6, corresponding to one of the initial structures of the 
simulations, is illustrated in Figure 5. Three FRET pathways are possible when MAMC is in 
close proximity of CYP2D6: (a) from the tryptophan residues to heme, a well-known and
efficient energy transfer route in heme-proteins [14], (b) from the tryptophan residues to 
MAMC and (c) from MAMC to the heme-moiety. Over the course of the 10 ns MD 
simulations the overall structure of the protein was well maintained. Atom-positional root-
mean-square deviations (rmsd) from the initial homology model leveled of to approximately
0.3 - 0.4 nm, important secondary structure elements and hydrogen bonds were maintained 
throughout the simulations. The molecular dynamics simulations to determine the 2/r6
factor of FRET yielded slightly different values for the starting configurations from the two
docking algorithms used (Autodock and GOLD), but the trends were identical.
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Table 3: Orientation factors ( 2/r6 values in nm-6) of the tryptophans to the heme, the tryptophans to 
MAMC, and of MAMC to the heme, obtained from MD simulations using the CYP2D6 homology model.
Hemea (MAMC present) Hemea (no MAMC present) MAMC
Average rmsd Average rmsd Average rmsd
W75 0.007 0.004 0.022 0.011 0.005 0.005
W128 0.330 0.192 0.362 0.145 0.079 0.048
W152 0.048 0.025 0.036 0.016 0.002 0.002
W262 0.002 0.002 0.003 0.003 0.001 0.000
W316 0.069 0.022 0.083 0.019 0.009 0.006
W409 0.017 0.013 0.029 0.011 0.003 0.003
MAMC 7.289 6.365
aboth dipole direc ions added t
(a) Tryptophan to heme. Apart from spectral overlap, the FRET efficiencies for the different
residues will not only depend on their distance to the heme group but also on the relative 
orientation of the donor and acceptor transition dipoles, expressed in 2. The value of 2/r6
was calculated from MD simulations for six of the tryptophans to the porphyrin ring in 
CYP2D6. The data of W29 could not be calculated, since its position is in the membrane
anchoring -helix, which is not included in the homology model. The 2/r6 factors thus 
obtained differ several orders of magnitude for the tryptophan residues concerned (Table 
3). The tryptophan-to-heme 2/r6 factor was found to be much higher for W128 than for the 
other tryptophan residues. This supports the suggestion that W128 contributes mainly to 
the shortest fluorescence lifetime, although it should be realized, that energy transfer to the 
heme may not be the only cause of lifetime-shortening, as mentioned above. The energy 
transfer from the other tryptophan residues to the heme does not seem to be important: 
the quantum yield of CYP2D6 as a whole is not extremely low (6% for wild-type CYP2D6, 
4% for W128F), and the lifetimes are mostly in the nanosecond range. 
(b) Tryptophan to MAMC. The spectral overlap of the tryptophan emission and the MAMC 
absorption is very large. However, as can be seen from Table 1, the fluorescence lifetimes
of CYP2D6 are not shorter in the presence of MAMC, while furthermore a negative exponent
(indicating an increase of intensity) is not needed to make a good fit of the MAMC intensity 
decay. Still, the tryptophan emission spectrum in the presence of MAMC decreases about
6%, but also the intensity of the MAMC spectrum itself decreases (Figure 2). Calculations of 
the 2/r6 value between the various tryptophan residues and MAMC from the MD simulations
show no significant changes for most tryptophan residues, and indicate only a possibility for 
W128 to transfer its energy to MAMC. However, in that case no decrease in emission 
intensity would be expected for the W128F mutant, in contrast to the results. On the other 
hand, because the heme-group is positioned between MAMC and W128, the tryptophan
emission will rather transfer its energy to heme instead of to MAMC. An explanation for the 
reduced tryptophan emission intensity upon the addition of MAMC may be a conformational
change in the protein, repositioning the tryptophan residues closer to quenching amino
acids or the heme-moiety.
The rmsd values of 2/r6 give the width of the distribution around the average value and are 
an indication of flexibility of the protein. As is seen in Table 3, the relative rmsd values are 
not much different for six tryptophans with or without MAMC present. Monitoring of the 
positions of the tryptophan transition dipole moments yielded the largest fluctuations for
W262 for the substrate-free CYP2D6, and for W75 in the presence of MAMC. However, the 
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fluctuations are smaller than 0.5 nm, which is small on the scale of the total protein (about 
7 nm diameter).
(c) MAMC to heme. Also for MAMC acting as the donor and the heme group as the acceptor, 
the spectral overlap is extensive. The 35% reduction of the MAMC emission intensity in 
presence of both wild-type CYP2D6 and W128F mutant indicate that, indeed energy transfer 
takes place. For the MAMC-heme pair the predicted 2/r6 value is very high. The values for 
tryptophan to MAMC are in general relatively small; also here the highest value is found for
W128, which is the closest to the active site. The MD simulations of r6 and 2 revealed a 
FRET efficiency of almost 100%, meaning that the excitation energy is completely 
transferred from MAMC to the heme and that no emission of MAMC when bound in the
active site can be seen at all. This would explain why the lifetimes of MAMC in presence of 
CYP2D6 are not shortened and why the quenching properties are not changed: emission is
only observed from unbound substrate. Thus, from the intensity reduction in MAMC 
emission (Table 1), it can be concluded that about 35% of the total amount of MAMC added 
to the sample is bound to CYP2D6, both for wild-type and W128F mutant. This is also 
reflected in the similar activities. Unfortunately, this explanation also implies that the 
emission spectra do not reveal any information on the properties of bound MAMC. On the 
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S0 and P0 are the initial MAMC and enzyme concentrations (resp. 2 µM and 1 µM) and x is 
the concentration of MAMC bound in the active site. It is calculated that Kd = 0.56 ± 0.10 















Figure 4: Steady-state anisotropy traces of 1 M wild-type CYP2D6 (dotted line), 2 M MAMC (dashed











Figure 5: Homology model of CYP2D6 based on rabbit CYP2C5, indica ing the positions of the six
tryptophans, the heme-group and the substrate MAMC. W29 is not p esent in the homology model. A
colored version of the figure is shown in the Appendix of this thesis. 
Table 4: Summary of the three types of MAMC in the presence of CYP2D6.
MAMC type WT W128F
I Unbound 62.6 ± 2.0 % 62.4 ± 2.1 % 
II Bound in active site 35.0 ± 1.5 % 35.2 ± 1.6 % 
III Associated to enzyme 2.4 ± 0.5 % 2.4 ± 0.5% 
Anisotropy
The results of steady-state anisotropy experiments are shown in Figure 4. The anisotropy of 
the tryptophan residues in the protein is about 0.2, as is expected for tryptophans rotating 
slowly on the fluorescence lifetime-scale [26]; the slow rotation is caused by overall 
tumbling of the protein, side-chain rotations are too fast to be seen. Free MAMC in solution 
rotates also much faster than its fluorescence decay, and indeed no residual anisotropy is 
observed.
Although the analysis of FRET suggests that MAMC bound to CYP2D6 will not contribute to 
the emission spectrum at all, a residual anisotropy of 0.015 is seen in the steady-state
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anisotropy traces of both wild-type and W128F CYP2D6. This anisotropy can most probably 
be explained by invoking a third type of MAMC present in the sample: MAMC that is also 
bound in some way to CYP2D6 (to be denoted as “associated MAMC”, Table 4). Its emission 
will be partly polarized, as it rotates with the enzyme, but it is not located close enough to 
the heme to be quenched by FRET. Maybe the substrate first binds to the access channel of 
the enzyme, which undergoes a conformational change before allowing it to enter [43, 44],
or it is located in the access channel. Using equations 5 and 6 and the initial anisotropy r0 =
0.39, the ratio of free MAMC to associated MAMC is calculated to be 41 ± 6, implying that
2.4 ± 0.5 % of the amount of MAMC that is not bound in the active site is associated in 
another way to the protein. As these MAMC molecules will experience a slightly more apolar 
environment, their emission is blue-shifted, as can be seen in Figure 2. However, the
observed shift of 6 nm is relatively large, if only 2.4% of MAMC is associated to the enzyme.
Presumably the associated MAMC molecules still have a large degree of rotational freedom, 
causing the amount to be underestimated when calculated from anisotropy experiments.
Conclusions
Wild-type and W128F mutant CYP2D6 were investigated by steady-state and time resolved
fluorescence experiments to determine the extent of conformational changes in the protein,
and the properties of MAMC upon binding. Because both the enzyme and the substrate 
contain fluorophores, it was possible to study emission properties of both compounds. The 
experiments do not show indications for large scale conformational changes in CYP2D6 in 
the presence of the substrate MAMC: there are only small changes in emission maxima and 
lifetimes when MAMC is present. However, the tryptophan residues in substrate-bound 
enzyme are quenched less efficiently than in substrate-free CYP2D6, which may be caused 
either by shielding of the tryptophans by MAMC or a “contraction” of the structure, induced 
by binding of the substrate. MD simulations indicated that the tryptophan residues are more
flexible in the presence of MAMC, but these changes are small on the scale of the total 
protein; no large fluctuations in protein structure are found. Mutagenesis of more
tryptophan residues would be helpful in the assignment of lifetimes to individual residues, 
and may provide more information on possible local conformational changes in the enzyme 
upon substrate binding. Several FRET pathways were evaluated from which was concluded 
that emission of MAMC when bound to CYP2D6 is completely transferred to the heme, and 
is therefore not observed. From anisotropy experiments it could be inferred that not all of 
the observable MAMC is free in solution, but that at least 2 % is associated to the protein. 
No differences were found in the dissociation constants.
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Cytochrome P450 2D6 (CYP2D6) is one of the most important enzymes in human drug
metabolism. It is involved in the metabolism of a large number of clinically relevant drugs 
and furthermore, due to genetic polymorphisms there is a wide variability in the enzyme 
activity in different human populations [1-3]. It would be a great advantage if the
metabolism of new chemical entities and drug-candidates by CYP2D6 could be rationalized 
and predicted in the early stages of drug discovery and development. A better 
understanding of the structure and functioning of CYP2D6 has been the major objective of 
this thesis. This goal was approached, by studying the most dominant factors that
determine the substrate binding, the catalytic activity, and the regio- and stereoselectivity of 
CYP2D6.
First of all, the active site topology may dictate substrate binding and conversion by specific
interactions with the compound, or by steric restriction. At second, the nature of 
oxygenating species can determine CYP activity and regioselectivity. At third, it is thought 
that the heme configuration can also influence the activity. Finally, the overall changes in 
conformation of the CYP during the catalytic cycle may allow for substrates to enter the 
active site. Furthermore, substrate mobility in the active site may determine the 
regioselectivity.
To address the impact of these factors on the activity and the selectivity of CYP2D6, the 
enzymology of site-directed mutants of CYP2D6 was studied and various spectroscopic 
techniques were used to examine the wild-type and mutants of the enzyme. These 
experimental techniques were complemented by computational techniques, to rationalize
the findings and to predict the enzyme and substrate conformations.
In Chapter 1 CYPs are introduced and their role in drug metabolism is explained. It is 
shown that in humans only a few CYP isoforms are involved in the oxidative metabolism of
about 90% of all prescribed drugs and that in this process, the isoform CYP2D6 is one of the
most important ones. Although the hepatic CYP2D6 expression levels are relatively low, the
enzyme is involved in the metabolism of about 30% of the currently marketed drugs.
Furthermore, the enzyme is known for its polymorphisms. This leads to an increased 
metabolite formation of drugs that are predominantly metabolized through CYP2D6 
dependent pathways by individuals having the ultrarapid metabolizer phenotype, while 
individuals having the poor metabolizer phenotype, hardly metabolize these drugs. This of 
course has a big impact on the wanted effects of a drug, and also on unwanted side effects 
due to improper dosing. Clearly there is a need for structural data on CYP2D6 in order to
rationalize and predict how it metabolizes its substrates. In the absence of crystallographic 
data, CYP2D6 has been subject of elaborate pharmacophore and homology modeling 
studies for rationalization and predictive purposes. Due to the availability of better
templates, the homology modeling kept evolving; so more experimental validation by site-
directed mutagenesis was needed. The quality of the models is discussed and an overview 
of the mutations is given. 
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Spectroscopic and other biophysical techniques that have been used to study structural
aspects of CYPs are also summarized in Chapter 1. Besides for the validation of 
computational models of CYPs, spectroscopic data can also be used to gain complementary
information on CYPs, like the characteristics of the porphyrin prosthetic group. So far, the 
applications of these techniques have predominantly been restricted to studies on bacterial
CYPs. Due to improved expression and purification methodologies, it has become possible to 
study human CYPs in a spectroscopic way too.
In Part I of this thesis, entitled Key determinants of CYP2D6 activity, site-directed 
mutagenesis and enzyme kinetic analysis were used to study the influence of the active site 
topology, and the role of multiple oxygenating species on the activity of CYP2D6. The active 
site residues F120, F483, and T309, are introduced as being crucial for the activity of 
CYP2D6.
In Chapter 2, the role of CYP2D6 active site residue F120 in ligand binding and catalysis 
was experimentally examined by mutating it into an alanine. Typical CYP2D6 substrates 
generally contain a basic nitrogen atom at about 7 Å, and an aromatic moiety adjacent to 
the site of metabolism. In homology modeling studies it has been suggested that there may
be an important role for F120 in fixation of this substrate aromatic moiety [4]. Strikingly, the 
F120A mutation led to a completely abolished 7-methoxy-4-(aminomethyl)-coumarin
(MAMC) O-demethylating activity of CYP2D6. On the other hand, bufuralol metabolism was 
hardly affected as was dextromethorphan O-demethylation. However, the F120A mutant 
also formed 3-hydroxymorphinan, i.e. double demethylated dextromethorphan, which was 
not detected using wild-type CYP2D6. 3,4-methylenedioxymethamphetamine (MDMA or 
XTC) was O-demethylenated to 3,4-dihydroxy-methamphetamine by both mutant and wild-
type CYP2D6. In addition the F120A mutant formed two additional metabolites: 3,4-
methylenedioxyamphetamine and N-hydroxy-3,4-methylenedioxymethamphetamine. Such 
substrate dependent effects of this mutation were not described before for any CYP2D6 
mutant. Studying the inhibition of dextromethorphan O-demethylation, a 6-fold decreased 
affinity of the F120A mutant for quinidine was found, due to the loss of the specific aromatic 
interaction, as was predicted using the homology model [4]. These data indicated for the 
first time the importance of F120 in the selectivity and regiospecificity in substrate binding 
and catalysis by CYP2D6. During writing and publishing of Chapter 2 [5], also other groups
reported mutagenesis studies on F120 [6, 7], and very recently we performed additional 
studies to the role of  F120 [8, 9], confirming our findings.
According to the CYP2C5 based CYP2D6 homology models, a second phenylalanine residue 
appered to be positioned in the active site, besides F120. This residue, F483, was examined 
in Chapter 3. It was hypothesized that F483 also would play an important role in the
interaction with the aromatic moiety of typical CYP2D6 substrates. Experimental data to 
support this hypothesis, however, was not yet available. In fact, in the only study 
performed, mutation of F483 to isoleucine or tryptophan did not affect the 1’-hydroxylation 
of bufuralol at all [10]. In Chapter 3, substrate binding and oxidative metabolism by wild-
type and F483A mutant CYP2D6 was experimentally examined. The F483A mutation 
resulted in a 30-fold lower Vmax for bufuralol 1’-hydroxylation, while the Km was hardly 
affected. The Vmax for MDMA O-demethylenation on the other hand decreased only two-fold,
whereas the effect on the Km was much larger. For dextromethorphan, in addition to 
dextrorphan (O-demethylation) and 3-methoxymorphinan (N-demethylation), two other
metabolites were formed that were not detected for the wild-type enzyme. The substrate 
MAMC was not metabolized at all by the F483A mutant CYP2D6, as we also reported for the 
F120A mutant. The presented data show that next to F120, residue F483 plays an important 
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role in the metabolism of typical CYP2D6 substrates. This influence of F483 on the oxidative 
metabolism by CYP2D6 was found to be substrate-dependent, like for F120. Besides the 
previously described active site carboxylates D301 and E216 [11, 12], we have now 
introduced the two phenylalanines F120 and F483 as key determinants for CYP2D6 activity 
[13].
In the previous two chapters, the critical roles residues F120 and F483 play in the oxidative 
metabolism of MAMC by cytochrome P450 2D6 (CYP2D6) were reported. In Chapter 4, a 
series of N-alkyl-7-methoxy-4-(aminomethyl)-coumarins (MAMC-analogs) were used as
substrates for the F120A and F483A mutants, in order to further probe the CYP2D6 active
site by increasing the substrate N-alkyl chain. The F120A and F483A mutants of CYP2D6 
displayed significant activity towards the MAMC-analogs. This indicated that additional 
substrate interaction points are present in the CYP2D6 site, which add in the 
accommodation of the longer chain MAMC-analogs in a reactive conformation. Automated 
docking studies of the MAMC-analogs in the CYP2D6 homology model suggested a distal
hydrophobic active site binding cleft for the substrate N-alkyl chains, consisting of the 
residues L213 and V308. Therefore, we propose L213 and V308 to be important as distal
active site restricting residues, involved in binding to the larger substrates via hydrophobic 
interactions. Future site-directed mutagenesis studies should confirm this hypothesis. 
The residues studied so far are all involved in binding the substrates in the active site of 
CYP2D6, as shown in Figure 1. Besides residues determining the active site topology, other 
active site residues may be involved in the mechanism of oxidation, by being involved in 
oxygen, proton and electron donation to the heme. Based upon sequence alignments and
homology modeling, we proposed threonine 309 in CYP2D6 to be the conserved I-helix 
threonine, which is supposed to play a role in dioxygen activation by CYPs [14]. In Chapter
5, T309 was therefore mutated into a valine and subsequently, the binding and metabolism 
of model substrates was studied. The T309V mutant of CYP2D6 displayed a strong shift 
from O-dealkylation to N-dealkylation reactions in oxidation of dextromethorphan and 
MDMA. This could be explained by an elevated ratio of hydroperoxo-iron to oxenoid-iron of 
the oxygenating species. In consistence, using CuOOH, which directly forms the oxenoid-
iron, the T309V mutant again selectively catalyzed these O-dealkylation reactions. The 
changed ratio of oxygenating species could also explain the decreased activity and changed
regioselectivity that was observed in MAMC and bufuralol oxidation respectively by the 
T309V mutant. Interestingly, the T309V mutant always showed a significantly increased, up 
to 75-fold, higher activity compared to the wild-type enzyme when using CuOOH. With 
these results, a residue of CYP2D6 involved in the mechanism of oxidation was introduced. 
We have shown that T309 in CYP2D6 is involved in maintaining the balance of multiple 
oxygenating species and thus influences substrate and regioselectivity [15]. 
In Part II of this thesis, entitled Spectroscopy and modeling of CYP2D6, the purified 
wild-type and mutants of CYP2D6 were subjected to several spectroscopic techniques. Spin
lattice relaxation NMR was used to correlate the active site orientation of substrates to the 
CYP2D6 catalytic regioselectivity. Resonance Raman spectroscopy was used to study the 
effects of the T309V mutation, known to cause changed activity, on the heme configuration 
of CYP2D6. Fluorescence spectroscopy was used to study the impact of substrate binding on
the conformation of the apoprotein of CYP2D6. Furthermore, substrate affinity and active 
site dynamics were studied using the intrinsic fluorescence of the substrate. The homology
model of CYP2D6 was used to relate the spectroscopy to protein structure, and also to 
calculate ideal substrate binding conformations and positions of amino acids.
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Figure 1: The CYP2D6 active site (heme in center, Fe as sphere) according to the homology model [16], 
with dextromethorphan bound according to automated docking (GOLD Chemscore), showing the key
residues involved in enzyme ac ivi y and the other residues that have been muta ed in this thesis. F120,
F483, L213, and V308 are identified as being involved in steric restric ion and/or hydrophobic
interac ion with subs ates, E216 is interac ing with basic substrate N-atoms D301 interacts with the
backbone of F120, W128 interacts via H-bonds with the pyrrole C-propionate and was muta ed to a
phenylalanine in Chapter 8, which did not af ect he ac ivity, and T312 was mutated to a valine in
Chapter 5  which did not affect activity either. The figure, of which a colored version is shown in the
Appendix of this thesis, was made using Pymol 0.98
In Chapter 6, a series of 3,4-methylenedioxy-N-alkylamphetamines (MDAAs) were 
automatically docked and subjected to molecular dynamics (MD) simulations in a CYP2D6
protein model. The predicted substrate binding orientations, sites of oxidation and relative 
reactivities were compared to experimental data of the wild-type and the F120A mutant of
CYP2D6. Automated docking results were not sufficient to accurately rationalize 
experimental binding orientations of MDMA in the two enzymes as measured with spin
lattice relaxation NMR. Therefore, the docking results were used as starting structures for 
MD simulations. Predicted binding orientations of MDMA and the sites of oxidation of the
MDAAs derived from MD simulations matched well with the experimental data. It appeared 
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that the experimental results were best described in MD simulations considering the 
nitrogen-atoms of the MDAAs in neutral form. Apparently, the CYP2D6 active site pH is
different from the enzyme environment, since at pH 7.4 the basic N-atom of the MDAA’s is 
expected to be protonated. Differences in regioselectivity and stereoselectivity in the 
oxidative metabolism of the MDAAs by the F120A mutant of CYP2D6 were correctly 
predicted from the MD simulations, and the effects of the F120A mutation could be 
rationalized as well. F120 was found to interact with the substrates by –stacking. The 
combination of automated docking of substrates, with MD simulations in the CYP2D6
homology model was a very successful way to predict sites of metabolism, and is a 
promising novel approach to use for other protein-ligand complexes as well [16].
In Chapter 7, resonance Raman (RR) spectroscopy was used to study the effects of the 
T309V mutation in CYP2D6 on the heme prosthetic group characteristics. In Chapter 4, we 
hypothesized that T309 in CYP2D6 is involved in the determining the balance of different 
activated oxygen species. The RR spectra of wild-type and the T309V mutant of CYP2D6 
revealed that in the wild-type enzyme a five coordinated high spin (5cHS) species is present 
in the absence of substrate, whereas in the T309V mutant only a six coordinated low spin 
(6cLS) species was observed. The addition of saturating amounts of the substrate 
dextromethorphan led to the formation of more 5cHS species in both the enzymes, 
however, the difference between wild-type enzyme and mutant was still significant. The 
T309V mutation had no effect on the CO-Fe stretching frequency in the spectrum of CO 
bound ferrous CYP2D6, indicating that this residue does not directly influence the 
hydrophobicity of a heme-bound axial ligand. So T309 influences the spin state in CYP2D6, 
but is at a too large distance from the axial heme ligand, i.e. CO or O2, to directly interact 
with it. Therefore it is thought to be involved in maintaining a network of hydrogen bonds
through water molecules in the enzyme active site [17]. Whether this role influences the
changed activity of the T309V mutant, or whether it is a secondary, not related effect, 
remains to be resolved. This is the first time that an effect of the conserved I-helix 
threonine on the heme spin state is reported for a CYP.
Enzyme structure and dynamics may play a main role in substrate binding and the
subsequent steps in the CYP catalytic cycle. In Chapter 8, for the first time changes in the 
apoprotein conformation of CYP2D6 upon binding of a substrate were studied. Steady-state 
and time-resolved fluorescence methods were used, focusing not only on the emission of 
the tryptophan residues, but also on emission of the substrate. As a substrate MAMC was 
selected, a compound exhibiting native fluorescence. Next to the wild-type enzyme, the 
W128F mutant of CYP2D6 was studied. W128 is the tryptophan residue most close to the
heme (Figure 1), therefore its fluorescence is expected to be quenched extensively, and to 
have a short lifetime. A mutation to another bulky but non-fluorescent phenylalanine residue 
at position 128, would validate this hypothesis. After binding of MAMC, a variety of energy 
transfer possibilities exist, and molecular dynamics (MD) simulations were performed to 
calculate distances and relative orientations of donors and acceptors. Energy transfer from 
W128 to the heme indeed appeared to be important; its emission was related to the 
shortest of the three average tryptophan fluorescence lifetimes observed for CYP2D6. 
Energy transfer from MAMC to the heme was very efficient as well: when bound in the 
active site, the emission of MAMC was fully quenched. Steady-state anisotropy revealed that 
besides the MAMC in the active site, another 2% of MAMC was bound to wild-type CYP2D6
outside of the active site. The tryptophan residues in CYP2D6 appeared to be less accessible 
for the external quenchers iodide and acrylamide in presence of MAMC, indicating a 
tightening of the enzyme structure upon substrate binding. However, the changes in the 
overall enzyme structure were not large, since the emission characteristics of the enzyme 
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were not very different in the presence of MAMC [18]. More extensive studies are needed to 
reveal the importance of apoprotein conformational changes during the rest of the catalytic
cycle of mammalian CYPs, and upon the binding of larger substrates. Nevertheless, in this
chapter the necessary tools have been introduced. 
Conclusions and perspectives 
The major objective of the research described in this thesis, was to increase the
understanding of the structure in relation to the catalytic activity of CYP2D6. Structural data 
is necessary for the rationalization of the oxidative metabolism of compounds by this 
enzyme and can eventually lead to a way of prediction of substrate, regio- and
stereoselectivity in catalysis by the enzyme. In this thesis several aspects have been 
investigated that may influence CYP2D6 activity: (i). The active site topology was examined 
making use of site-directed mutagenesis and spin lattice relaxation NMR, in combination 
with homology modeling. (ii). The influence of the balance of multiple oxygenating species 
on CYP2D6 was studied in relation to the role of residue T309. (iii). The changes in the
heme configuration of CYP2D6 upon substrate binding and active site mutagenesis were
investigated using RR spectroscopy. (iv). Finally, protein conformational changes and
substrate dynamics were studied making use of the native fluorescence of the endogenous
tryptophan residues. In the following sections general conclusions based upon the findings 
in the experimental chapters will be drawn and related to future research. 
Homology model versus crystal structure of CYP2D6 
In the process of writing the last parts of this thesis, the first X-ray structure of CYP2D6 was 
reported [19]. This substrate-free structure (PDB file 2F9Q) shows the characteristic fold as 
seen in other CYP members and shows a very high similarity to the homology model used in
this thesis; after fitting, 88% of all C -atoms of the model are within 2Å of their crystallized 
counterparts. There are however also some significant differences between the two 
structures. In the allover structures, relatively large differences are found between the B’ 
helix and in the F-G helical region. The differences can partly be explained by the low 
resolution of the crystal structure of CYP2D6 at some regions (F-G loop, N-terminus).
Another crucial difference is that for the homology model the substrate-bound crystal
structure of CYP2C5 was used, so the model is biased towards a substrate bound structure. 
This can clearly be observed from the position of F483 in the protein model. The active site 
residues in the homology model that have been mutated, or otherwise mentioned in this 
thesis have been aligned to their crystal structure positions in Figure 2. The phenyl-ring of 
F483 is twisted about 90  in the two structures. A similar difference is observed when
comparing the crystal structures of substrate bound and substrate free CYP2C9 (PDB files 
1OG5 and 1R9O respectively [20]). In CYP2C9 a homologous phenylalanine residue, F476, is 
present in the active site, which is twisted to the same extent upon substrate binding. The 
other active site residues are in general in almost identical positions in the model as in the 
X-ray structure. So while there already is high similarity between the crystal structure of 
CYP2D6 and the homology model used in this thesis, the homology model probably even
better represents a substrate-bound enzyme. The resolving of the crystal structure of 
CYP2D6 increased the confidence in the quality of our homology model, and our
interpretations of it, used in this thesis.
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Figure 2: Overlay of the active site residues examined in this thesis from the homology model [16] in
dark, and from the c ystal struc ure of CYP2D6 [19] in light, around the modeled heme (Fe as sphere). 
The figure, of which a colored version is shown in the Appendix of this thesis, was made using Pymol
0.98.
r t
Present research versus the CYP catalytic cycle
The general overall reaction CYPs catalyze can be schematically represented in a catalytic 
cycle, in which each step represents a change in the heme configuration (Chapter 1 and 
[21]). The research described in this thesis involves different parts of the catalytic cycle of
CYP2D6. In Figure 3, it is indicated which stages of the catalytic cycle are studied in the 
experimental chapters. The cycle starts with the binding of a substrate (Stage 1-2). 
Substrate binding is the easiest step to follow by spectroscopic means, and has been 
studied in all chapters. In Chapter 7, the binding of the artificial ligand CO to the heme was 
investigated by RR spectroscopy, as a model for the binding of O2. In Chapter 5, the 
reactivities of the oxygenating species, stages 5-7 in the cycle, have been studied in relation 
to residue T309.
The boxes representing the experimental chapters include all stages of the cycle in Figure 3, 
indicating that in this thesis a large part of the cycle has been under examination. On the 
other hand, the reactions leading from one stage to the next have not been addressed in
detail in this thesis. For example, the ways of entrance of substrate, electrons, oxygen, and 
protons were not examined. Nor were studied product egress, or the velocities of individual 
steps. Therefore there is still much experimental and computational research to be done, 
not only for CYP2D6, but also for CYPs in general. The mechanistic understanding and
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experimental validation of the CYP catalytic cycle is a near future goal for CYP research [22]. 
Due to the improving of freeze-quenching and stop-flow techniques, it has recently become
possible to study most stages of the cycle spectroscopically (Chapter 1 and [23]). Also 
recently, crystal structures of CYPs with oxygen heme-bound have become available 
(Chapter 1 and [24]), enabling to study protein conformational changes during the catalytic 
cycle. It will soon become possible to calculate the electronic structures of all intermediates 
of the cycle, as was recently shown possible for example, for Stage 7 of human CYPs [25]. 
New methods are being developed for this goal also within the CCM research program [26]. 
Finally, the relevance of the experimentally observed intermediates will be related to the 
eventual activity of the enzyme. 
Chapter 5
Chapters 2,3,4,5,6,7,8
       Chapter 7 
Figure 3  The catalytic cycle of CYPs, as discussed in Chapter 1. Dashed boxes indicate what stages are
investigated in each experimental chapter.
:
Allosterism and suicide inhibition 
In this thesis, allosteric effects on product formation by CYP2D6 are reported (Chapter 4). A 
second substrate-binding site is proposed for CYP2D6, as an explanation for the atypical 
kinetics in formation of 6-OH-bufuralol. In a former study, potentiation of MAMC O-
demethylation by CYP2D6, when co-incubated with the substrates sparteine or phenformine, 
was already reported [4]. Furthermore, an additional CYP2D6 binding-site is proposed for 
MAMC in Chapter 8. It is known that CYP3A4 although having in crystallized form a relatively 
small active site [27], is well capable of binding more than one substrate simultaneously 
[28]. Also crystal structures of CYP2C9 suggest that more than one ligands fit together in 
the enzyme active site [20]. The capability of CYP2D6 to bind several substrates at the 
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same time, may potentially have a great impact on the prediction of CYP2D6 mediated 
metabolism and thus on the extrapolation of in vitro experiments to in vivo extrapolations 
[29]. Obviously more experimental and computational research is needed to investigate the 
nature of the observations of allosterism in CYP2D6.
Another issue of high interest in CYP research is suicide inhibition; the process in which the 
product formed by a CYP covalently binds to the enzyme thus disabling it to metabolize any 
other substrate. Besides being involved in activating heme-bound oxygen, the conserved I-
helix threonine of CYPs was shown to be involved in irreversible inhibition in CYP2B4 [30], 
and in CYP2E1 [31]. In the case of CYP2D6, time-dependent inhibition has been described 
for a number of substrates, including methylenedioxy-containing compounds like MDMA 
[32], and paroxetine [33]. Using the T309V and T312V mutants of CYP2D6 to study the 
inhibition of suicide inhibitors like MDMA could reveal the mechanism of this inhibition. 
Progress in molecular modeling 
The mutagenesis studies in the first part of this thesis were guided by predictions from the 
homology model of CYP2D6. The experimental observations that residues F120, F483 and 
T309 had large effects on the CYP2D6 activity, in a way matching with what was predicted, 
can therefore be seen as the validation of the computer model. Thus, with confidence the 
model could be used to predict active site substrate orientations and enzyme residue 
conformations in the following chapters.
The approach of combining automated docking and MD simulations in a protein model as 
described in Chapter 6 was a successful way to rationalize the oxidative metabolism of a
series of 3,4-methylenedioxy-N-alkylamphetamines (MDAAs) by CYP2D6. The differences in 
oxidative metabolism of these closely related substrates could be predicted in terms of 
regioselectivity and stereoselectivity. Furthermore, the effects of the active site F120A 
mutation on the substrate selectivity could be rationalized. The presented integrated
modeling method is apparently a promising tool in the prediction of the metabolic properties 
of new (drug-like) compounds by CYP2D6 and may very well be applicable for other drug 
metabolizing enzymes as well.
Using substrate active site orientations as determined using spin lattice relaxation NMR to 
rationalize the effects of active site mutations, was found to have its limitations. The 
experimentally determined orientations of both enantiomers of MDMA in the active sites of 
wild-type and F120A mutant CYP2D6 were not as different as expected, based on the 
measured product formation by the enzymes. Relatively small substrates, like MDMA, may 
have more than one energetically favorable binding orientation and may be highly mobile 
within the active site. This was confirmed by the automated docking, where several distinct 
modes of binding could be appointed for MDMA and its analogs in the active site of both
enzymes. Furthermore, in the MD simulations complete conversions of orientations were
observed. Despite this apparent disadvantage, the performed spin lattice relaxation NMR 
experiments were useful, since they could be used well to validate the molecular modeling
procedure. However, to study the effects of an active site mutation on substrate orientation 
other experimental techniques (i.e. anisotropy, see Chapter 8) may be better suited. 
One aspect that was not taken into account in Chapter 6 was the relative reactivity of the 
various atoms in substrates. The ease of hydrogen abstraction or electron abstraction may 
very well determine product formation [34, 35]. In the case of the MDAA’s in Chapter 6, this 
is probably not the rate-determining factor, for the molecular modeling was well capable to 
predict sites of oxidation. But to predict sites of metabolism of a wide variety of compounds
energy barriers for hydrogen and electron abstraction should be calculated and added to the
molecular modeling procedure. 
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Spectroscopy on CYP 
Various techniques, i.e. spin lattice relaxation NMR, resonance Raman scattering and 
fluorescence spectroscopy have been applied to CYP2D6 in this thesis, in order to validate 
predictions about the enzyme based upon its homology model. Besides this validation of a 
model that is practically useful for pharmaceutical research, these techniques were also
chosen to explore more fundamentally how a heme-containing enzyme works.
It is shown that RR spectroscopy is a useful tool in studying in detail the characteristics of 
the porphyrin prosthetic group. Small differences in spin state (Chapter 7) and 
conformations of vinyl and propionate side-chains [36], can be detected at room
temperature, using a minimal amount of enzyme. Although absorbance spectroscopy is
more sensitive than RR, it cannot be used to distinguish small changes in spin state nor can 
it be used to study porphyrin side chain conformations. EPR can be used to sensitively
measure spin state but has the disadvantage that it can only be used at low temperatures,
which may influence the spin and substrate binding equilibria.
RR spectroscopy yields information complementary to that obtained by homology modeling. 
The homology model does not contain information about the heme configuration, but
quantum mechanical/molecular mechanics (QM/MM) methods can be used instead [37]. For
instance, to determine the influence of T309 on the heme spin state (Groenhof et al., 
unpublished results).
Interestingly, the active site residues may have an indirect influence on the heme reduction
potential. In CYP102, it was shown that mutation of residue F393, neighboring the heme 
ligating residue C400, led to changes in the reduction potential and catalytic activity [38]. 
Although in CYP2D6 F120 and F483 are positioned on the other side of the heme, it would 
be interesting to see the influence of the alanine mutations on the heme reduction potential. 
The cause of the change in reduction potential of the F393 mutants of CYP102 was
suggested to be a steric interaction between the residue and the heme vinyl side-chains 
[36]. In CYP2D6 no changes in the vinyl conformations were observed after the F120A
mutation [9], nor after the F483A mutation (unpublished results). So if only steric 
interaction with the vinyl groups could be responsible for a changed reduction potential, 
then this is unlikely for CYP2D6 after the F120A and F483A mutations.
It is necessary to study mammalian CYPs in a more fundamental way as well, instead of 
restricting the fundamental research on CYPs to relatively easily produced bacterial isoforms
of the enzyme family. The steady-state and time-resolved fluorescence experiments on 
CYP2D6 revealed small-scale conformational changes in CYP2D6 upon binding of MAMC 
(Chapter 8). This result was somewhat surprising since larger conformational changes were 
reported previously for CYP101 upon substrate binding [39]. These results might therefore 
be indicative that CYP101 is not a good model for the dynamics of mammalian CYPs.
To really study the dynamics of CYPs during the whole catalytic cycle, a trigger like an 
electron donating substrate [40] or a temperature jump [41], is needed. Then, the 
fluorescence techniques described in Chapter 8 are well suited to study CYP2D6 time 
resolved. Also when CYP2D6 is immobilized on a silver electrode, surface enhance RR 
scattering (SERRS) is possible (Bonifacio et al. unpublished results). The electrode might 
then be used to trigger the catalytic cycle, during which the SERR spectra of the enzyme 
can be followed in time. 
CYP2D6 as a model 
In this thesis, expression, mutagenesis, enzymology, spectroscopy, and molecular modeling 
have been used as tools to learn more about how the enzyme CYP2D6 metabolizes its 
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substrates. By combining these techniques we were able to make a well validated model of 
CYP2D6, usable to predict binding [42], and metabolism [16] of model substrates and 
unknown compounds. The fact that the model is of high quality is confirmed by the recently 
resolved crystal-structure of the enzyme [19]. Therefore it can be concluded that the
combining of homology modeling with site-directed mutagenesis studies, enzymology and 
various spectroscopical studies, as has been the aim of this thesis, is an excellent way to 
study enzymes and is a very promising approach to use for other proteins, of which
structural information is lacking, as well. 
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Het peilen van menselijke cytochromen P450: analyse van 
CYP2D6 met behulp van mutaties en spectroscopie
In het dagelijks leven wordt de mens voortdurend blootgesteld aan giftige stoffen, zoals 
bijvoorbeeld uitlaatgassen, verbrandingsresten in voeding, maar ook andere giftige
bestanddelen van planten en dieren, die via de voeding in de mens belanden. In het
lichaam zijn daarom mechanismen aanwezig, die ervoor zorgen dat dergelijke stoffen zo min 
mogelijk schade kunnen veroorzaken. Deze ontgiftigings-processen vinden in het ganse
lichaam plaats, maar met name in de lever. Daar komen via het bloed de meeste 
lichaamsvreemde stoffen vroeger of later terecht en daar is dan ook de concentratie van
ontgiftende enzymen het hoogst. Enzymen zijn eiwitten die een chemische reactie kunnen
versnellen. Een van de belangrijkste groepen ontgiftigings-enzymen zijn de zogenaamde
cytochromen P450 (CYPs). Deze enzymen ontlenen hun naam aan hun kleur (het woord
cytochroom is afgeleid uit het Grieks en staat voor kleurgevend aan cel, de P staat voor 
pigment), en aan hun unieke eigenschap dat ze licht met een golflengte van 450 nm 
selectief kunnen absorberen. Helaas zijn er ook stoffen die wel degelijk goed (kunnen) zijn 
voor het lichaam, maar die toch door CYPs worden herkend als mogelijk giftig, en dus 
worden afgebroken. Hierbij kan gedacht worden aan medicijnen. Om een medicijn goed te 
laten werken, is het een voordeel als deze zo min mogelijk wordt afgebroken. Dan kan de 
dosering omlaag en is er minder kans op bijwerkingen. 
Er zijn ongeveer 60 menselijke CYP enzymen bekend waarvan de unieke vorm CYP2D6 één 
van de belangrijkste is wat betreft de afbraak van medicijnen. Ongeveer een derde deel van 
de  medicijnen die momenteel worden voorgeschreven, wordt door CYP2D6 aangevallen en 
omgezet in een stof die uiteindelijk makkelijker via de urine het lichaam kan verlaten. 
Daarnaast is het ook nog eens zo dat bij verschillende personen, de hoeveelheid van
CYP2D6 verschillend is. Dit is erfelijk bepaald en heeft een grote invloed op het vaststellen 
van een goede dosering van medicijnen voor iedere individuele patiënt. 
Cytochromen P450 zijn enzymen met een kleur. Net als hemoglobine, het eiwit dat bloed
haar rode kleur geeft, bevat cytochroom P450 ijzer. Vandaar dat gezuiverd CYP2D6 een 
rood/bruine kleur heeft, zoals de kaft van dit boekje. En net zoals het ijzer op de kaft van dit 
boekje verroest is door het reageren met zuurstof (oxidatie), zo kan ook CYP2D6 zuurstof
binden, wat nodig is voor de activiteit van het enzym. CYP2D6 (en andere CYPs) splitst 
zuurstof; O2  2O, en bouwt één atoom daarvan in het medicijn. Zo wordt het medicijn
vaak beter wateroplosbaar en dus makkelijker uit te scheiden.
Het is dus niet alleen een wetenschappelijke uitdaging, maar het heeft ook een direct
praktisch nut om te weten hoe het enzym CYP2D6 werkt. Als dat bekend is, dan kan van 
tevoren worden voorspeld of een nieuw medicijn door CYP2D6 zal worden afgebroken.
Eventueel kan het ontwerp van zo een stof hierop worden aangepast zodat dat niet meer
het geval zal zijn. Natuurlijk bepaald niet enkel CYP2D6 het lot van een medicijn door een
mens geslikt. Desalniettemin was dat de afgelopen vier jaar, en samengevat  in dit boekje, 
wel de centrale vraag: hoe werkt CYP2D6? 
Om met behulp van experimenten een antwoord op deze vraag te kunnen geven was in de
eerste plaats het enzym zelf nodig in een reageerbuis. Bij een gebrek aan vrijwilligers is er 
voor gekozen CYP2D6 recombinant te maken. Het gen coderend voor CYP2D6 is gekloneerd 
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in bacteriën. Dit kloneren heeft als bijkomend voordeel dat het enzym te manipuleren is. Zo 
kunnen er kleine wijzigingen aangebracht worden, mutaties, waarbij gekeken kan worden
wat het effect is op de medicijn-afbrekende activiteit. Deze experimenten zijn beschreven in 
Deel I van dit boekje. 
In de hoofdstukken 2 en 3 hebben we door middel van het aanbrengen van mutaties
aangetoond dat CYP2D6 een tweetal specifieke plekken heeft, die cruciaal zijn voor
activiteit. Deze plekken, de aminozuren fenylalanine 120 en 483 zijn er voor nodig om een 
stof (het medicijn) op de goede plek aan CYP2D6 te laten binden, zodat het kan worden 
afgebroken. Vervolgens hebben we in hoofdstuk 4 aangetoond dat fenylalanines 120 en 483 
niet exact dezelfde functie hebben en bovendien hebben we laten zien dat er meerdere
aminozuren van belang zijn voor het binden van stoffen. Met de aminozuren reeds genoemd
in de literatuur en degenen geïntroduceerd in de hoofdstukken 2 t/m 4 denken we dat de 
plekken in CYP2D6, die van belang zijn voor het binden van stoffen, voor het grootste deel 
in kaart zijn gebracht.
Ook in hoofdstuk 5 hebben we een mutatie aangebracht in CYP2D6, dit keer aan aminozuur 
threonine 309. Door middel van deze mutatie hebben we de activiteit van CYP2D6 kunnen 
veranderen, ofschoon de stoffen nog wel gewoon aan het enzym konden binden. Door naar 
specifieke reacties te kijken en deze te vergelijken met reeds beschreven onderzoek hebben 
we aannemelijk gemaakt dat threonine 309 betrokken is bij de activering van zuurstof in 
CYP2D6. De manier waarop zuurstof wordt geactiveerd is bepalend voor welke reactie het 
enzym uitvoert.
Dat CYP2D6 een atoom ijzer bevat is een prettige eigenschap voor het doen van onderzoek 
aan dit enzym. Hierdoor zijn kleine veranderingen aan het enzym (denk aan het binden van
zuurstof of van een medicijn) namelijk gemakkelijk te meten, mits er aan het ijzer of de
directe omgeving daarvan iets verandert. Dan namelijk verandert de exacte kleur van het 
enzym (de absorptiegolflengte verschuift), of de magnetische eigenschappen veranderen, of 
de trillingen van het ijzer in het enzym veranderen. Deze eigenschappen zijn bestudeerd 
(spectroscopisch) in deel II van dit boekje.
Zoals een kleine ijzeren spijker of een naald zich richt wanneer het bij een magneet wordt 
geplaatst, zo is ook het cytochroom P450 door zijn ijzeratoom, (para)magnetisch. Als er een 
medicijn aan het cytochroom P450 gebonden is, dan voelt deze stof als het ware het
paramagnetische effect van het cytochroom P450 in een magneetveld. Dit effect is sterk
afstandsafhankelijk en omdat het van één punt afkomstig is, het ijzeratoom, is door het
meten van kernspin resonantie (NMR) de oriëntatie van het medicijn ten opzichte van het
ijzer atoom te meten. Door in hoofdstuk 6 gebruik te maken van deze techniek, was het 
mogelijk een computermodel van CYP2D6 te valideren, waarmee de binding en oriëntaties 
van medicijnen in het enzym kunnen worden bepaald. Zo kon worden aangetoond, dat met 
het computer model goed te voorspellen viel hoe XTC en verwante stoffen door CYP2D6
worden afgebroken. XTC is nu bekend als feestdrug, maar is ooit ontwikkeld als medicijn
tegen eetstoornissen. Daarnaast konden we met het computermodel het effect van de 
mutatie van fenylalanine 120 uit hoofdstuk 2 verklaren.
Alle moleculen trillen bij kamertemperatuur, zo ook CYP2D6. De frequenties waarmee 
trillingen van moleculen plaatsvinden, hangt af van de chemische structuur van de
moleculen. De bindingen tussen atomen kunnen wat dat betreft vergeleken word met een 
gewicht aan een veer; het gewicht en de sterkte van de veer bepalen de heftigheid en 
levensduur van de trilling. In hoofdstuk 7 hebben we gekeken naar de frequenties waarbij 
CYP2D6 trillingen veroorzaakt na activering met behulp van een laser (resonantie Raman 
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spectroscopie). Daarbij hebben we met name gekeken of er een verschil was tussen het 
gewone, natuurlijke enzym en de T309V mutant, zoals we die hebben gemaakt in hoofdstuk
5. We hebben een aantal typische verschillen gevonden die veroorzaakt werden door de 
mutatie. Daaruit hebben we geconcludeerd dat het aminozuur T309 naast het activeren van 
zuurstof, ook betrokken is bij de organisatie van de watermoleculen in het enzym rondom
het ijzeratoom. Uit andere studies blijkt dat dit van grote invloed kan zijn op de werking van 
andere CYP enzymen. Er was nog niet eerder onderzoek verricht naar dergelijke trillingen
van CYP2D6. De relevantie van de verschillen die wij hier rapporteren na mutatie van T309 
moet dus nog verder worden onderzocht. 
Als een medicijn bindt aan CYP2D6 zodat het kan worden omgezet in een stof die makkelijk 
uit te scheiden is, dan zou je kunnen verwachten dat CYP2D6 van vorm veranderd, als een 
soort happende ‘Pacman’ die een blokje op eet. Het medicijn moet namelijk diep in CYP2D6 
bij het ijzeratoom worden gebracht, want daar vindt de reactie plaats, en vervolgens moet 
het gevormde product weer uit het enzym. De medicijnen kunnen vrij grote moleculen zijn,
terwijl CYP2D6 geen grote openingen heeft naar het goed beschermde ijzer atoom toe, 
vandaar de analogie met een happende Pacman. In hoofdstuk 8 hebben we geprobeerd 
deze mogelijke vormveranderingen in kaart te brengen. Daarbij hebben we weer gebruik 
gemaakt van het computermodel van CYP2D6 en we hebben het gemeten. Er zijn namelijk 
aminozuren in CYP2D6 die fluorescerend zijn; tryptophanen. Als deze worden beschenen 
met licht van een bepaalde golflengte dan zenden ze vervolgens zelf ook licht uit van een 
andere golflengte. De fluorescentie van deze tryptophanen kan vervolgens worden gedoofd 
door het ijzer bevattende centrum van het CYP2D6. Deze uitdoving vindt meer plaats indien
de tryptophanen dichterbij het ijzeratoom zijn, en de uitdoving van de fluorescentie is dus 
een maat voor de afstanden in CYP2D6 van de tryptophanen naar het ijzeratoom. Door de 
fluorescentie van CYP2D6 te meten in aan en afwezigheid van een model-medicijn, hebben 
we kunnen vaststellen dat CYP2D6 een klein beetje van vorm veranderd als het een 
medicijn bindt. Deze vormveranderingen hebben we beschreven in hoofdstuk 8.
Door het doen van de experimenten beschreven in dit boekje, zijn we wijzer geworden over
hoe CYP2D6 precies werkt. Daarnaast is het belangrijk dat we met de beschreven 
experimenten hebben laten zien dat ons computermodel van CYP2D6 in hoge mate
overeenkomt met de werkelijkheid. Een computermodel van een eiwit is relatief gemakkelijk 
gemaakt, maar de kwaliteit van een model wordt bepaald door experimentele validatie.
Door de technieken die we hebben gebruikt ook te gaan toepassen op andere CYPs en 
andere medicijn-afbrekende enzymen, kan uiteindelijk een soort virtuele lever ontwikkeld 
worden. Daarmee kan tevoren worden nagegaan of een nieuw ontworpen molecuul met 
medicinale potentie niet wordt afgebroken alvorens het gewenste effect wordt verkregen.
Bovendien kunnen er suggesties worden gedaan hoe het nieuwe medicijn zo aan te passen,
dat het minder zal worden afgebroken. Door de ontwikkeling van deze modellen vallen 
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List of abbreviations 





cDNA copy Deoxyribose Nucleic Acid 
CPR cytochrome P450 NADPH-reductase 
CuOOH cumene hydroperoxide
CYP cytochrome P450




F120A phenylalanine 120  Alanine 
F483A phenylalanine 483  alanine 
FRET Förster resonance energy transfer 
FU fluorescence units
HAMC 7-hydroxy-4-(aminomethyl)-coumarin
KPi buffer 50 mM potassium phosphate buffer, pH 7.4 
MAMC 7-methoxy-4-(aminomethyl)-coumarin
MAO monoamine oxidase 
MD molecular dynamics 
MDA methylenedioxyamphetamine
MDAAs N-alkyl 3,4-methylenedioxymethylamphetamines





NADPH reduced nicotinamide adenine dinucleotide phosphate 






T309V threonine 309  valine 
T312V threonine 312  valine 
tR retention time






,Chapter 1  Figure 4: Conformations of the template substrates debrisoquine and dextromethorphan
used to construct the pharmacophore model of CYP2D6. The sites of oxidation are fixed and the red

















Chapter 2, Figure 4: Binding orientation of dextromethorphan automatically docked in the active site of
he homology models of CYP2D6 using Autodock with standard condi ions  In wild type CYP2D6 the
orientation of dextromethorphan (in yellow  with its O-methyl pointing towards the heme is favored (A), 
in the F120A mutant two distinc  orientations, supporting both N-demethylation (in magenta) as O-









Chapter 3, Figure 1: The active site of the homology model of CYP2D6 [5], showing the active site 
residues F120, E216, D301 and F483. The pink ball is the heme i on atom. In yellow, the subs ate
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Chapter 4, Figure 3 MAMC (cyan) and BMAMC (purple) (left panel), and MMAMC (yellow) and BMAMC
(purple) (right panel , docked in o the CYP2D6 homology model as described in he Me hods sec ion.
The molecular Connoly surface of the active site of CYP2D6 is depicted; the surfaces of carboxyl oxygen
atoms of D301 and E216, and the apolar sidechain atoms of L213, V308, and F483 are colored red and 
green, respectively. Amino acid side chains involved in substrate binding are shown as sticks. For











Chapter 5, Figure 1A: Protein model displaying the ac ive site of CYP2D6 with dioxygen and S-bufuralol
bound, showing the positions of the substrate in erac ing residues F120, F483 and E216, the conserved









Chapter 6, Figure 6: Molecular dynamics (MD) simulations starting orientations of charged R MDMA,
generated by automated docking studies in wild- ype (A) and F120A mutant (B) CYP2D6 homology
models. Two orientations are corresponding to O-demethylenation, with the substrate nitrogen-atom
ei her in close contact with E216 (pose 1, in yellow) or placed between E216 and D301 (pose 2, in
cyan). A third orientation is corresponding to N-demethylation or N-hydroxylation (pose 3, in purple). 






Chapter 7, Figure 6: Protein model displaying the active site of CYP2D6 with dextromethorphan bound.
The porphyrin is shown in red with Fe as a sphere, he Fe coordinating C443 is shown and the puta ive












Chapter 8, Figure 5: Homology model o  CYP2D6 based on rabbit CYP2C5, indica ing the positions o
he six tryptophans (red; purple for W128), the heme-group (green) and the substrate MAMC (yellow).
W28 is not p esent in the homology model.
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Chapter 9, Figure 1: The CYP2D6 active site (heme in red, Fe as sphere) according to the homology
model, with dextromethorphan (in orange) bound according to automated docking (GOLD-Chemscore),
showing the key residues involved in enzyme activity and the other residues that have been mutated in
his thesis. F120, F483, L213, and V308 are ident ied as being involved in s eric res ric ion and/or
hydrophobic in erac ion wi h subst ates, E216 is interac ing with basic substrate N-atoms  D301 
interacts with the backbone of F120, W128 interac s via H-bonds with the pyrrole C-propionate and was
muta ed to a phenylalanine in Chapter 8, which did not affec the ac ivi y, and T312 was mutated to a 
valine in Chapter 5  which did not affect activity either. The figure was made using Pymol 0.98.
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Chapter 9, Figure 2: Overlay of the heme (red, Fe as sphere) and the active site residues examined in 
his thesis f om the homology model, depic ed in blue, and f om the crystal s ructure of CYP2D6
depicted in gray. The figure was made using Pymol 0.98.
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